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Abstract 
Abnormal vascular smooth muscle cell (VSMC) proliferation and migration contribute to 
vascular narrowing during the pathogenesis of atherosclerosis and restenosis. An ideal 
compound for treating both diseases should therefore impair both proliferation and 
migration of VSMC. A major proliferative stimulus and the strongest chemoattractant for 
VSMC is the Platelet Derived Growth Factor-BB (PDGF-BB). The kinase inhibitor 
roscovitine (ROSC) shows a high specificity for cyclin dependent kinases (CDKs) which 
are crucial for cell cycle progression. We therefore wanted to investigate the mode of 
action of ROSC and promising derivatives in PDGF-BB stimulated VSMC and define the 
changes in cell signalling. Screening a panel of synthetic ROSC derivatives for a general 
antiproliferative activity in VSMC we identified LGR1406 which showed significant higher 
potency than ROSC itself. We showed that LGR1406 and ROSC both inhibit proliferation 
of VSMC without affecting early signalling pathways downstream of the activated PDGF 
receptor. LGR1406 is hereby the far more potent compound with an apparent IC50 of 3.0 
µM in the BrdU assay compared with an IC50 of 17 µM of ROSC. A detailed molecular 
analysis using western blot analysis as well as in vitro kinase assays showed that both 
compounds affect entry of cells into S-phase of the cell cycle, expression of cyclin A and E 
as well as phosphorylation of pocket proteins presumably by inhibition of CDK activity. 
However, ROSC only delayed these events whereas LGR1406 permanently blocked cell 
cycle progression in G1-phase of the cell cycle. We conclude that LGR1406 could be 
used for further development as e.g. stent coating agent but in vivo studies as well as 
further investigations on its molecular mechanism of action are needed.  
 
Additionally we investigated the influence of Indirubin-3'-monoxime (I3MO) on PDGF-BB-
induced migration of VSMC. In our group it had previously been shown that I3MO potently 
blocks VSMC proliferation in response to PDGF-BB and neointima formation in a mouse 
model (in vivo experiments were performed in cooperation with Prof. Binder, medical 
university of Vienna). Furthermore we had shown that it suppresses the production of 
reactive oxygen species (ROS) and the activation of the transcription factor STAT3, 
without interfering with other common early signalling events. In this study we now show 
that I3MO dose-dependently inhibits PDGF-BB-induced migration of VSMC in the same 
concentration range as it limits proliferation. Also we found that I3MO interferes with early 
cytoskeletal rearrangements involved in cell migration without affecting the small GTPase 
Rac-1.  However, we found that I3MO reduced the expression of STAT3 target genes 
involved in migration. Our data suggest that the antimigratory effect of I3MO is probably 
  
mediated via the reduction of ROS production in the cell and consequent inhibition of 
STAT3 phosphorylation. Our studies further substantiate that I3MO is a promising 
compound for the treatment of vasculoproliferative diseases. But also here are some open 
questions regarding its molecular mechanism of action.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Zusammenfassung 
In der Pathogenese von Atherosklerose und Restenose spielen die abnorme Proliferation 
(Zellteilung) sowie Migration von glatten Gefäßmuskelzellen (VSMC) eine große Rolle, 
indem beide Prozesse wesentlich zur Einengung von Blutgefäßen beitragen. Ein idealer 
Wirkstoff zur Bekämpfung von beiden Krankheitsbildern sollte sowohl die Proliferation als 
auch die Migration von VSMC verhindern. Ein wichtiger Stimulus für die Zellteilung und 
zugleich der stärkste Stimulus für die Migration von VSMC ist PDGF-BB (Platelet Derived 
Growth Factor-BB). Der Kinase Inhibitor Roscovitine (ROSC) zeigt eine erstaunliche 
Spezifität für Cyklin-abhängige Kinasen (CDKs). Darum wollten wir mit dieser Studie den 
genauen Mechanismus von ROSC auf PDGF-BB-stimulierte VSMC untersuchen und 
außerdem neue Derivate der Substanz testen. Wir untersuchten unterschiedliche ROSC 
Derivate auf ihre wachstumshemmenden Eigenschaften auf VSMC und stießen dabei auf 
eine vielversprechende Substanz, LGR1406, die eine bedeutend bessere Wirkung zeigte 
als die Ausgangsstruktur ROSC selbst. Wir fanden heraus, dass beide Substanzen die 
Proliferation von VSMC inhibieren ohne frühe Signaltransduktionswege im PDGF 
Signalling zu behindern. LGR1406 zeigte allerdings mit einem IC50 von 3 µM eine 
bedeutend bessere Wirkung als ROSC mit einem IC50 von 17 µM. Eine detaillierte 
molekulare Analyse mittels western blot und in vitro Kinase Assays zeigte dass beide 
Substanzen den Eintritt der Zelle in die S-phase des Zellzyklus behindern, ebenso die 
Expression von Cyclin A und E und die Phosphorylierung der Pocket Proteine Rb und 
p107. Allerdings konnten wir zeigen, dass ROSC selbst diese Vorgänge nur verlangsamt 
wohingegen LGR1406 die Zellen permanent in der G1 Phase des Zellzyklus arretiert. Als 
Ursache für die Wirkungen von beiden Substanzen vermuten wir die Inhibierung von 
CDKs durch ROSC und LGR1406. In weiterer Folge sind noch genauere Untersuchungen 
zum Wirkmechanismus und Tierstudien nötig, aber wir konnten mit dieser Studie erstmals 
zeigen, dass ROSC Derivate wie LGR1406 die Proliferation von VSMC verhindern 
können. Darum könnten solche Substanzen möglicherweise zur Beschichtung von Stents 
für die Therapie der Restenose weiterentwickelt werden. 
 
Außerdem untersuchten wir den Einfluss von Indirubin-3'-monoxime (I3MO) auf PDGF-
BB-induzierte Migration von VSMC. In unserer Gruppe konnte in vorangegangenen 
Studien gezeigt werden, dass I3MO die Proliferation von VSMC nach PDGF-BB 
Stimulierung verhindern kann. Ebenso konnte I3MO die Neointima-Bildung in einem 
Maus-Modell verringern. Zudem konnten wir zeigen, dass I3MO die Produktion von 
reaktiven Sauerstoffspezies (ROS) und die Aktivierung des Transkriptionsfaktors STAT3 
verhindert ohne andere frühe Signaltransduktionswege zu beeinflussen. In der 
vorliegenden Arbeit  wird nun gezeigt, dass I3MO die Migration von VSMC nach PDGF-
  
BB Stimulierung dosisabhängig reduzieren kann und zwar im gleichen Dosisbereich wie 
es auch die Proliferation von VSMC hemmt. Außerdem konnten wir zeigen, dass I3MO 
frühe Umlagerungen des Zytoskeletts die mit der Migration von Zellen in Zusammenhang 
stehen verhindert und zwar ohne die Aktivierung des kleinen GTP-Proteins Rac-1 zu 
beeinträchtigen. Andererseits konnten wir eine Reduktion der Expression von STAT3 
abhängigen Genen beobachten welche eine Rolle in der Migration spielen. Unsere 
Ergebnisse führen zu dem Schluss, dass der anti-migratorische Effekt von I3MO 
möglicherweise vermittelt wird über die Reduktion von ROS und die daraus folgende 
Inhibierung von STAT3 vermittelt wird. Unsere Resultate untermauern, dass I3MO eine 
gute Substanz zur Behandlung vaskuloproliferativer Erkrankungen sein könnte. Aber noch 
sind weitere Studien zum Wirkmechanismus nötig.  
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Atherosclerosis 
About 50% of the overall mortality in western societies is related to cardiovascular 
diseases comprising infarction, stroke, heart failure and restenosis 1. Atherosclerosis, the 
main underlying disease of stroke and heart failure is the leading cause of death in the 
western world 1, 2. The pathology of atherosclerosis is characterised by multiple processes 
including endothelial dysfunction, activation of macrophages, changes in levels of distinct 
cytokines and growth factors, abnormalities in lipoprotein metabolism and matrix 
alterations, all leading to a chronic inflammatory response in the arterial wall 3, 4. These 
alterations in a vessel wall trigger various effects in different cell types and finally lead to 
lumen loss due to migration and hyperproliferation of vascular smooth muscle cells 
(VSMC), deposition of lipids and extracellular matrix (ECM) and invading macrophages. 
The lesions that narrow the vessel lumen are called plaques and in the worst case these 
can become instable and disrupt. Subsequently plaque contents are exposed to the blood 
stream resulting in platelet aggregation and clotting which often directly leads to strokes or 
infarctions. There are various treatment modalities either preventing the progression of 
atherosclerosis or re-widening diseased arteries. These strategies are ranging from drug 
administration to surgeries. However, even if an artery has been re-widened its lumen is 
often reduced again, a process called restenosis. The latter is characterized by the 
formation of a new inner layer of the vessel wall (neointima). Combating atherosclerosis is 
a major goal of medical investigations and since it is a complex disease the ultimate 
solution has not been found until today. 
 Pathology of atherosclerosis 
For a long time the altered lipoprotein metabolism, more precisely the high plasma levels 
of low-density lipoproteins (LDL), their accumulation within the intima and their 
modification (e.g. oxidation) has been considered to be the main cause of the disease 2, 5. 
However, during the last two decades it has become more and more evident that 
inflammatory processes play a crucial role, too 5. The initial cause of atherosclerosis is still 
controversially discussed, but a disturbed or injured endothelium certainly plays a pivotal 
role 6, 7. This so called endothelial dysfunction can be caused for example by shear stress, 
modified lipoproteins, bacterial antigens or oxidative stress. Furthermore it is out of 
question that a number of risk factors, such as smoking, hypercholesterolemia, 
hypertension, obesity and diabetes, contribute to the development of atherosclerosis 2, 5. It 
has been reported that these risk factors also reduce the number and functionality of bone 
marrow derived endothelial progenitor cells. They hereby negatively affect the repair 
capacity of the endothelium and are causally linked to endothelial dysfunction 7, 8. 
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However, it seems that there is no exclusive model to explain this complex pathology. It is 
rather a multifactorial process ultimately leading to an inflammatory state of arterial walls 4.  
The consequence of endothelial dysfunction and the altered conditions in the artery in 
general is deposition of lipids within the arterial wall. The lipid is taken up by invading 
macrophages observable as fatty streaks characterising early lesions which do not 
present clinical symptoms 2. Moreover, it comes to migration and hyperproliferation of 
VSMC, consequential narrowing the vessel lumen and finally formation of fibrous plaques, 
also called fibroatheroma 5, 9. Those are histologically characterised by layers of VSMC 
embedded in a matrix of collagen fibrils and elastin overlying a core of lipid-laden 
macrophages, free lipids and potentially necrotic tissue 2. Furthermore these plaques can 
develop into so called ‘complicated lesions’ characterised by enhanced necrosis and 
calcification. Finally the plaques can eventually become instable and this may result in 
plaque rupture and thrombotic occlusion of the overlying artery 5. A clinical symptom that 
arises from the limited blood flow is chronic stable angina but it has become clear that up 
to 50% of individuals affected by myocardial infarction have not experienced any kind of 
premonitory symptoms 5, 10.  
 Early phase of atherosclerosis  
A healthy arterial vessel wall is composed of the adventitia, an outer layer of connective 
tissue, the media, which is built up of VSMC and the intima, a monolayer of endothelial 
cells (EC) separated from the media by a basement membrane 10. The differentiated 
VSMC are responsible for the contraction and dilation of an artery because they possess 
a contractile potential due to specialized proteins such as smoothelin or smooth muscle 
alpha actin (α-SMA). These proteins are part of the unique cytoskeleton of differentiated 
VSMC that allows for contraction and dilation of the cells and hence the artery. As most 
known cell types, VSMC can exit from the cell cycle and enter a quiescent state termed 
G0, which is the normal, differentiated state of most cells in higher organisms. Likewise in 
healthy vessels VSMC show a low proliferation rate and express a set of cell type specific 
markers including α-SMA, myosin heavy chain or caldesmon 11, 12. If exposed to an 
appropriate signal e.g. growth factors or cytokines, VSMC can exit from this resting state 
and undergo phenotypic changes. This dedifferentiation is marked by the reinitiation of 
cell proliferation and by enhanced motility. Furthermore the cells start to produce and 
secrete ECM. Therefore the new phenotype is often called ‘synthetic’ phenotype (Fig.1).   
 
It is now widely accepted that the first step in the development of atherosclerosis is 
endothelial dysfunction 1. This perturbation of endothelial function is marked among other 
things by the expression of adhesion molecules such as vascular cell adhesion molecule-
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1 (VCAM-1) by EC. This allows leucocytes (e.g. monocytes) to attach to and invade the 
vessel wall whereas in healthy vessels EC resist leukocyte adhesion (Fig.1A) 10. Attached 
leucocytes as well as EC secrete monocyte chemoattractant protein 1 (MCP-1) in 
response to high levels of LDL. This leads to the recruitment of T-cells further enhancing 
the inflammatory response 5. Monocytes that invaded successfully the endothelium and 
reached the subendothelial space release a panel of cytokines and growth factors. 
Amongst others these are platelet derived growth factor (PDGF), transforming growth 
factor α and β (TGFα /β), insulin like growth factor (IGF) and interleukin 1 (IL1) all acting 
on the endothelium as well as on the underlying VSMC (see section 2.1.3) 13. The EC 
thereupon magnify the expression of adhesion molecules and proinflammatory factors like 
MCP-1. This clearly leads to a positive feedback loop because even more leucocytes are 
attracted and invade the endothelium. 
 
Also the invading monocytes themselves are influenced by the surrounding cytokines (e.g. 
M-CSF), proliferate and differentiate into macrophages. In the meantime more and more 
oxidised lipoproteins aggregate within the intima where they are taken up by 
macrophages via the scavenger and oxidized LDL receptor pathways. The cells 
thereupon turn into foam cells, meaning lipid-laden, less mobile macrophages that mark 
early atherosclerotic lesions 2, 5, 10 (Fig.1B). The macrophages themselves additionally 
oxidise LDL thereby potentiating the process 5. 
 
The whole pathological process includes structural and functional changes of EC, VSMC 
and leucocytes all contributing to progression of the disease but our knowledge of in vivo 
interactions between these cell types is still fragmentary 2.  
 The role of VSMC in atherosclerosis  
The endothelial dysfunction and the resulting inflammatory state of a vessel wall also 
influences the underlying VSMC. As already mentioned, in healthy vessels VSMC are in a 
differentiated state, possess contractile properties and show a low proliferation rate. If 
they are exposed to an appropriate stimulus, VSMC can undergo phenotypic changes and 
reinitiate cell proliferation. Such stimuli (e.g. PDGF) are found among the factors secreted 
by EC and leucocytes as a result of endothelial dysfunction. The VSMC react with 
migration from the media into the intima and hyperproliferation leading to an accumulation 
of more and more VSMC within the intima. Furthermore they start to secrete cytokines (IL-
1, TNFα /β, M-CSF and others), likewise contributing to the proinflammatory cytokine 
cocktail (Fig.1A). Also VSMC react with the production of large amounts of ECM required 
for the retention of lipoproteins within the intima (‘synthetic’ phenotype) 3.  
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Therefore VSMC actively contribute to the progression of atherosclerosis not only by 
narrowing the vessel lumen through their rising cell mass but also by production of 
cytokines and by indirectly leading to the accumulation of lipids within the intima. The 
cytokine production is a major part during early steps of atherosclerosis but the deposition 
of ECM strongly contributes to the disease as well. At first sight the proliferation of VSMC 
does not seem to play a major role during the early phase of atherosclerosis but every cell 
that dedifferentiates and starts to produce cytokines and ECM drives the progression of 
the disease a little forward. Therefore VSMC contribute to the maintenance of the 
inflammatory state of the vessel wall from the very beginning 1, 3. 
 
Later on, during the progression of atherosclerosis a huge number of VSMC accumulates 
and strongly contributes to the narrowing of the vessel. However, the migration and 
beginning proliferation of the cells during early stages is the basis for this accumulation of 
VSMC during later stages of atherosclerosis. The first step in VSMC activation is their 
response to cytokines such as PDGF and it would be beneficial if we could already 
interfere at this point to prohibit VSMC migration and proliferation and stop the feedback 
loop 3. 
 
Next to local VSMC from the media, smooth muscle progenitor cells (SMPC) may be 
recruited from the blood stream and invade the endothelium, further contributing to the 
accumulation of smooth muscle cells within the intima 3, 14, 15. In animal models these 
SMPC substantially contribute to arterial narrowing 15. However in human atherosclerosis 
the contribution of SMPC has not been proven so far. There is one report where tissue 
samples of atherosclerotic lesions in response to organ transplantations (transplant 
atherosclerosis) were studied and the VSMC found were at least partially derived from 
SMPC 15. Therefore it has been suggested that treatment of atherosclerosis should not 
only interfere with local VSMC growth but should also target mobilization, homing, 
differentiation and proliferation of circulating SMPC 14.  
 
Irrespective of their origin, VSMC contribute not only to lesion growth by proliferation and 
production of ECM but also form a fibrous cap covering the lipid core thereby stabilising 
the plaque and preventing plaque rupture 2. On the other hand the formation of a fibrous 
cap also traps the foam cells and leads to their necrosis further complicating the situation 5.  
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Fig.1.  The initiation of atherosclerosis. The initiation of atherosclerosis is marked by 
endothelial dysfunction leading to the secretion of proliferative, pro-inflammatory and pro-migratory 
factors of the endothelium acting on the underlying media composed of VSMC. These factors 
activate the VSMC and cause their dedifferentiation from a resting state into a proliferative 
phenotype. (B) The VSMC thereupon migrate through the intima and start to hyperproliferate. This 
process is accompanied by the invasion of monocytes into the vessel wall where they take up LDL 
cholesterol and turn into foam cells further contributing to the inflammatory process. Figure adopted 
from Dzau et al. 3. For abbreviations see section 8.1. 
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There is no doubt that interference with VSMC proliferation and migration would help to 
reduce the number of VSMC and SMPC within the atherosclerotic lesion and therefore 
progression of the disease. Therapeutical approaches following this direction hence are 
strongly investigated. Unfortunately, all compounds interfering with VSMC proliferation 
that have been developed so far show side effects and new antiatherogenic drugs are still 
in the focus of research (see also section 2.5.2.4).  
 
Summarising, it can be said that once started, the whole process of atherosclerosis 
becomes self-maintaining by employing a network of positive feedback loops leading to 
strong inflammation, accumulation of large amounts of lipoproteins, ECM and VSMC, 
altogether contributing to plaque formation and enlargement. VSMC thereby play a pivotal 
role in formation, growth and stability of atherosclerotic plaques and therapeutical 
approaches to interfere with VSMC activation, proliferation and migration are highly 
welcome to stop the progression of atherosclerosis 13. 
 Treatment of atherosclerosis 
To combat atherosclerosis first of all changes in lifestyle, such as eating a healthy diet and 
exercising are recommended to eliminate or reduce risk factors. If the patient reached an 
advanced state of the disease medications or surgical procedures are, however, 
unavoidable. 
 Pharmacological treatments  
In earlier stages of atherosclerosis, namely before a plaque has been formed, the 
prescription of different drugs is the preferred treatment modality. One strategy is to 
reduce the elevated plasma cholesterol levels (hyperlipidemia). Statins, the most 
commonly used drugs for this purpose, have been quite successfully applied 16. However, 
statins have been found to potentially lead to serious toxicities and although rare these 
complications ask for the development of new anti-hyperlipidemic compounds 16. Also not 
every patient suffering from atherosclerosis exhibits hyperlipidemia. Moreover the 
reduction of cholesterol levels albeit lowering the risk, does not protect from all forms of 
atherosclerotic vascular disease. Still 70% of patients with hyperlipidemic treatment will 
get symptomatic disease regardless of this therapy 17.  
 
To reduce the likelihood of platelet aggregation in narrowed arteries so called anti-platelet 
therapies are used 18. They all target key elements of the platelet regulatory machinery. 
Among the several drugs used Aspirin is the most common one, irreversibly targeting the 
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cyclooxygenase (COX) and therefore platelet aggregation, inflammation and clotting. 
These therapies are also widely used but are associated with side effects including gastric 
ulcer, renal failure and bleeding 19.  
 
Another way of treating atherosclerosis is lowering the blood pressure that is mainly 
regulated by the renin-angiotensin system (RAS). Therefore inhibitors of key elements of 
this hormone system such as angiotensin-converting enzyme (ACE) inhibitors and 
calcium channel blockers are commonly prescribed to combat hypertension. Studies using 
animal models have shown a positive effect of ACE inhibitors on the development of 
atherosclerosis however large clinical trials were not conclusive 20. 
 
Additionally other medications may be used to control for specific cardiovascular risk 
factors such as diabetes. 
 Surgical  treatments  
If medication fails or the disease has progressed too far, surgeries e.g. angioplasty, 
endarterectomy, thrombolytic therapy or bypass surgery may be necessary.  
 
An endarterectomy means the incision of the affected artery and removal of the plaque. 
Thereby the endothelium is injured, too, leading to an inflammation and possibly to a 
renarrowing (restenosis) of the artery. Depending on the clinical study looked at, the 
incidence of restenosis after an endarterectomy lies between 6-14% 21. 
 
For a thrombolytic therapy either a thrombolytic substance (e.g. tissue plasminogen 
activator) is administered intravenously or a thin catheter is inserted into the affected 
artery to either deliver drugs that dissolve blood clots or to mechanically break up the 
occlusion. This method has been considered to be rather ineffective for chronic 
atherosclerotic lesions but is used for the acute treatment of cerebral infarctions or strokes 
22, 23.  
 
Bypass surgeries (e.g. coronary artery bypass surgeries) are another type of interventions 
that have been widely used in the past. Arteries from elsewhere in the patient's body or 
tubes made of synthetic fabric are used to bypass the narrowed region of the 
atherosclerotic artery and thereby improve blood flow. However, it is a rather severe 
surgery and due to the development of percutaneous interventions the number of 
coronary bypass surgeries was reduced 24. 
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Today the most common method used is the angioplasty. Depending on the artery 
affected it is distinguished between coronary angioplasty, peripheral angioplasty and renal 
artery angioplasty. During the year of 2000 more than one million patients underwent 
angioplastic procedures worldwide 25. 
 Angioplasty  
The term angioplasty describes a panel of procedures that are employed to mechanically 
improve perfusion by widening the vessel lumen. The most prevalent method is the 
percutaneous transluminal angioplasty (PTA) generally accompanied by the implantation 
of a tube-like mesh structure, a so called stent 26. It is used for peripheral, cerebrovascular 
as well as for coronary vessels 27. First a tightly folded balloon catheter is inserted into the 
narrowed artery (Fig.2A). Next it is inflated to a fixed size using water pressure and then 
the catheter is removed again (Fig.2B). If a stent is to be used it is tightly folded, too, and 
inserted together with the balloon catheter 3(Fig.2A). Unfortunately the widened vessel 
often undergoes restenosis (Fig.2C). 
 
Fig.2. In-stent restenosis. (A) A narrowed artery can be widened again by an angioplastic 
surgery using a balloon catheter. (B)This can be accompanied by the insertion of a stent in order to 
better maintain the vessel lumen. (C) One of the major complications of such an intervention is the 
renarrowing (restenosis) of the artery due to inflammatory processes followed by hyperproliferation 
and migration of VSMC.  
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Restenosis 
 Pathology of restenosis 
Angioplasty with or without stent placement is not a gentle process but virtually always 
leads to tissue trauma and complications. A major problem is that the endothelium is 
injured and at least partially stripped away (endothelial denudation). This may promptly 
lead to thrombosis or to an inflammatory cascade within the vessel wall 28. In both cases 
the artery will be renarrowed either by a blood clot or by hyperproliferating VSMC 
overgrowing the stent (building a neointima). The latter is called restenosis and is 
generally defined as a narrowing of the vessel lumen by more than 50% 11, 26(Fig.2C). It 
should be noted that restenosis is not only a problem after angioplasty but also affects 
20% of patients who received a bypass surgery and 6-14% of those who were subjected 
to an endarterectomy 21. As it is true for atherosclerosis, also restenosis is a complex 
disease and its pathophysiology is still incompletely understood 28. 
 
Atherosclerosis and restenosis obviously share a common etiology, namely inflammation 
of the vessel wall, though the underlying cause is different. Atherosclerosis results most 
likely from endothelial dysfunction whereas mechanical injury is the initial cause of 
restenosis. Nonetheless both result in a different pathologic outcome, probably because in 
atherosclerosis we observe a normal artery whereas restenosis hits an already diseased 
one 29. One difference that can be seen is that during atherosclerosis single lipid-rich 
plaques accumulate in the vessel wall whereas restenosis is characterised by concentric 
neointimal thickening 28.  
 Inflammation and restenosis 
After angioplasty an elevation of activated leucocytes and distinct inflammatory factors is 
observed. The strength of the inflammatory response is greater in individuals that had 
already displayed elevated baseline levels of several inflammatory parameters. Therefore 
such factors as e.g. C-reactive protein (CRP) or fibrinogen levels can be used as 
predictive markers for restenosis 29, 30. This inflammatory process leads to the expression 
of selectins and other adhesion molecules in EC, mediating the binding and invasion of 
circulating monocytes to and through the vessel wall 27. The involvement of monocytes 
very much resembles the early events in atherosclerosis. Also in restenosis the secretion 
of MCP-1 and expression of VCAM-1 play a critical role, directing transmigration of 
monocytes through the endothelium were they play again a pivotal role in maintaining and 
enhancing the inflammatory state 27.  
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Moreover the endothelial denudation caused by angioplasty leads to an exposure of the 
subendothelial matrix to the blood stream and the release of thrombogenic contents of the 
atheroma, thereby triggering platelet adhesion and activation 11. Especially thrombin elicits 
further platelet activation and consequently the secretion of proliferative and pro-migratory 
factors such as platelet derived growth factor (PDGF) acting on VSMC which in turn 
undergo phenotypic modulations 28.  
 
The endothelial denudation depicts a major problem and therefore research is not only 
focused on interference with VSMC growth but also on strategies to induce 
reendotheliasation of the stented area. 
 The role of VSMC in restenosis 
As already highlighted in previous sections, in healthy vessels VSMC are in a 
differentiated resting state but if they encounter distinct cytokines or growth factors such 
as PDGF they can dedifferentiate a so called ‘synthetic’ phenotype. 
 
Consequently the inflammatory state caused by e.g. an angioplasty initiates VSMC 
hyperproliferation and migration towards the source of chemotactic stimuli. The VSMC 
thereby form a neointima within the artery. Once formed the neointima is subjected to so 
called vascular remodelling, meaning a complex array of events that modulate matrix 
production and cell proliferation, gradually reducing blood flow 26. First the neointima is 
composed mainly of VSMC which subsequently deposit huge amounts of ECM. Later on 
other cell types such as myofibroblasts and also SMPC accumulate and add to neointimal 
growth 11.  
 
All together restenosis is marked by an acute and strong inflammation which is then 
followed by excessive proliferation of VSMC and further on by aberrant production of ECM 
and finally vascular remodelling ending up in a renarrowed artery 26, 28. As in the pathology 
of atherosclerosis, VSMC play a crucial role in restenosis if not an even greater one 
because the neointima is mainly built up of VSMC. Already within one week after 
endothelial denudation VSMC loose their typical phenotypic markers and contractile 
properties and are transformed into a synthetic phenotype producing large amounts of 
ECM. PDGF-BB is one of the most potent suppressors of the contractile gene expression 
11. Therefore it is a major goal for the treatment of restenosis to interfere with (e.g. PDGF-
BB-induced) VSMC signalling.  
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 Stenting 
Restenosis usually occurs within half a year after the surgery and concerns about 40-60% 
of patients who were treated with balloon angioplasty alone, whereas the insertion of  a 
stent reduces the incidence of restenosis to 25% 27, 31. Therefore restenosis depicts the 
major drawback of this minimal invasive technique 27. The insertion of conventional stents 
is providing a rigid scaffold for the vessel and reduces the immediate renarrowing of the 
vessel that usually occurs due to elastic recoil but does not limit neointima formation 28.   
However, further advancements have been made by the development and use of drug-
eluting stents (DES) interfering with VSMC growth and reducing the chance of in-stent 
restenosis to less than 5% 26, 32. A major problem of stenting is that not only the 
angioplasty itself injures the endothelium but also the insertion of a stent injures the vessel 
wall and strips away endothelial cells (denudation). 
 
Current marketed first-generation DES use drugs, such as rapamycin and paclitaxel 
targeting an effector of a signal transduction pathway (mTOR) involved in VSMC 
proliferation and tubulin, respectively (for more detail see chapter 2.5.2.4) 33. Unfortunately 
these drugs exert side effects on endothelial cells and evidence is growing that several 
patients develop late-stent-thrombosis 34. Therefore research is still focused on finding 
new drug candidates that interfere with VSMC proliferation and migration. Additionally 
effort is made to develop different materials for stents themselves, as for example 
biodegradable matters 35.  
 
The ideal stent-coating agent is still to be found and most probably is not a single 
compound but rather a mixture of anti-proliferative/ anti-migratory compounds on the one 
hand and endothelium-protective factors on the other hand in order to achieve re- 
endothelialisation without neointima formation 26, 34.   
PDGF signalling 
PDGF is the most potent stimulus of VSMC proliferation and migration. Therefore drugs 
interfering with PDGF signalling and thereby inhibiting activation of VSMC depict 
interesting targets for the further development as stent-coating drugs 26, 36. 
 PDGF receptor activation  
PDGF was first detected in platelet-derived granules showing growth-promoting activity for 
VSMC and fibroblasts 37. Soon the corresponding receptor has been identified and the 
importance of PDGF signalling during embryonic development has been emphasized 
using gene-targeted mice showing lethality at the time around birth 38. There exist two 
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receptor subunits, α and β, that form homo- or hetero-dimers upon binding of PDGF to 
build a functional PDGF receptor (PDGFR) 39. The ligand PDGF itself exists in four 
isoforms (A-D) that are only functional if forming homo or heterodimers. Among the PDGF 
dimers PDGF-BB is the only one binding to all types of receptor dimers, whereas the other 
dimers show selectivity for one or the other receptor dimer (see Table I). This might be the 
reason why PDGF-BB has been shown to be the far most potent stimulus for VSMC 
migration and proliferation 40. 
 
Table I. Binding specificities of PDGF and PDGFR isotypes 
 
Up to now the five homo and heterodimers shown in Table I are considered to constitute 
the complete PDGF-family. However, it cannot be excluded that other PDGF dimers exist, 
such as PDGF-AC or PDGF-AD but so far these have not been found in vitro or in vivo 39.  
 
Both PDGFR isotypes are receptor tyrosine kinases  (RTK) and possess an intrinsic 
kinase activity within their intracellular domains (Fig.3). Upon ligand-induced receptor 
dimerisation and accompanying conformational changes the kinase domains come close 
enough to each other and enable mutual phosphorylation on crucial tyrosine residues 
(Y857 of PDGFRβ, Y849 of PDGFRα) 41. This autophosphorylation is leading to further 
activation of the kinase domains themselves because their substrate clefts get accessible 
41. Therefore the receptor kinase is fully active, phosphorylating a number of target 
proteins, most prominently the PDGFR itself thereby providing docking sites for SH2 
domain-containing proteins.  
 Early events in PDGFR signalling 
Within minutes after receptor activation different signalling molecules are recruited 
including kinases like Src (Rous sarcoma virus kinase) or PI3K (phosphoinositol 3 kinase), 
adaptor proteins such as Grb2 (growth factor receptor-bound protein 2) or Nck but also 
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phosphatases as e.g. the phosphotyrosine phosphatase (PTP) Shp-2 (SH2-containing 
phosphatase 2).  
 
The recruitment of distinct signalling proteins is defined by the surrounding amino acids of 
each phospho-tyrosine residue. For example Src kinase is binding specifically to the 
phosphorylated tyrosines 579 and 581 in the juxtamembrane domain of the receptor 
(PDGFRβ). Stable interaction of the PDGFR and PI3K requires phosphorylation of the 
tyrosines 740/751 (PDGFRβ) and Shp-2 specifically binds to phosphotyrosine residues 
763 and 1009 (Fig.3). 
 
The signalling cascades are tightly regulated and require changes in localisation and 
modification of many different proteins. The most important players are kinases and 
phosphatases that change the phosphorylation status of their target proteins. 
 
 
Fig.3. Schematic overview about PDGF receptor signalling. Receptor dimerisation upon 
ligand binding leads to autophosphorylation of the intracellular parts of the receptor and 
subsequently to recruitment of several signalling molecules and hence the activation of a panel of 
signal transduction pathways. Shown are the positions of tyrosine residues of the PDGFRβ chain. 
For abbreviations see section 8.1. 
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 Activation of kinases in early PDGFR signalling 
Binding of the Src kinase leads to a relaxation of its intrinsic inhibitory conformation of the 
kinase domain and thereby to its activation. PI3K as well as phosholipase C (PLC) are 
both activated by recruitment from the cytosol to the plasma membrane and concomitant 
co-localisation with their lipid substrates. PLC is additionally activated by phosphorylation 
through the PDGFR or Src. The PI3K is additionally activated by binding to active Ras. 
The latter is a small G-protein that accumulates in the proximity because its activating 
GTP-exchange factor Sos is recruited by several adaptor proteins such as Grb-2 39. Ras 
plays a pivotal role in many signalling cascades and is activated by a panel of different 
growth factors and cytokines 41. The recruitment and activation of Ras is also responsible 
for triggering the mitogen activated protein kinase (MAPK) pathway via MEK and ERK 41.   
 Activation of phosphatases in early PDGFR signalling 
One of the best described phosphatases which is recruited to the activated PDGFR is 
Shp-2 that has been implicated in the regulation of proliferative as well as migratory 
responses of VSMC 42. Next to Shp-2 another important phosphatase for PDGF signalling 
is PTEN (phosphatase and tensin homolog) dephosphorylating the PI3K 40. PTPs 
counteract receptor activation by dephosphorylation of tyrosine residues thereby inhibiting 
RTK function and diminishing docking sites for signalling molecules. However, the activity 
of PTPs is almost simultaneously inhibited with the activation of the PDGFR by production 
of reactive oxygen species (ROS) such as hydrogen peroxide via activated PI3K (Fig.3) 39. 
The local increase in hydrogen peroxide concentration leads to the oxidation of an 
essential cystein residue within the catalytic side of PTPs. So although PTPs are recruited 
to the activated receptor they can not exert their phosphatase activity immediately but 
come later into play when hydrogen peroxide concentration decreases for example due to 
recruitment of peroxiredoxin. Then they are important to shut off the signal in order to 
prevent persistent receptor activation 41. Shutting off the receptor signal is as important as 
the well-controlled activation of it because persistent activation leads to hyperproliferation 
of VSMC which is associated with atherosclerosis and restenosis.  
 Signalling cascades downstream of the PDGF receptor  
Each of the signalling molecules mentioned above is directly and immediately activated by 
the PDGFR leading to the activation of complex networks driving many different signalling 
cascades.  
 
Fig.3 shows a schematic overview about current knowledge of early PDGFR signalling. 
How exactly these signalling cascades are connected to the cellular events of migration 
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and proliferation is only incompletely understood. Investigating these events is difficult 
because it is hard to distinguish the primary PDGF-dependent events from secondary 
effects resulting from the expression of immediate early genes 41. Even enzymes that 
direct immediate effects such as PI3K and PLC are also activated at later timepoints. 
Moreover genes that are expressed upon PDGF stimulation are often targeted by several 
pathways simultaneously for example activation of the cyclin D1 promoter requires active 
STAT3/5 as well as the Ras/ Raf/ MEK/ ERK pathway 43. 
 Mitogen activated protein kinase (MAPK)-signalling 
Among the signalling pathways activated, the ERK-MAPK pathway is probably best 
understood. As depicted in Fig.3 it finally leads to the phosphorylation and activation of 
ERK1/2 which is thereupon accumulating in the nucleus and regulating transcription 
factors as e.g. Elk. Thereby it leads to the expression of target genes involved in cell cycle 
progression such as cyclin D1. Next to the ERK MAPK, other MAPKs such as p38 or the 
c-jun N-terminal kinase (JNK) are activated as well. The MAPKs play a crucial role in 
PDGF-induced proliferation and seem to have less importance in migration. Especially 
Ras significantly contributes to cell proliferation but there are also Ras-independent 
pathways involved 38. JNK is less well studied concerning its role in PDGF-signalling. It 
can be activated by PI3K under certain circumstances or through the conventional MAPK 
pathway via MEKK1/4 and  MKK but is definitely influenced by the adaptor protein Nck 40. 
All MAPKs influence the cellular response through modulation of expression of their target 
genes 38. 
 PI3K and PLC-signalling 
First of all, PI3K and PLC both phosphorylate lipids within the plasma membrane and 
thereby provide docking sites for distinct proteins that are then recruited from the 
cytoplasm to the plasma membrane. Therefore they both play crucial roles in regulating 
the localisation of downstream signalling molecules. 
 
The PI3K has several responsibilities in PDGF-induced signalling. The activation of PI3K 
triggers the local production of ROS (reactive oxygen species like hydrogen peroxide) via 
the activation of Nox (NAD(P)H-oxidase) protein complexes. Thereby the PI3K influences 
the activity of phosphatases and other redox-sensitive proteins. Moreover, via its role in 
the modification of membrane lipids the PI3K also mediates the phosphorylation of Akt. 
Activated Akt in turn induces a number of pro-survival signals. It positively regulates 
transcription factors that lead to the expression of survival genes and negatively regulates 
pro-apoptotic factors as e.g. caspases. Next to this, activated PI3K is also involved in 
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calcium mobilisation together with PLC and activates small G-proteins as Rac and Rho 
that are involved in cytoskeletal rearrangements and migration. Hence PI3K-signalling is 
very important for both cell migration and proliferation upon PDGF induction 40.  
 
The recruitment and activation of PLC as mentioned before leads to an increase in 
cytoplasmic calcium. Additionally it activates certain members of the protein kinase C 
(PKC) family and influences the activity of Na+/H+ channels 38. It has been demonstrated 
that PLC-dependent effects mediate cell proliferation as well as migration 40. Activation of 
PKC may lead to the degradation of p21 an inhibitor of cell cycle progression thereby 
providing a link between PLC/ PKC and proliferation 44.  
 STAT-signalling 
Also other signalling molecules such as STAT1/3/5 (Signal Transducers and Activators of 
Transcription 1/3/5) are recruited and activated upon PDGF stimulation, but those 
processes are currently not as well described as the signalling events mentioned before 39. 
For the activation of STATs it has been shown that Src kinase is involved but there are 
additional papers claiming that JAKs (janus kinases) play a role, too. STAT transcription 
factors are activated through multiple extracellular signals and are probably best 
described in inflammatory processes where they are major players in e.g. interferon 
signalling. However, STATs have also been implicated in growth factor signalling. 
 
STATs have to be phosphorylated at crucial tyrosine residues in order to form homo- or 
heterodimers with other STATs and are thereupon translocated into the nucleus where 
they bind to distinct promoter-sequences called IREs (interferon response elements) 45. 
The cellular responses to different stimuli (cytokines or growth factors) often result in a 
remarkable specificity of STAT activation. Whereas most of the STATs mediate 
antiproliferative signals in response to inflammatory processes STAT3 stimulates cell 
proliferation and prevents apoptosis. PDGF has been shown to stimulate the transcription 
of the proliferative factor c-myc via a Src-STAT3 axis. C-myc is a proto-oncogene involved 
in early phase of cell cycle progression 38. Hence it is not surprising that overstimulation of 
the STAT3 pathway has been shown to cause cellular transformation in mice. STAT3 will 
be discussed in more detail in a later chapter (section 2.7.2.2). 
 
In interferon-induced signal transduction the activity of STATs is additionally regulated by 
negative feedback loops employing so called ‘suppressors of cytokine signalling’ (SOCS). 
Those proteins seem to regulate STATs by direct inhibitory interactions with receptors and 
signalling proteins as well as targeting associated proteins for degradation. Concerning 
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growth factor-induced STAT activation, there is not much known regarding shut down of 
the signal but it is thought that SOCS play a role here, too 46.  
 Regulation of PDGF signalling 
All together there are many signalling cascades involved in the cellular responses to 
PDGF and it seems that none of them influences any outcome exclusively. Moreover, 
these signalling cascades are not activated in isolation, but there is also crosstalk 
between pathways, feedback loops play a role and this is why our knowledge is far from 
showing a complete picture of all these signalling events 39. It should be noted that the 
molecules involved in PDGFR signalling are also involved in many other pathways and 
can be recruited to many different receptors within a cell. Moreover PDGFR activation 
leads to cross-activation of the FGF receptor 47. Changes in subcellular localisation of 
distinct pools of enzymes and molecules are now thought to significantly contribute to 
signalling outcome 41. All together signalling events downstream of the PDGF-receptor 
show a network-like pattern that is far more complex than shown in  Fig.3 38.  
 
The different receptor dimers elicit similar but not identical cellular responses 38. Both 
PDGFRαα and PDGFRββ mediate proliferation but their influence on migration is different. 
Although both lead to partially similar cytoskeletal rearrangements PDGFRαα rather 
inhibits whereas PDGFRββ clearly enhances chemotaxis. PDGFRαβ also enhances 
chemotaxis but is in general less well investigated 38.  
 
It is out of question that PDGF signalling is tightly regulated by feedback control 
mechanisms in a healthy cell and that deregulation is associated with disease such as 
atherosclerosis because PDGF is the most potent stimulus for VSMC growth and 
migration 40. Therefore interference with PDGF signalling is an important goal for the 
treatment of atherosclerosis and restenosis.  
 PDGF signalling in vascular disease 
Since PDGF-BB is the far most potent stimulus for both, proliferation and migration of 
VSMC, it is not surprising that strong data exist linking PDGF activity to human 
atherosclerosis 48. For example elevated levels of PDGF A and PDGF B have been found 
in tissue samples obtained from endarterectomy surgeries. Moreover several signalling 
molecules downstream of the PDGFR have been found to be hyperactive in human 
atherosclerotic plaques 49, 50. Additionally the selective inhibition of distinct PDGF-induced 
signalling cascades has been shown to inhibit neointima formation in animal models 51. 
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PDGF-BB stimulated VSMC are therefore used to investigate the underlying molecular 
mechanisms of hyperproliferation and migration. 
Cell Cycle 
The mammalian cell cycle is divided into several phases and is a complex process 
involving numerous regulatory proteins. Its tight regulation is essential and many of the 
proteins involved are proto-oncogenes connected to the development of cancer or other 
proliferative disorders such as atherosclerosis and restenosis. 
 Cell cycle phases 
Morphologically the cell cycle can be divided into the interphase, when chromosomes are 
decondensed and mitosis (M-phase) when chromosomes are highly condensed and 
therefore visible using an optical microscope. During M-phase the cell divides and gives 
rise to two genetically identical daughter cells. During interphase the cell grows, carries 
out its life function and prepares for cell division if the appropriate stimuli as e.g. growth 
factors are present. The interphase itself is subdivided into different phases (Fig.4) 52. 
 
Cells that are not cycling but still possess the potential of cell division entered a state of 
quiescence termed G0. If the appropriate stimuli are present the cell exits from G0 and 
enters the first ‘gap’ phase (G1), where it prepares for doubling the genome. A lot of 
enzymes necessary for DNA synthesis are produced now. Here the cell also checks 
whether the conditions are favourable for cell division or not, whether the cell is healthy 
enough or not and may still stop the cell cycle. In very late G1-phase the cell passes the 
so called restriction point and enters S-phase (synthesis phase). From now on the cell will 
complete cell division even if it is deprived from growth stimuli. During S-phase DNA 
synthesis takes place and this phase is generally low in protein synthesis except of 
histone production. During late S-phase there is another checkpoint where the cell 
controls for DNA damage and decides whether to proceed with cell division or to undergo 
apoptosis. It is followed by a second gap-phase (G2) where the cell prepares for cell 
division. The G2-phase is the last part of the interphase and is followed by the M-phase 52. 
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Fig.4. Cell cycle. (A) The cell cycle is divided into 4 phases, two ‘gap’ phases (G1 and G2), the 
‘synthesis’ phase (S) when DNA is replicated and the mitosis phase (M) when cell division takes 
place. An important protein that is tightly regulated through phosphorylation during cell cycle 
progression is the Rb protein. (B) Upon phosphorylation it releases E2F transcription factors and 
therefore allows expression of proteins crucial for cell cycle progression. For abbreviations see 
section 8.1. (figure adopted from 53)  
 Cyclin-dependent kinases (CDKs) 
The family of CDKs currently consists of 13 members and most of them play an essential 
role in cell cycle regulation. However, not all of them share the same responsibilities within 
a cell and some of them do not participate in cell cycle regulation at all. 
 
Progression through the cell cycle is mainly driven by CDKs that form complexes with 
cyclins and are thereby activated. Additionally CDK activity is influenced positively and 
negatively by threonine and tyrosine phosphorylation 41. CDKs themselves are rather 
ubiquitously expressed throughout the cell cycle. Their activity is regulated by the limited 
expression of distinct cyclins during each phase of the cell cycle.  
  INTRODUCTION 
- 26 -  
 CDK1/2/3/4/6 
Entry into, progression through and exit from G1 phase are controlled by D-type cyclins 
(D1, D2, D3) complexing with CDK4/ 6 and later on E-type cyclins (E1, E2) complexing 
with CDK2. CDK3 is only poorly investigated but is suggested to complex with cyclin C 
and to stimulate G0/G1 transition 54. During S-phase, cyclin A and later cyclin B are 
expressed and control for the activity of CDK2 and CDK1, respectively (Fig.4A) 52. The 
expression levels of cyclin D and E have been considered for a long time to be the rate-
limiting step in G1-S-phase transition 55. There are many reports supporting this notion but 
data from gene targeted mice showed that progression through cell cycle can take place 
without these cyclins (discussed below). In cultured cells overexpression of D-type cyclins 
shortens G1 phase and the inhibition of CDK4 either by pharmacological inhibitors or by 
overexpression of CDK inhibitor proteins (CKI) lead to an arrest in G1 phase. Additionally 
cyclin D1 overexpression can drive cell cycle progression even when cells are arrested in 
response to DNA damage. Also enhanced cyclin E expression can shorten G1 phase and 
the absence of cyclin E stops cell cycle progression 55.  
 
However, gene-targeted mice for different cyclins and CDKs showed that there must be 
ways of compensation for all of those proteins because none of the knockouts was 
completely deficient in cell replication. Cyclin D1, D2, D3, cyclin E1, E2 as well as CDK4 
single knock out mice were all viable. Most surprisingly also a CDK2 knock out is viable 
and apart from male and female sterility free of pathologies 56. This finding was really 
astonishing because CDK2 activity has been considered to be indispensable for cell cycle 
progression 55. Double or triple knock outs of D-type cyclins were in part embryonic lethal 
or lead to death within the first weeks after birth. Cyclin E1/E2 as well as CDK4 and 6 
double knock outs were embryonic lethal, too. But still all of these knock out mice 
developed until midgestation what requires cell division 55. Therefore there must be more 
than cyclins D, E and CDK2/4/6 to drive cell cycle progression through G1 phase. 
Recently it has been shown that in fact only CDK1 is essential for cell cycle progression of 
most cell types because even the combined knock out for CDK2/3/4/6 was still allowing 
organogenesis and development to midgestation 57.  
 
Interestingly, simple eukaryotes such as yeast possess only a CDK1 homologue and get 
along with a single CDK 58. So nowadays the model presented in Fig.4 is in general valid 
for most mammalian cell types with the notion that some cell types may have different 
requirements for single CDKs, and that CDK1 can compensate for all other CDKs in most 
cells 57, 59.  
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 Other CDKs  
Besides CDK1/2/3/4/6 there are more CDKs known but none of them has been shown to 
be directly involved in cell cycle regulation until know except of CDK7. 
 
Today 13 CDKs are known. However, until 2000 nine of them had been identified only. 
Therefore it is very likely that the list will further grow in the future. CDK10-13 are not very 
well described in the literature because they are known only for a short time. Also CDK8 
and 9 are poorly investigated 60.  
 
CDK7 and CDK9 play a role in RNA polymerase II activation and are therefore regulating 
transcription in general 61, 62. Hence they both are indirectly involved in cell cycle 
regulation because gene transcription is necessary for cell cycle progression. CDK7 is 
additionally  involved in DNA repair whereas CDK9 acts as transcriptional cofactor and is 
possibly playing a role in AIDS progression as well as differentiation processes in distinct 
tissues 61, 62. Moreover CDK9 is overexpressed in neuroblastoma 62.  As already 
mentioned CDK7 is also involved in cell cycle regulation. It binds to cyclin H thereby 
forming the CDK-activating kinase (CAK) and phosphorylates CDK2 and CDK1 63. 
 
CDK5 is an atypical CDK that is not ubiquitously expressed. It is found mainly in the 
neuronal system where it does not influence cell cycle but rather differentiation, cell 
morphology and motility 64. It is most abundant in post-mitotic neurons where its activity is 
obligatory for migration and differentiation processes within the developing brain. CDK5 
has been best characterised in influencing the cytoarchitecture of the central nervous 
system. It is activated by non-cyclin proteins p25, p35 and p39. Recently it has been 
found in some other cell types as well and roles for CDK5 have been proposed e.g. in 
myogenesis and haematopoietic cell differentiation 65.  
 Pocket proteins and E2F transcription factors 
A central role in driving cell cycle progression is played by so called pocket proteins, 
namely Retinoblastoma protein (Rb), p107 and p130 which are residing in the nucleus. 
These are the main targets of active CDKs and if hyperphosphorylated they dissociate 
from members of the E2F family of transcription factors (E2F1/2/3a/3b/4/5/6/7 and E2F8). 
The pocket protein- E2F complexes are further influenced by CDK inhibitor proteins such 
as members of the INK or KIP family of proteins. Those bind to and stabilise the 
complexes thereby inhibiting transcription (Fig.4A) 66.  
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The pocket protein-E2F complexes already reside in the nucleus bound to the E2F 
promoters and dissociation of the pocket proteins in general enables target gene 
transcription and therefore leads to cell cycle progression. The pocket proteins not only 
influence E2Fs by binding to them but also recruit chromatin-modifying enzymes such as 
histone deacetylases or methyltransferases and are therefore thought to ‘actively’ repress 
the promoters 67. Among the E2F target genes are cyclins themselves and proteins 
involved in DNA synthesis such as DNA polymerase II (Fig.4B) 66, 67. Together the E2F 
target genes are required for ordered progression through the cell cycle not just at the 
G1/S transition but throughout the cell cycle 67.  
 
During G0 phase the pocket proteins are only minimally (or hypo-) phosphorylated, 
therefore bound to E2Fs. During cell cycle progression the pocket proteins are 
subsequently more and more phosphorylated (hyperphosphorylated) by CDKs. It has 
been found that in serum deprived cells almost all E2F responsive  promoters are 
occupied by E2F4/ p107 or E2F4/ p130 complexes 66. The cyclin E promoter is so far the 
only E2F responsive promoter known that is strongly bound by Rb. Therefore the 
expression of the late G1-phase cyclin E is dependent on the phosphorylation of the 
retinoblastoma protein whereas most of the other E2F target genes require 
phosphorylation of p107 and p130 66.  
 
It should be noted that during the last years it has become clear that the pocket proteins 
can also positively regulate gene expression if bound to distinct members of the E2F 
family. The nine members of the E2F family identified so far are therefore grouped into 
activator E2Fs and repressor E2Fs. E2F1/2/ and 3a are activators of transcription and are 
only low expressed in quiescent cells but highly expressed during late G1 and found in 
complexes with Rb. On the other hand E2F3b/4/5/6/7/8 are repressors of transcription and 
found in complexes with p107 and p130 66, 68. The activating E2Fs are themselves target 
genes of E2Fs. Therefore during G1 phase when the hyperphosphorylation of pocket 
proteins leads to expression of E2F target genes one result is the transcription of the 
activator E2Fs 1/ 2/ 3 67. Despite binding different E2Fs another difference between the 
single pocket proteins is their level of expression. Whereas Rb is expressed in 
proliferating and quiescent cells, p107 is most prominent in proliferating cells only and 
p130 is expressed mainly in arrested cells 66.  
 
Despite the obvious differences between the pocket proteins it has been shown that they 
can in part compensate for each other although p107 and p130 are more closely related 
to each other than to Rb 66. Therefore it is not clear whether it is really helpful or even 
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possible to distinguish strictly between Rb or p107/p130 dependent genes. Cobrinik 
concluded in 2005 that much remains to be learned about pocket proteins and their 
function in cell cycle regulation in development and disease 66. 
 
Summarising it can be said that although the model presented in Fig.4 is very likely valid 
for most of the mammalian cells there are many levels of redundancies between the 
single players. Different CDKs as well as single pocket proteins can compensate for each 
other and there are additional enzymes exerting CDK independent activities on cell cycle 
progression. 
VSMC cell cycle regulation and disease 
As it is true for most tightly regulated biological processes defects in cell cycle control 
have severe consequences such as cancer, fibrotic disorders or cardiovascular diseases 
like atherosclerosis and restenosis. 
 
As described in previous chapters atherosclerotic lesions are very heterogeneous at the 
cellular level, containing not only VSMC but also endothelial cells, macrophages and other 
inflammatory cells, each of which participate in lesion formation. Injury or dysfunction of 
the endothelium is the earliest event but VSMC proliferation occurs rapidly afterwards and 
plays a central role in lesion formation and growth. The same is true for restenosis where 
mainly VSMC build up the neointima. Interfering with VSMC proliferation is therefore 
considered as a major strategy to combat vasculoproliferative disorders. 
 
In general VSMC cell cycle is controlled as discussed in previous chapters and usually in 
a healthy artery the cells do not proliferate at all. But some aspects of mammalian cell 
cycle seem to be cell type specific and there is still much to be learned about VSMC. 
There is much effort made to better understand VSMC cell cycle and find unique targets 
that would allow a specific inhibition of VSMC proliferation without targeting other cell 
types 3. 
 Regulation of cell cycle progression of VSMC  
 Early signalling events in cell cycle progression of VSMC 
As highlighted in previous chapters VSMC proliferate in response to several stimuli as e.g. 
growth factors such as PDGF and many of these factors activate the same or similar 
signalling cascades. Amongst these are MAPK, PI3K or JAK-STAT pathways (see section 
2.3). 
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Using pharmacological inhibitors, dominant negative or constitutively active enzymes it 
has been shown that Ras, PI3K, PLC, ERK and Src trigger G1/S-phase transition of 
VSMC 69-74. Goncharova et al. showed that PI3K signalling was necessary and sufficient 
for VSMC proliferation and migration and suggest a pivotal role of PI3K in vascular 
remodelling 71. This was confirmed by Liu et al. who found that PI3K as well as PLC were 
necessary for PDGF-induced proliferation 73. Another group found that interfering with Ras 
activation also inhibits smooth muscle cell proliferation and discuss the possible use of 
Ras signalling inhibitors to control smooth muscle proliferation after vascular injury 70. The 
inhibition of JNK, p38 or ERK with either dominant negative mutants or pharmacological 
inhibitors has proven the importance of MAPK in VSMC proliferation. However, the effect 
was much stronger for ERK compared with the other MAPKs 74, 75. Also Akt activation has 
been shown to play an essential role in VSMC proliferation, for example via the activation 
of the mTOR/p70 S6 kinase pathway 33. 
 Regulation of cell cycle progression of VSMC at the transcriptional 
level 
As in most mammalian cell types studied so far E2F transcription factors play a pivotal 
role in VSMC cell cycle. Next to E2Fs also other partly cell type specific, transcription 
factors are essential during cell cycle progression, too. This is also true for VSMC. In 
quiescent VSMC specific transcription factors are expressed (GAX and GATA-6) that 
stimulate the expression of the CDK inhibitor p21. Upon PDGF stimulation these factors 
are downregulated, hence p21 levels drop and CDKs are activated 3.  
 
Next to signalling proteins also other molecules influence VSMC cell cycle. For example, 
the addition of nitric oxide (NO) leads to a blockade of the cyclin A promoter and moreover 
to an enhanced expression of p21 3. 
 Inhibition of VSMC cell cycle progression as treatment 
modality for vasculoproliferative diseases  
The inhibition of VSMC proliferation is a major goal in preventing atherosclerosis or 
restenosis after angioplasty. This has been tried by many different approaches targeting 
various stages of cell cycle progression. However, the therapeutic application of all these 
strategies has so far been limited to local treatments and hence to restenosis. Systemic 
administration of drugs or other therapeutical strategies would be problematic as they 
target every cell they encounter thereby eliciting severe side effects. Moreover the activity 
of the liver would lead to drug metabolism and clearance before the agents even reach 
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their target site. For restenosis treatment the local delivery of the drugs can be achieved 
by directly coating stents. A main problem remains that the adherence of endothelial cells 
to stent surfaces under flow conditions is particularly poor, thereby hindering re-
endothelialisation 35.  
 Brachytherapy 
One idea was to apply either β or γ radiation locally to the stented area (called 
brachytherapy) but there are major concerns about this method because it leads to DNA 
damage of all surrounding cells and additionally may cause cell death rather than cell 
cycle arrest 3, 76. Also DNA damage could lead to cellular transformation and cancer. 
Therefore research is focused on finding more specific methods to hinder VSMC 
proliferation. 
 Targets for anti-restenotic therapies 
Because PDGF is the most potent proliferative stimulus for VSMC, first it has been tried to 
directly inhibit the PDGFR using PDGFR antibodies or gene silencing (via RNA 
interference strategies). All attempts failed most likely because such a multifactorial 
pathology can not be treated by interfering with a single mitogenic factor. Therefore, the 
focus of interest has shifted towards targeting directly the VSMC cell cycle where all 
mitogenic stimuli come together 3. Simultaneously, cytotoxic effects should be avoided 
because this again would elicit an inflammatory process rather than contribute to healing 
of the vessel.   
 Gene therapy 
Another strategy envisages gene therapies such as e.g. antisense RNA to silence genes 
essential for VSMC proliferation 77. This is a field of intensive investigations because the 
last decade has seen immense advances in gene therapy strategies and gene vector 
technology. Hence researchers aim to treat a diverse number of diseases with such 
strategies. For vascular pathologies gene therapies are expected to exert local and 
transient actions with minimal side-effects 78. Possible targets range from classical cell 
cycle targets such as Rb and p21 to signalling molecules such as caldesmon 77, 79. 
Another important issue for the development of gene therapies is the mode of vector 
delivery. Because the liver takes up very efficiently systemically administered vectors, 
cardiovascular gene therapeutic strategies are limited to local delivery. This is mostly 
achieved by directly coating the inserted stent with the vector 77. In a pig model stable 
expression of green fluorescent protein (GFP) in the vasculature has been shown over a 
4-week period using a fibronectin-coated stent platform 80. 
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 Pharmacological inhibitors – drug eluting stents 
The most used strategy to inhibit VSMC proliferation after angioplasty is the use of 
pharmacological inhibitors and the delivery via drug eluting stents (DES). There are a 
number of DES on the market but they all target only 3 different proteins, namely mTOR, 
calcineurin and tubulin.  
 
The Akt target mTOR, a serine/ threonine kinase is involved in cell cycle regulation at 
different levels. It integrates both intracellular and extracellular signals and regulates a 
variety of essential biological processes, such as cell proliferation and survival. Therefore 
it is not surprising that the knock out is embryonic lethal. Interestingly it exerts different 
physiological functions when bound to different proteins. The best-studied mTOR 
downstream effectors are S6K1 (p70 ribosomal protein S6 kinase 1) and 4EBP1 (eIF4E 
binding protein 1). Their phosphorylation by mTOR releases them from inhibitory factors 
and subsequently leads to enhanced cell growth by enhancing protein translation. Cells 
overexpressing mTOR often are larger in size (hypertrophic) and gain proliferation 
advantages. Besides the involvement in atherosclerosis mTOR has been shown to be 
dysregulated in other human disorders, including obesity and diabetes as well as in many 
tumors 81. In the 1970s rapamycin (traded as Sirolimus) was isolated from Streptomyces 
hygroscopicus and later on it was shown to potently inhibit mTOR 82. In VSMC rapamycin 
potently inhibits G1/ S-phase transition 34. Additionally rapamycin shows 
immunosuppressive activity and therefore it was used to treat restenosis. Since then 
several derivatives have been placed on the market 34. 
 
Calcineurin, a protein phosphatase, induces NFAT transcription factors (nuclear factor of 
activated T cell) and is crucially involved in T-cell activation 83. Therefore the potent 
calcineurin inhibitor tacrolimus (FK506) is primarily an immunosuppressive compound but 
moreover also limits VSMC proliferation 84. Tacrolimus and its derivatives in use 
(Pimecrolimus) complex with intracellular factors (immunophilins) and then bind to and 
thereby inhibit calcineurin 83. Among the NFAT target genes are mainly proinflammatory 
cytokines such as IL-4 and IL-5 85. However, it was also demonstrated that the calcineurin 
pathway in VSMC is required for the maintenance of a normal VSMC phenotype 86. 
Therefore the use of tacrolimus could implicate dedifferentiation of VSMC.  
 
Finally stents coated with a stabiliser of microtubules, Paclitaxel (taxol), are in use. 
Microtubule-paclitaxel complexes can not disassemble anymore and normal cellular 
functions such as disassembly of the mitotic spindle apparatus are blocked. Therefore 
paclitaxel leads to a mitotic arrest in VSMC 87. An advantage of this compound is its 
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hydrophobicity that allows it to be fixed to tissue elements, thus most likely leading to 
prolonged tissue residence 88. However, arresting cells in M-phase of the cell cycle often 
leads to apoptosis and excessive apoptosis in the stented area is not beneficial. Therefore 
compounds that stop early cell cycle progression are preferable. 
 
All currently marketed DES show side effects on endothelial cells and evidence is growing 
that several patients develop late-stent-thrombosis 34. Therefore it is still searched for new 
drug candidates that interfere with VSMC proliferation and migration. As highlighted in 
section 2.2.4 the ideal stent-coating agent is most probably not a single compound but 
rather a mixture of anti-proliferative/ antimigratory compounds and endothelium-protective 
factors. Future DES should allow re- endothelialisation without neointima formation 26, 34.   
Cell Migration 
 Basics of cell migration 
Cell migration is an important process during development and life of multicellular 
organisms. It is essential for embryonic development for tissue formation and remodelling 
but also for immune responses and wound healing. Cell migration requires complex and 
orchestrated rearrangements within the cell but also precise sensing of, and orientation 
within the environment 89. Inappropriate cellular migration is involved in several diseases 
including chronic inflammatory disorders, tumour formation and metastasis and 
atherosclerosis as well as restenosis 90.  
 
Directed migration requires a gradient of either a chemoattractant or a repellent and a cell 
that is able to sense the gradient and then actively move towards or against it. The 
process therefore needs first of all extracellular signals and receptor mechanisms (Fig.5A). 
Upon sensing the cell needs to be asymmetrically polarized, to detach from its 
surrounding and form protrusions towards direction of migration (Fig.5B). This requires 
fundamental reorganisation within the intracellular cytoskeleton as well as breakdown of 
extracellular associations. Subsequently the front part of the cell (leading edge) is 
attached to the substrate and the cell is contracted leading to the movement of the whole 
cell body. Simultaneously the rear part detaches from the substrate (Fig.5C, D). Migration 
can therefore be seen as a cyclic process of detachment, formation of protrusions, 
contraction and re-attachment 89, 91. However in fast migrating cells such as neutrophils it 
is not possible to observe the distinct stages separately and they do not develop strong 
cell-matrix interactions during migration but it rather looks like they were gliding over the 
substrate (amoeboid motility). Also it should be noted that migration in vitro obviously 
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differs from migration in vivo where it is much more directed with cells forming longer and 
more stable prolongations 89. 
 
Fig.5. Cell migration. (A) 
Upon sensing of an 
extracellular signal the cell 
becomes polarised. 
(B)Thereupon the 
cytoskeleton is rearranged 
and protrusions are formed. 
(C) The cell attaches at the 
leading edge to the substrate 
and the rear section of the 
cell detaches. (D) Next the 
cell contracts and the cell 
body is moved forward. (E) 
The cycle is repeated until the 
cell reached its final 
destination.  
 
 
 
 
 
 
 Cytoarchitecture 
The central role in migration is played by the cytoskeleton that is made up of three types 
of filaments: microfilaments (or actin filaments), intermediate filaments and microtubules. 
The reorganisation of the cytoskeleton is conducted by a whole machinery of enzymes 
positioning, breaking down and building up these complex networks.  
 
Micro- or actin filaments are composed of two intertwined actin chains approximately 8 nm 
in diameter. They are most concentrated beneath the cellular membrane and responsible 
for resisting tension and keeping the cell’s shape (Fig.5A). Together with myosin they are 
important for muscular contraction and cytoplasmic streaming. The term intermediate 
filaments (about 10 nm in diameter) denominates a group of chemical diverse structures 
namely vimentin, keratin, lamin and neurofilaments. They all play similar roles in the cell 
as they function in the maintenance of cell-shape by organizing the internal three-
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dimensional structure of a cell and anchoring organelles. Lamin for example builds up the 
nuclear envelope. Finally the cytoskeleton is formed also by microtubules that are hollow 
cylinders commonly built of 13 protofilaments which are in turn polymers of α-tubulin and 
β-tubulin. They are about 25 nm in diameter and can reach up to 25 µm in length. The 
microtubules are anchoring and transporting membranous organelles, are responsible for 
intracellular vesicle traffic and also confer stability to the cell. They are positioned and 
organised by MTOCs (microtubule-organisation centres) such as the centrosome and are 
located within the inner parts of the cell (Fig.5A) 92. Among the three elements of the 
cytoskeleton only actin and intermediate filaments become associated with cell–cell and 
cell–matrix junctions 93. 
 Migration step by step 
 The cytoskeleton  
The actin cytoskeleton is the main cellular engine that connects complex signal cascades 
downstream of receptors such as the PDGFR with cell migration 94. The positioning as 
well as assembly and disassembly of single actin filaments and functional higher-order 
networks is regulated by a panel of actin-binding proteins (ABP) such as integrins or 
vinculin. Up to now more than 70 families of ABPs have been identified, comprising more 
than 250 different proteins 95. These ABPs are essential for migration because actin 
filaments on their own would be ineffective and their usefulness depends on linkage 
between each other and to other cell components such as microtubules or the cell 
membrane 96.  
 
An important feature of actin filaments but also of microtubules is their intrinsic polarity 
that results from head-to-tail association of different protein subunits. This is the molecular 
basis that allows for polarisation of the cell which is mainly built up by rearranging of actin 
filaments and maintained by microtubules and also needs extensive crosstalk between the 
two systems 97. Moreover both types of filaments are dynamic structures that can either 
polymerise or depolymerise and the net growth is depending on the concentration of free 
subunits. All three characteristics of actin filaments and microtubules their polarity, the 
dynamic structure and the interaction with each other are the basis of cell migration 97. 
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 Polarisation  
When a cell is exposed to a distinct migratory stimulus the cell either initiates directed 
movements or simply changes from a resting into a more motile or chemokinetic 
phenotype. A directed migratory response requires a gradient of the stimulus that can be 
either soluble (chemotactic stimulus) or be found in the substrate itself as for example 
matrix components or surface markers on surrounding cells (haptotactic stimulus) 89. The 
corresponding receptors themselves are usually equally distributed over the cell surface. 
Therefore the signalling response needs to convert the extracellular signal into 
intracellular polarity. For this reason the receptors are generally more or less loosely 
associated with or located in the proximity of the cytoskeleton. Such hotspots of signalling 
often comprise integrins and several different types of membrane bound receptors and 
are called focal adhesions because here cells are also anchored to the extracellular matrix 
91.  
 Cellular adhesions  
Adhesions to the substrate at the front part stabilise protrusions and serve as traction 
points for movement of the whole cell body 89. They are built up or broken down in 
response to extracellular cues but the molecular mechanisms underlying the decision of 
where and when to assemble or disassemble such adhesions remain unclear so far. 
Integrins and their interaction with the actin cytoskeleton play a role as well as Rho 
GTPases or the extracellular cleavage of adhesion components by proteases but we are 
far from understanding these complex events 91. 
 Signalling cascades  
Since most of the receptors for chemo- or haptotactic stimuli are recruiting the PI3K one of 
the first results of receptor activation is the local conversion of membrane 
phosphatidylinositol to phosphatidylinositol-3-phosphat (PIP3). This asymmetric 
accumulation of PIP3 in turn leads to the local activation of members of the Rho family of 
small GTPases (Rac, RhoA, cdc42) and consequently to the polymerisation of actin. The 
localisation of small GTPases is a key event in polarisation and cells lacking cdc42 are 
unable to respond to chemotactic stimuli anymore. The process of actin polymerisation 
begins with a nucleation event where either complexes made of Arp2/3 (actin-related 
protein 2/3) or of formins (mDia1/2) determine the starting point 91. Nucleation is favoured 
by PIP2 because it frees actin from the inhibitory capping protein gelsolin 98. Arp 
complexes are regulated by WASP, a molecule downstream of Rac and cdc42, and bind 
to existing actin filaments where they promote the growth of a branch at an angle of 70°. 
The formin complexes in contrast are regulated by cdc42 and RhoA and bind to actin 
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filaments promoting their linear extension 91. The single actin monomeric subunits (G-actin) 
assemble into long filaments (F-actin) and two of those each form the actin filament. The 
addition of each monomer is ATP dependent and makes migration a costly process for a 
cell. The assembly of actin filaments is controlled by different capping enzymes that bind 
to growing filaments and either stabilise or destabilise them. Additionally these enzymes 
control the availability of activated actin monomers. The polymerisation of actin and its 
interaction with myosin (actomyosin-based contraction) pushes the cell forward into the 
direction of migration 89. These contraction events are again regulated by small GTPases. 
Cdc42 as well as RhoA promote contraction while Rac mediates relaxation 91. 
 
Many signalling cascades are involved in regulating cell migration and it is not possible to 
mention all of them. It is out of question that most of them employ small GTPases and 
influence the cytoskeleton in one way or the other.  
 Cytoskeletal rearrangements  
After establishing the cell polarity by actin reorganisation the microtubule network plays a 
pivotal role in maintaining it. Again small GTPases are essential for positioning the 
MTOCs that in turn control the placement and movement of organelles e.g. the nucleus 91. 
Microtubules are anchored with their minus-end to the MTOCs and constantly growing 
and shrinking at the plus-end until they are captured and stabilised at target destinations. 
During migration, this search-and-capture of microtubules leads to reorganisation of the 
microtubule network because in a polarised cell the microtubules are selectively stabilised 
at the cell cortex of the leading edge. The molecular mechanism underlying the capture of 
microtubules by cortical molecules is not clear. However, not surprisingly the small 
GTPases cdc42 and Rac are discussed to be involved. Interestingly, it has been shown 
that microtubules often seem to be guided through the cell and grow right in the direction 
of adhesion sites. Since this is also true in cells lacking intermediate filaments, it is most 
likely the actin cytoskeleton that is assisting the microtubule guidance. This is again 
underlining the importance of crosstalk and interaction between these two cytoskeletal 
systems. As it is true for the actin filaments, also the polymerisation and depolymerisation 
of microtubules is controlled by a huge number of different proteins, so called MAPs 
(microtubule-associated proteins)  99. 
 
While the cell is moving forward it is necessary that the cytoskeleton is not only 
rearranged at the leading but also at the rear edge of a cell (Fig.5C). Therefore adhesions 
need to be broken down, actin filaments have to be depolymerised and cross-links need 
to be loosened 91. Also the rear edge has to be contracted and moved forward which is 
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conducted again by actin and myosin and controlled by RhoA 99. Parts of the membrane, 
rich in adhesion molecules, are endocytosed. Moreover, some of the connections are 
simply cleaved by e.g. metalloproteinases (MMPs) and the binding affinity of some 
adhesion molecules is reduced by modifications such as dephosphorylation. Again small 
GTPases but also calcium dependent enzymes such as calcineurin are important for rear 
edge retraction 91.  
 
Finally it should also be noted that during migration a lot of intracellular trafficking is 
required. Old components are released from the rear edge and are transported to the 
leading edge wherefore the cytoskeleton is used as ‘rail track’. Migration is a very complex 
process challenging the whole cell and a huge number of proteins are involved in its tight 
regulation 89. 
VSMC Migration and the role of PDGF 
Because migration is a pivotal factor in the pathology of atherosclerosis and restenosis 
the migration of VSMC is intensively investigated. But VSMC migration is not only a 
hallmark of disease but is also necessary during vascular development. A lot of signalling 
cascades and effectors of VSMC migration have been identified during the last years but 
still a lot of open questions remain 36. 
 
As it is true for other cell types, the central role in VSMC migration plays the cytoskeleton 
and cellular polarisation in response to distinct stimuli. Furthermore, next to reorganisation 
of the actin cytoskeleton and the activation of actomyosin motors migrating VSMC also 
remodel their microtubule network. Therefore it is not surprising that the tubulin stabiliser 
paclitaxel that is used for stent coating (see 2.5.2.4 ) also inhibits VSMC migration 100. 
However detailed studies addressing signalling cascades and microtubules in VSMC 
migration are missing 98. 
 Migratory stimuli for VSMC  
A panel of growth factors (PDGF, bFGF, IGF-1, VEGF) and cytokines (IL-1, IL-6, TNFα) 
as well as single components of the extracellular matrix (collagen I, IV, VIII, fibronectin, 
laminin and others) which are released at the sites of lesions have been linked to VSMC 
migration. Up to now more than 25 different stimuli for VSMC have been identified 98. In a 
healthy vessel wall VSMC are nonmigratory not only because of the lack of promigratory 
stimuli but also because of the presence of antimigratory signals. These include soluble 
factors as cytokines or the presence of stable focal adhesions with the surrounding, low 
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amount of metalloproteinases or higher levels of inhibitors of the latter (tissue inhibitors of 
metalloproteinases, TIMPs). 
 
VSMC do not only respond to soluble factors but can also move along a gradient of 
varying adhesiveness due to different components of the ECM (haptotaxis). This is mostly 
mediated by integrins and associated signalling events 98. Moreover physical factors such 
as shear stress can influence VSMC migration. Among the various chemotactic factors, 
PDGF-BB has been shown to strongly influence neointima formation and is the most 
potent chemoattractant for VSMC in vitro. Moreover gene targeted mice for PDGF or 
PDGFR do not develop normal blood vessels. However, the exact signalling cascades 
mediating the migratory response to PDGF-BB or other chemotactic factors in VSMC are 
not completely understood 36. The migration of VSMC in vivo is determined by complex 
processes through multiple interacting signal transduction pathways and needs the 
integration of both soluble signals and changes in matrix attachment. The experimental 
approaches of this study were focused on PDGF-BB signalling.  
 Signalling cascades involved in PDGF-BB-induced VSMC 
migration 
Like other moving cells VSMC build different kinds of protrusions during migration, very 
thin and long ones called filopodia and broader ones called lamellipodia. This requires the 
reorganisation of the cytoskeleton as already highlighted in a previous chapter. The 
subsequent polymerisation of the actin cytoskeleton is controlled by ABPs that are largely 
dependent on the small GTPases Rac, RhoA and cdc42 as well as on calcium release or 
the accumulation of PIP2. PDGF-BB binding to PDGFRβ leads to the activation of the 
three GTPases. Moreover, PLC is activated and hence it comes to PIP2 accumulation and 
furthermore calcium release as depicted in Fig.6. Thereupon nucleation events take place 
mediated by formins and Arp2/3 complexes and new actin filaments are formed (as 
described in 2.6.1).  
 Small GTPases in PDGF-BB-induced VSMC migration 
There are many reports on Rac-1 in VSMC and its role for migration in response to 
different stimuli including PDGF-BB. Both Rac and Cdc42 activate members of the PAK 
kinase family (p21 activated protein kinase) (Fig.6). Depending on cofactors and context, 
PAKs can either stabilise or destabilise actin as well as microtubules. However, in VSMC 
the expression of dominant negative PAK potently inhibits migration and PAKs seem to be 
essential for the formation of lamellipodia 98. Moreover Rac and cdc42 activate WAVE and 
WASP, respectively thereby causing nucleation and hence the formation of new actin 
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filaments. Cdc42 has been shown to be important for the formation of filopodia 101. RhoA 
has been shown to activate ROCK1/2 in VSMC and the inhibition of ROCK also leads to 
impaired migration. ROCK itself influences on the one hand directly the activity of myosin 
motors and it is found to be important for the formation of stress fibres and focal 
adhesions on the other hand (Fig.6). ROCK activates a kinase that is also found in VSMC 
that counteracts actin depolymerisation 101. 
 STAT3 signalling in PDGF-BB-induced VSMC migration 
STAT3 is another immediate early protein that has been implicated in VSMC migration 
upon PDGF-BB as well as thrombin stimulation 102, 103. It has been clearly shown to be 
phosphorylated upon PDGF stimulation but concerning the kinase responsible for this 
event the data available are contradictory. A number of groups demonstrated an 
involvement of JAK using siRNA as well as chemical inhibitors and also in a cell free 
system the activation of STAT3 by PDGF could be blocked by JAK2 blocking antibodies 
103-107. In addition to JAK, Src contributes to STAT3 activation and accordingly STAT3 
activity has been reported to be elevated in cells expressing activated Src and abrogated 
in cells expressing dominant-negative Src 108, 109. It is also possible that both types of 
kinases, Src family members as well as JAKs play a role or even act together in 
phosphorylating STAT3.  
 
It is out of question that inhibition of STAT3 activation or downregulation of STAT3 itself 
clearly showed a strong inhibitory effect on VSMC proliferation. This is not surprising 
because STAT3 binds to and activates the cyclin D1 as well as the c-myc promoter and is 
responsible for the expression of several more proliferative proteins 103, 105. However, the 
connection between STAT3 and migration in VSMC is less clear. It has been shown that 
the cytosolic phospholipase A, a target gene of STAT3 is essential for migration because 
it produces lipid second messengers that mediate migration 105.  
 
STAT3 has also been shown to be important for the migration of cancer cells and 
fibroblasts 110-112. For fibroblasts it is speculated that STAT3 influences RhoA driven stress 
fibre formation 112. In studies using carcinoma cells it was suggested that STAT3 target 
genes such as VASP are responsible for its promigratory actions 111.  
 
All together the data available support an important role of STAT3 in VSMC migration, but 
more investigations are needed to clarify how exactly it is involved. A final interesting point 
is that the activation of different STATs by PDGF was found to be significantly inhibited by 
antioxidants indicating that ROS production contributes to STAT activation in response to 
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PDGF 113. Considering the contribution of oxidative stress in the pathology of vascular 
diseases this should be kept in mind. 
 Other signalling cascades in PDGF-BB-induced VSMC migration 
Calcium release via the PLC/PKC axis (Fig.6) plays a role in VSMC migration, too. It leads 
to the activation of myosin motors and therefore to contraction and moreover stabilises 
actin filaments. Accordingly in migrating VSMC oscillating calcium levels have been 
reported 98.  
 
 
Fig.6. PDGF signalling and migration. Upon PDGF binding to its receptor a number of 
signalling cascades are activated. The key regulators of early migratory signalling are the small 
GTPases Rac, cdc42 and RhoA. They in turn activate effector proteins that lead to the formation of 
protrusions such as lamellipodia and filopodia or intracellular structures like stress fibres. 
Furthermore PLC as well as Src kinase are activated leading to calcium release and STAT3 
activation, respectively. Also JAK2 has been implicated in STAT3 activation. For abbreviations see 
section 8.1. 
 
Moreover Src kinases, the PI3K as well as MAPK have been shown to act on VSMC 
migration. Many of the migratory stimuli known for VSMC lead to MAPK activation. 
However, inhibition of single components of the pathways had not such strong effects on 
migration as inhibition of other signalling pathways. ERK as well as p38 inhibition have 
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been shown to stop VSMC migration but other reports demonstrated the opposite 74, 101, 114. 
It is suggested that ERK activates myosin motors but since many factors do so, a lack of 
ERK would most likely be compensated. Whether PI3K inhibition interferes with VSMC 
migration is depending on the stimulus used. Where effects have been observed it has 
been attributed to impaired microtubule remodelling. PDGF-BB induced migration is not 
sensitive to PI3K inhibition. Different members of the Src kinase family are expressed in 
VSMC (Src, Fyn, Yes and Lyn) and have been implicated in migration of the cells. 
Inhibition of Src impairs VSMC migration most likely at multiple levels because it is 
involved in FAK activation (see below), Rac activation and provides a link to STAT as well 
as ERK MAPK signalling 101.  
 
Finally it should be noted that PDGF not only acts immediately on migration but also leads 
to the expression of other migratory stimuli (such as EGF or FGF-2) and proteins that are 
later on involved in migration such as the cytosolic phospholipase A 98.  
 Focal adhesions in VSMC migration 
The building and breakdown of focal contacts with the ECM are important during migration. 
These contacts are less rigid than stable adhesions of nonmigrating cells and are also 
called nascent adhesions. In VSMC the components of complexes mediating the local 
adhesion to the substrate contain the focal adhesion kinase (FAK), vinculin, paxillin, tensin, 
Src and p130. The FAK is a central molecule in these complexes serving as docking site 
or platform for many different partners but also actively contributing to signalling through 
its kinase activity. The FAK itself is regulated through multiple tyrosine phosphorylations 
and it has been found to be upregulated in intimal hyperplasia. PDGF-BB treatment of 
VSMC in vitro leads to a robust activation of FAK especially if the cells are grown on 
fibronectin 115. Although the importance of FAK and associated complexes in VSMC 
migration has been known for some time, the spatial and temporal regulation of its 
assembly is still not clear. In other cell types it has been demonstrated that formation of 
nascent contacts requires ligation and subsequent clustering of integrins, phosphorylation 
of distinct proteins and an intact cortical actin network. Once formed the local contacts 
serve as traction points for contraction accomplished by actomyosin motors. In VSMC all 
components necessary for these processes are present but the details of how they are 
regulated in health and disease are not known 98. However this is a field of active research, 
and it has been shown recently that cells growing on different amounts of ECM display 
different activity of myosin motors and altered traction forces 116. 
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Roscovitine and derivatives 
 The history and development of roscovitine 
In the early nineties Laurent Mejier and his group screened different purines for protein 
kinase inhibitors using enzyme-based assays. They reported a widely used plant hormone 
(cytokinin) isopentenyladenine to be a CDK inhibitor. Furthermore they showed a growth-
limiting activity on starfish oocytes (Fig.7) 117. However it turned out to be a rather 
unspecific general kinase inhibitor and moreover the IC50 for CDK1 was with 45 µM quite 
high (Table II) 118. Further screening of available isopentenyladenine analogues for CDK 
inhibition identified a commercially available antagonist of a plant cytokinin 
glucosyltransferase later on called olomoucine (Fig.7). It showed first a much lower IC50 
for CDK1 (7 µM) and second an unexpected selectivity for CDK1/2/5/7/9 without affecting 
CDK4/6 but still inhibited some other families of protein kinases as well, e.g. MAPKs 
(Table II) 117. A follow-up structure-activity study revealed that 2,6,9-trisubstituted purines 
show the highest activity and selectivity for CDKs 119. Soon afterwards the first crystal 
structures of CDK2 with purine inhibitors, namely with isopentenyladenine and olomoucine 
were published, showing that both bind within the ATP binding pocket 120. All these 
findings were especially interesting because they clearly contradicted the dogma that it is 
not possible to achieve selectivity for protein kinases with inhibitors that compete for ATP 
binding due to the conserved structure of ATP binding pockets in general 117. Olomoucine, 
however, was found to also bind and inhibit the MAPK ERK. It was co-crystallized with this 
kinase but in an enzyme-based kinase assay it showed a much higher IC50 value for ERK 
(30 µM) than for CDKs (3-10 µM, see Table II) 117, 121, 122.  Further screening of 2,6,9-
trisubstituted purines then led to the development of several other more effective 
analogues of olomoucine. After extensive testings investigators focused on roscovitine 
(ROSC) that was first introduced in 1996 and has been characterised as even more 
selective inhibitor of CDK 1,2 and 5 (Fig.7, Table II) 123, 124.  
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Fig.7. Chemical structures of Isopentylalanine, Roscovitine, Olomoucine and the ROSC-
derivatives LGR1406, LGR1406 and LGR1492. Olomoucine (2-hydroxyethylamino-6-
benzylamino-9-methylpurine) as well as ROSC (2-(R)-(1-ethyl-2-hydroxyethylamino)-6-
Benzylamino-9-isopropyl-purine) and its derivatives LGR1406 (N-5-(2-Aminocyclohexyl)-N-7-
benzyl-3-isopropyl-1(2)H-pyrazolo[4,3-d]pyrimidine-5,7-di-amine)), LGR1407 (N-5-(4-
Aminocyclohexyl)-N-7-benzyl-3-isopropyl-1(2)H-pyrazolo[4,3-d]pyrimidine-5,7-di-amine)), LGR1492 
(N-5-(1-ethyl-2-hydroxyethylamino)-N-7-(1-amino-2-benzyl)-3-isopropyl-1(2)H-pyrazolo [4,3-d] 
pyrimidine-5,7-di-amine))  carry a benzylamino-group at the C6 atom of the purine-ring or purine-
like ring structure. Olomoucine differs structurally from ROSC and LGR1406 by carrying a 
methylgroup instead of an isopropyl group at the C9 atom of the purinering. ROSC and its 
derivatives first differ in the ring structure itself. LGR1406, LGR1407 and LGR1492 have a 
pyrazolo-4,3-pyrimidine-5,7-di-amine ring as structural basis instead of a purine-ring. Furthermore 
LGR1406 and LGR1407 differ structurally from ROSC at their side chains at the C2 position where 
ROSC shows an ethyl and a hydroxymethyl group whereas the derivatives show a 2’-amino-
cyclohexane ring. 
 
 Selectivity of roscovitine 
Out of 150 kinases tested ROSC inhibits almost exclusively CDKs 117. However, ROSC, 
like olomoucine, is not solely acting on CDKs but also inhibited ERK in enzyme-based 
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assays. Moreover it was co-crystallized not only with CDK2 but also with a kinase involved 
in vitamin B6 metabolism (pyridoxalkinase, PDXK) 125, 126. Additionally it should be noted 
that for some kinase assays published, ROSC was used in 10 µM as maximal 
concentration. Therefore it still might be that it also inhibits some other kinases with higher 
IC50s 127.  
 
 
Table II. IC50 values obtained from enzyme-based kinase assays on roscovitine, 
olomoucine and isopentenyladenine 119, 127, 128 
 
 Today’s and future use of roscovitine 
Today ROSC is widely used in cell culture experiments to inhibit CDKs but also for cell 
synchronisation during cloning procedures for e.g. cattles, horses and pigs 129-131. As 
blocking CDK activity seems to be a promising target to combat pathological cell 
proliferation, it is not surprising that research focused on the development as an anti-
cancer drug. ROSC is marketed as Seliciclib or CYC202 and is in phase II clinical trials 
against breast cancer 132. However, ROSC shows a rather high IC50 value concerning its 
antiproliferative activity (about 25 µM depending on cell type) and therefore several 
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groups work on the development of better analogues. Recently some publications 
introduced new ROSC-derivatives, exerting even stronger anti-cancer effects 133, 134. 
 Literature on roscovitine 
ROSC has been studied in a panel of different cell types but most of the studies focus on 
cancer cell lines. When searching the Pubmed data base in March 2009 for original 
research articles using ROSC (or Seliciclib, CYC202) within the title about 60 out of 150 
articles deal with cancer. In 33 publications other cell types were investigated and another 
20 describe mechanistic studies or provide data about metabolism of ROSC (Table III). 
The remaining articles deal with inhibition of viral replication (nine) or use ROSC for 
ameliorating cloning strategies (30). Although some publications on non-cancer cells are 
available, the number of different cell types investigated is limited because most of these 
papers deal with either proliferative/ inflammatory renal diseases (nine) or neuronal cells 
(15). The last nine articles out of this group cover fibroblasts, keratinocytes, macrophages 
and tobacco cells. A single publication investigated the influence of ROSC on VSMC. It 
should be noted that ROSC is mentioned in a huge number of publications (a pubmed 
search for ROSC gives out 625 articles) where it is used as ‘specific’ inhibitor of CDKs in 
control experiments. 
 
 
Table III. Pubmed search for roscovitine/ Seliciclib or CYC202 mentioned within the 
title, March 2009 
 
 Roscovitine and cancer 
In cancer cells ROSC either leads to apoptosis or elicits G2/ M arrest 132. Depending on 
the cell type and experimental conditions the IC50s of ROSC for growth inhibition vary from 
8-40 µM. The majority of publications report an IC50 of about 20 µM for growth inhibition 
but in many cells this concentration already leads to apoptosis. Therefore the right 
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concentration has to be determined for each cell type. In human colon cancer cells ROSC 
treatment led to a moderate increase in G2/M phase, decreased both retinoblastoma 
protein phosphorylation and total retinoblastoma protein but increased the 
phosphorylation of ERK1/2. However, the latter did not contribute to the cell cycle effects 
of the drug. Furthermore a clear reduction in cyclins D1, A, and B1 mRNA and a reduced 
expression of cyclin D1 that was independent of the p38 and PI3K pathways were 
observed. Also a loss of RNA polymerase II phosphorylation as well as total RNA 
polymerase II protein was reported suggesting that ROSC was inhibiting transcription, 
possibly via inhibition of CDK7 and CDK9 complexes 135. In human breast cancer cells 
ROSC leads to a G2 arrests and concomitantly induces apoptosis. The induction of 
apoptosis was explained by the stabilization and activation of p53 protein through 
phosphorylation at Ser-46 which in turn initiates caspase-independent apoptosis 136. This 
is especially interesting because a lot of breast cancer cell lines lack caspase-3 137. But 
other studies suggested CDK5 to be the molecular target of ROSC-triggered apoptosis of 
highly invasive breast cancer cells 138, 139. On the other hand an upregulation of p53 was 
not only found in ROSC-treated breast cancer cells but also in cervix cancer cells (HeLa 
cell line) 140. All together it is so far not clear how exactly ROSC elicits apoptosis and most 
likely this has to be investigated separately for each cell type. The effects on cell cycle 
distribution, however, can easily be explained by CDK inhibition but it is not clear why 
ROSC preferentially leads to G2/M and not to G1 arrest as it most potently inhibits CDK2 
not CDK1 (Table II, Fig.4).  
 Roscovitine and other cell types 
As already mentioned the influence of ROSC has not only been studied in cancer cells but 
also in other cell types. Jhou et al. found that ROSC limits growth and diminishes nitric 
oxide production as well as cytokine gene expression in lipopolysaccharide-stimulated 
macrophages. They suggest that ROSC-induced cell cycle arrest is capable of reducing 
pro-inflammatory responses via down-regulation of NF-kappaB 141. In normal human 
fibroblasts ROSC induced a dose-dependent arrest in G1 phase accompanied by a 
significant reduction of hyperphosphorylated retinoblastoma protein and CDK2 activity 
whereas levels of cyclin D1, and cyclin E were not affected 142. ROSC also inhibited 
proliferation of human epidermal keratinocytes in a dose-dependent manner and at higher 
concentrations it induced apoptosis evidenced by caspase-3 activation 143. Moreover one 
group showed antiproliferative effects of ROSC on VSMC and claimed that ERK inhibition 
is responsible but there are some major concerns about this paper that will be discussed 
later on (section 5.1) 144. An additional publication used ROSC with VSMC but did not 
focus on mechanistic questions and just used it as control 145. It can be concluded that the 
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few data available on non-cancer cells show that ROSC also inhibits proliferation of 
normal cells and suggest that this is also mainly due to CDK inhibition. 
 
Besides its growth limiting activity a couple of publications showed that ROSC additionally 
exerts effects on calcium and potassium channels 146. For example Ganapathi et al. 
showed that ROSC inhibits distinct potassium channels that act as a delayed rectifier in 
cardiac myocytes 147. Moreover it has been reported that ROSC impairs L-type calcium 
channel activity and has in this regard been suggested for the treatment of  cardiac 
arrhythmias and hypertension 148. But ROSC not only affects cardiac channels but 
additionally slows down deactivation of neuronal calcium channels and therefore could 
cause side effects 149. 
 Roscovitine derivatives 
ROSC shows a rather high IC50 for growth inhibition and there are concerns about side 
targets as e.g. ERK MAPK, therefore more effective and specific derivatives should be 
developed. As already mentioned recently new ROSC-derivatives have been introduced. 
In cooperation with Prof. Strnad (Olomouc, Czech Republic) new ROSC-derivatives have 
been synthesized. These differ from ROSC in the purine structure itself as well as 
regarding their side chains. The purine rings of ROSC have been replaced by a pyrazolo-
pyrimidine structure (for depicted structures see Fig.7). In addition some of the derivatives 
possess an aminocyclohexyl-group instead of an ethyl-2-hydroxyethylamino group.  
 
In conclusion ROSC has been extensively studied in cancer cells and there are also a lot 
of data available on its metabolism and pharmacokinetics. Because of its growth-limiting 
activity ROSC could be a promising compound for stent coating. However, its effects 
seem to be cell type specific and conclusive studies on its action on VSMC are missing.  
Indirubine-3’-monoxime 
 Source and traditional use 
Indirubin-3'-monoxime (I3MO) is a derivative of indirubin which is an active component 
from a recipe of traditional chinese medicine called Danggui Longhui Wan used for the 
treatment of various diseases in particular chronic myelogenous leukaemia but also as 
antiinflammatory drug 150. The red-coloured indirubin is found in indigo naturalis (Qing Dai), 
a powder obtained from the leaves of several plants of various genera including Indigofera 
tinctoria (Fabaceae) or Isatis indigotica (Brassicaceae) 151. However, the major constituent 
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of indigo naturalis is not indirubin (3,2’-bisindole) but its dark blue 2,2’-isomer indigo 
(Fig.8).  
 
Fig.8. Chemical structures of indirubin-3’-monoxime, indirubin, indigo and its precursor 
molecules indican and isatan B. The precursor molecules indican and isatan are enzymatically 
cleaved or undergo hydrolysis and the resulting substances indoxyl and isatin dimerize to form 
indigo, isoindigo and indirubin, respectively. Indirubin-3’-monoxime is a common synthetic 
derivative of  indirubin (figure is adopted from  157) 
 
Although it is only a minor by-product, the biological actions of Qing Dai have been 
attributed to indirubin. Both compounds are not found in fresh leaves but are converted by 
enzymatic or acidic lysis and consequent dimerisation of colourless precursor substances 
(indican, isatan B, Fig.8) 152, 153. Interestingly indigo as well as indirubin have been also 
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found in various molluscs and bacteria and in human urine where it seems to be a by-
product of tryptophan catabolism 154. As indirubin itself displays a low aqueous solubility 
and absorption and furthermore leads to gastrointestinal toxicity, a huge number of 
derivatives have been introduced during the last years. These include halogenated and 
alkylated indirubins or indirubin-N'-glycosides 155, 156. Among those derivatives indirubin-3’-
monoxime (I3MO) is the best characterised and most widely used and is one of the few 
commercially available derivatives (Fig.8)154. 
 Cellular effects of I3MO 
Indirubin is known to exert anti-cancer function by either inducing G2/M-arrest or 
apoptosis. The latter was shown for a variety of different types of human cancer cell lines 
such as cervical cancer, leukaemia, laryngeal carcinoma, hepatoma and colon cancer 
cells 150, 158. But also anti-apoptotic effects have been demonstrated in cerebellar granule 
neurons 159. Furthermore indirubin inhibited inflammatory reactions of murine splenocytes  
and in a mouse model of delayed-type hypersensitivity 160. Moreover I3MO has been 
reported to be effective against replication of wild-type and drug-resistant strains of HIV-1 
161. All together there have been a number of biological activities contributed to indirubin 
(and derivatives) many of which seem to be cell type specific 162. 
 Molecular targets of I3MO 
The molecular mechanism of action is, however, not completely understood so far. Also it 
seems that indirubin has probably more than one single target in a cell or that the targets 
differ between cell types and/or species. In in vitro kinase assays it has been shown to 
inhibit GSK-3, CDK1/5, AMPK, LCK and SGK and it is commercially marketed as GSK3 
and CDK inhibitor 163-165. Also in cell based assays it has been demonstrated that I3MO 
inhibits CDKs 166, glycogen synthase kinase-3β (GSK-3β) 166, JNK 159, Src 167 and FGFR1 
autophosphorylation 168 and furthermore suppresses activation of nuclear factor-kappa B 
(NF-κB) 169 as well as STAT3 167. But next to these inhibitory effects I3MO activates the 
co-transcriptional factor aryl hydrocarbon receptor (AhR) 170 as well as p38 MAPK 168. 
Moreover the induction of apoptosis in cancer cells has been shown to be mediated 
through the activation of caspase-3 and caspase-7 171.  
 
Cell cycle arrest observed upon indirubin treatment can easily be contributed to CDK 
inhibition but some investigators state different mechanisms. For example Zhen et al. 
claim that inhibition of myeloid leukaemia cell proliferation by I3MO is solely due to 
inhibition of FGFR1 autophosphorylation 168. Sethi et al. on the other hand suggest that 
anti-cancer and anti-inflammatory activities of indirubin may be at least in part mediated 
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through the suppression of the NF- B activation because they observed inhibition of 
activation of IκBα kinase in several cancer cell lines 169. The antiinflammatory activity of 
I3MO could also be explained by the binding to AhR. AhR plays a role in proliferation and 
differentiation during development, is involved in the recognition and response to antigenic 
substances and can down-regulate inflammatory responses 170. The anti-apoptotic effects 
on cerebellar granule neurons have been linked exclusively to JNK inhibition because 
other inhibitors of CDKs and GSK-3β were ineffective. In macrophages, however, I3MO 
had not the same effect as well established JNK inhibitors 159, 172.  
 
Concerning the inhibition of cancer cell growth by I3MO also STAT3 was suggested to 
play an important role at least in breast and prostate cancer cells 167. This idea is further 
supported by the fact that STAT3 is constitutively active in many tumor cells and is 
activated by the oncogenic kinase Src 173. Nam et al. demonstrated that different indirubin 
derivatives inhibited Src activity and the expression of anti-apoptotic target genes of 
STAT3 173. 
 
Summarising, I3MO exerts various effects on different cell types and directly or indirectly 
affects a number of proteins. But although several targets have been identified in in vitro 
assays the direct link between cellular effects and molecular targets is often missing. 
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Aims of the study 
 Characterisation of Roscovitine derivatives for anti-
proliferative effects in VSMC  
 
Within the framework of the EU project ‘Pro-Kinase-Research’ we were looking for new 
anti-atherogenic compounds. We focused on CDKs and other protein kinases as potential 
drug targets. Preliminary screens had revealed that several ROSC-derivatives could limit 
the growth of rat aortic VSMC. As discussed in chapter 2.8 ROSC is known to act as a 
CDK inhibitor 123, but most of the publications only show in vitro data and there are only 
two publications mentioning effects on VSMC 144, 145. None of them solved the mechanism 
of action of ROSC satisfyingly. We therefore wanted to investigate the mode of action of 
Roscovitine and promising derivatives in PDGF-stimulated VSMC and define the changes 
in cell signaling. We planed to examine the effect of Roscovitine and its derivatives on 
mitogen activated kinases, cell cycle parameters and the effect on VSMC migration 
towards PDGF. As discussed in section 2.2.1 an ideal antiatherogenic compound should 
impair both proliferation and migration of VSMC.  
 Influence of Indirubine-3’-monoxime on VSMC migration  
 
In her PhD Thesis Andrea Schwaiberger 154 showed that I3MO potently inhibited PDGF-
BB-induced VSMC cell cycle progression (Fig.9). More precisely she showed that I3MO 
reversibly inhibited PDGF-induced VSMC cell cycle progression in a concentration-
dependent manner, leading to a G0/G1-phase arrest. Accordingly, a reduction in Rb 
hyperphosphorylation was found. However, effects on cyclin D1 levels were inconclusive. 
Furthermore it was demonstrated that I3MO impaired PDGFR autophosphorylation on a 
residue essential for tyrosine kinase activity and specifically inhibited the activation of 
STAT1/3/5/6 without affecting other common early signalling pathways (p38, ERK, Akt) 
(Fig.9). The work further focused on STAT3 and showed that I3MO inhibited the activation 
and subsequent nuclear accumulation of this transcription factor. Due to these results it 
was suggested that the effect on STAT3 may be at least partially responsible for the 
antiproliferative activity of I3MO. Additionally, Andrea Schwaiberger showed that the effect 
on STAT3 was stimulus-independent since I3MO prevented phosphorylation of STAT3 in 
response to IFN-γ as well as H2O2. Moreover, an antioxidative effect of I3MO was 
demonstrated because it attenuated the PDGF-induced generation of ROS indicating an 
impact on redox-regulated signal transduction in VSMC (Fig.9). Furthermore it was shown 
that I3MO attenuated neointimal hyperplasia in an experimental animal model (mouse 
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femoral cuff-model, in cooperation with Prof. Dr. Binder, Medical University, Vienna). The 
studies indicated that I3MO is a promising compound for e.g. stent coating but left some 
open questions regarding its molecular target(s). As both proliferation and migration 
contribute to neointima-formation we not only wanted to further investigate the underlying 
molecular mechanism of the antiproliferative effect of I3MO but also its potential to 
influence PDGF-BB-induced migration of VSMC. 
 
Fig.9. Molecular actions of I3MO in the context of PDGF-induced signal transduction and 
proliferation as shown by Andrea Schwaiberger, PhD thesis 2008 (figure is adopted from 154) 
I3MO slightly inhibits PDGF-BB-induced autophosphorylation of the PDGFRβ and strongly impairs 
the ROS generation caused by PDGF-BB stimulation. The treatment of VSMC with I3MO 
completely abrogates the phosphorylation of STAT1/3/5/6 upon PDGF-BB stimulation as well as 
the translocation of STAT3 to the nucleus. For abbreviations see section 8.1. 
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Materials 
Unless noted otherwise all cell culture reagents and media were obtained from Lonza 
Group Ltd. (Basel, Switzerland) and all other reagents from Carl Roth (Karlsruhe, 
Germany). Trypsin, collagenase II and HAM’s F-12 medium were purchased from 
Invitrogen (Carlsbad, CA, USA) and DMSO from Fluka (Buchs, Switzerland). Roscovitine 
was obtained from Calbiochem (La Jolla, CA, USA) and recombinant human PDGF-BB 
from Bachem (Weil am Rhein, Germany). Laurent Mejier (CNRS, Roscoff, France) kindly 
provided indirubine-3’-monoxime and Miroslav Strnad (Laboratory of Growth Regulators, 
Olomouc, Czech Republic) kindly provided the Roscovitine derivatives. 
 
 
Table IV. Chemical inhibitors used for the study. 
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Cell Culture 
 Buffers and solutions 
PBS-Phosphate buffered saline: 
123 mM NaCl, 12.3 mM Na2HPO4, 3.2 mM KH2PO4, pH 7.4 
PBS+: 
137 mM NaCl, 9.6 mM Na2HPO4, 1.5 mM KH2PO4, 0.5 mM MgCl2 x 6 ddH2O, 0.5 mM 
CaCl2 x 2 ddH2O pH 7.4 
Trypsin/ EDTA: 
0.05% Trypsin, 0.02% EDTA 
Standard medium: 
DMEM supplemented with 2 mM L-glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin, 
10% calf serum 
Starvation medium: 
DMEM supplemented with 2 mM L-glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin, 
0.1% calf serum 
Freezing medium: 
DMEM supplemented with 2 mM L-glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin, 
30% calf serum, 10% DMSO 
Digestions buffer: 
HAM’s F12 medium supplemented with 253 U/ml collagenase II, 10 mM HEPES, 0.28 mM 
ascorbic acid, 0.1% BSA 
 Isolation of rat aortic VSMC 
VSMC employed in this study originate from two independent isolations from rat thoracic 
aortas of 3 sibling Sprague-Dawley rats each. Aortas were washed in PBS+, detached 
from surrounding fat tissue, cut open and incubated with digestion buffer for 15 min at 
37°C. Aortas were thoroughly cleaned from surrounding tissue, washed with digestion 
buffer, cut into small pieces and incubated for 3 h in digestion buffer at 37°C. After 
centrifugation for 10 min at 230xg the supernatant was discarded and cells were 
incubated with standard medium in a humidified incubator at 37°C, in the presence of 5% 
CO2. Purity of VSMC cultures was checked by immunostaining of α-smooth muscle actin 
with a FITC-labled antibody. Early passages (3-6) were frozen in liquid nitrogen. 
 Smooth muscle alpha actin staining 
Cells were seeded at a density of 0,2 x 106/ well on to coverslips  in 12-well plates for 24 h 
and washed once with ice-cold PBS. Cells were fixed with 1 ml of 1:1 acetone/ MeOH for 
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15 min on ice and washed twice with ice-cold PBS. Coverslips were incubated with 20 µl 
of antibody solution (SMA-antibody 1:250 in PBS supplemented with 1% of BSA) for 60 
min in a dark and humified chamber at 4 °C. Afterwards the coverslips were washed twice 
with PBS and mounted on a glass slide using mounting medium (Sigma Aldrich, MO, 
USA). After drying overnight in the dark the specimens were analysed using a 
fluorescence microscope (Olympus BX51, Olympus Europe GmbH, Hamburg, Germany) 
and cell imaging software (cell^F software, Europe GmbH, Hamburg, Germany). 
 Culture of VSMC 
VSMC were cultured in a humidified incubator at 37°C, 5 CO2 using standard medium. For 
passaging the cells were washed once with PBS and incubated with trypsin/ EDTA for 3-5 
min at 37 °C. The reaction was stopped using standard medium and cells were 
centrifuged for 4 min at 1400 rpm (373 x g). Cells were  counted with a trypan-blue 
staining based cell viability analyser (VicellTM XR, Beckman Coulter, Fullerton, CA, USA), 
seeded at the indicated density and after 24 h serum-starved for another 24 h prior to all 
experiments. Passages 6-14 were used. 
 Storage of VSMC 
Cells were frozen in aliquots of 1 x 106 cells each in liquid nitrogen using freezing medium 
and the following freezing protocol. Cells were kept at 4 °C for 20 min, afterwards at -
20 °C for 24 h and at -80 °C for 2-3 days and were then kept in liquid nitrogen. For 
thawing cells were put into 15 ml of standard medium, centrifuged for 4 min at 1400 rpm 
(373 g) and put again into fresh standard medium.  
Protein extracts 
 Buffers and solutions 
Lysis buffer: 
50 mM HEPES, 50 mM NaCl, 50 mM NaF, 10 mM Na4P2O7x10H2O, 5 mM EDTA, pH 7.5  
prior to usage complemented with 1% Triton X, 1x completeTM and 1 mM PMSF (0.1 M 
stock diluted in isopropanol)  
3xSDS sample buffer: 
0.1875 M Tris HCl pH 6.8, 0.2 M SDS, 3% Glycerol, 0.2 mM Bromophenol blue with 15% 
2-Mercaptoethanol 
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 Protein isolation 
VSMC were seeded into 60 mm dishes (1 x 106 cells/dish), serum-starved, pretreated with 
test drugs or vehicle (DMSO 1%) for 30 min and subsequently stimulated with PDGF-BB 
(20 ng/ml). Cells were washed with ice-cold PBS, incubated with lysis buffer for 10 min at 
4°C and centrifuged for 10 min, 16,000xg at 4 °C. Supernatants were mixed with 3xSDS 
sample buffer and heated to 95 °C for 5 min.  
 Measurement of protein concentration (Bradford) 
The assay is based on the shift of the absorbance maximum of Commassie Brilliant Blue 
G-250 from 470 nm to 595 nm when binding to basic or aromatic amino acids. Therefore 
the absorbance at 595 nm is a measure for protein concentration (after Bradford 174). 
Protein concentration was determined using Rotiquant© reagent according to 
manufacturer’s instructions (Carl Roth, Karlsruhe, Germany). Briefly Rotiquant reagent 
was diluted 1:4.75 with ddH2O and aliquots of protein samples were diluted 1:10. In a 96 
well plate 190 µl of diluted Rotiquant were mixed with 10 µl of diluted protein sample and 
optical density at 595 nm was determined using a 96-well plate reader (TECAN SunriseTM). 
The measurements were performed in triplicate and for quantification a linear calibration 
curve was determined using different concentrations of BSA (50 – 500 µg/ml). 
Rac-1 activity assay 
Rac-1 belongs to the protein family of small GTPases and is therefore active when bound 
to GTP. Only GTP-bound Rac-1 is able to bind to the p21-binding domain (PBD) found in 
p21-activated protein kinase (PAK). The assay is based on binding of active Rac-1 to 
PAK-PBD domains coupled to agarose beads. We used a commercially available kit 
including PAK-PBD-agarose beads, lysis buffer and a monoclonal antibody against Rac-1 
(Cell Biolabs, San Diego, CA, USA).  
VSMC were seeded into 60 mm dishes (1 x 106 cells/dish), serum-starved, pretreated with 
test drugs or vehicle (DMSO 1%) for 30 min and subsequently stimulated with PDGF-BB 
(20 ng/ml) for 3 min. Samples were processed in the 4 °C room. Cells were washed with 
ice-cold PBS, incubated with lysis buffer for 1 min at 4°C and immediately added to 20 µl 
of PAK-PBD-agarose beads. The samples were incubated on a rotator at 4 °C for 45 min. 
Samples were centrifuged for 10 min, 16,000xg at 4 °C and washed three times with lysis 
buffer. Supernatants were discarded and the beads were mixed with 40 µl of 3xSDS 
sample buffer and heated to 95 °C for 5 min. Samples were subjected to a standard 
western blotting procedure (see section 3.5.). 
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SDS page and western blotting 
 Buffers and solutions 
Stacking gel: 
5% final conc. of PAA (stock solution: 30% polyacrylamid, 0.8% bisacrylamid), 125 mM 
Tris HCl pH 6.8, 0.1% SDS, freshly prepared and just prior to usage complemented with 
0.1% TEMED and 0.05% APS. 
Resolution gel: 
7,5-12% final conc. of PAA (stock solution: 30% polyacrylamid, 0.8% bisacrylamid), 375 
mM Tris HCl pH 8.8, 0.1% SDS, freshly prepared and just prior to usage complemented 
with 0.1% TEMED and 0.05% APS. 
Electrophoresis buffer (10x): 
250 mM Tris base, 1,92 M Glycine, 35 mM SDS  
Blotting buffer (5x): 
125 mM Tris base, 0,97 M Glycine 
prior to usage diluted 1:5 with ddH2O and complemented with 20% Methanol 
TBS-T (10x): 
25 mM Tris base, 190 mM NaCl, 0,1% Tween-20 (add after pH adjustment), pH 8.0  
Home made ECL: 
0.1 M Tris base pH 8.5, 1.25 mM luminol (250 mM stock solution in DMSO), 0.2 mM p-
coumaric acid (91 mM stock solution in DMSO) freshly prepared and just prior to usage 
complemented with 0.009% H2O2 (30% stock) 
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 Antibodies 
 
Table V. Antibodies used for the study. 
 Procedure 
Stacking and resolution gels were poured into gel chambers (Biorad Laboratories, 
Hercules, CA, USA) and after loading samples and prestained protein marker (Precision 
Plus Protein Standard, Laboratories, Hercules, CA, USA) put into electrophoresis 
chambers filled with electrophoresis buffer (Mini-ProteanTM, Biorad Laboratories, Hercules, 
CA, USA). SDS page was run at constant voltage of 80 V for 20 min and at 120 V until the 
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loading dye front reached the bottom of the chamber. For blotting, gels were put onto 
Immun-BlotTM PVDF membranes (Biorad Laboratories, Hercules, CA, USA) covered with 
filter paper (Whatman plc, Kent, UK) and placed into gel holder cassettes (Mini-Trans-
BlotTM, Biorad Laboratories, Hercules, CA, USA). The cassettes were put into cooled 
blotting chambers and run at constant current of 110 mA/ gel for 120 min. Membranes 
were washed three times with TBS-T for 10 min, blocked with 5% milk powder in TBS-T 
for 60 min and incubated with primary antibody-solutions (in 2% BSA in TBS-T) overnight 
at 4 °C. Membranes were washed three times with TBS-T for 10 min, incubated with 
secondary antibody-solutions (in TBS-T) and washed again three times with TBS-T for 5 
min. For detection, home made ECL was prepared freshly and added to the membranes 
which were incubated for 3-5 min prior to signal detection with a luminescent image 
analyser (LAS-3000TM, Fujifilm, Tokyo, Japan). 
Viability measurement – trypan blue  
VSMC were seeded into 6 well plates (0.5 x 106 cells/ well), serum-starved, pretreated 
with test compounds or vehicle (DMSO 1%) for 30 min and subsequently stimulated with 
PDGF-BB (20 ng/ml). After 24-48 h cells were trypsinized with 300 µl trypsin/ EDTA and 
the reaction was stopped using 1 ml of standard medium. Cells were centrifuged and the 
pellet was dissolved in 600 µl of standard medium. Cell viability and number were 
evaluated with a trypan-blue staining based cell viability analyser (VicellTM XR, Beckman 
Coulter, Fullerton, CA, USA). Measurement parameters were the following: min. diameter 
5 µM; max. diameter 35 µM; cell sharpness: 75; cell brightness: 85; viability spot 
brightness: 70%; viability spot area: 5%, at least 300 cells have been counted for each 
measurement. 
Propidium iodide staining and flow cytometry 
Cell cycle distribution of VSMC was determined after propidium iodide (PI) staining 
according to Riccardi and Nicoletti 175. The assay is based on the different amount of DNA 
during each cell cycle phase and the binding of propidium iodide to double stranded DNA. 
When excited by laser light (488 nm), propidium iodide can be detected with 562-588 nm 
filters. Therefore the intensity of fluorescence at 588 nm is a measure for DNA 
concentration and doubles from G1 to G2 phase ().  
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Fig.10. Propidium staining. The flow cytometer determines the fluorescence intensity of 10,000 
single cells. The histogram shows an example of cycling VSMC. Since the fluorescence intensity is 
proportional to the amount of DNA in a single cell it can be concluded that cells within the ‘M3’ gate 
have the double amount of DNA compared to cells within the ‘M1’ gate. Therefore ‘M1’ reflects 
cells in G1 phase with a single copy of the genome, ‘M3’ depicts diploid cells in G2/M phase and 
‘M2’ includes the cells in S-phase with an intermediate DNA content. Cells that have less than a 
single copy of the genome are found in ‘M4’ (also called sub-G1) and are generally thought to 
reflect dead or dying cells because they obviously lost DNA material. 
 
VSMC were seeded into 12 well plates (1 x 105 cells/ well), serum-starved, pretreated with 
test compounds or vehicle (DMSO 1%) for 30 min and subsequently stimulated with 
PDGF-BB (20 ng/ml). After 8-28 h cells were trypsinized, fixed with cold HFS buffer (0.1% 
(w/v), sodium citrate 0.1% (v/v) Triton X-100 in PBS) containing 50 µg/ml PI and incubated 
for 2 h at 4 °C.  10,000 cells were analysed by flow cytometry on a FACSCaliburTM (BD 
Bioscience Pharmingen, San Diego, CA, USA). 
 
FACS buffer: 
139 mM NaCl, 20 mM Na2HPO4, 2 mM KH2PO4, 3.8 mM KCl, 10 mM LiCl, 3.1 mM 
NaN3, 1 mM Na2EDTA, pH 7.4 
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Crystal violet staining 
The assay is based on binding of crystal violet to DNA, therefore staining cell nuclei. The 
optical density can be measured at 595 nm. Therefore the absorbance at 595 nm is a 
measure for cell density in the well.  
VSMC were seeded into 96 well plates (2 x 104 cells/ well), serum-starved, pretreated with 
test compounds or vehicle (DMSO 1%) for 30 min prior to stimulation with PDGF-BB (20 
ng/ml). After 48 h cells were extensively washed with PBS, immediately fixed and stained 
with crystal violet staining solution (0.5% (m/v) crystal violet in 20% MeOH) for 15 min at 
room temperature. Plates were washed, dried and the dye was re-solubilised in 
ethanol/sodium citrate solution (50% (v/v) sodium citrate in ethanol). Optical density was 
determined using a 96-well plate reader (TECAN SunriseTM, Mannedorf, Switzerland). 
5-Bromo-2-deoxyuridine (BrdU) assay 
As a measurement of DNA synthesis BrdU incorporation was determined using a cell 
proliferation kit (Roche Diagnostics, Basel, Switzerland). The assay is based on 
incorporation of the thymidine-analogue 5-bromo-2-deoxyuridine (BrdU) during DNA 
synthesis. BrdU can be detected using a monoclonal antibody coupled to horse radish 
peroxidase (HRP) which oxidises luminol and thereby emits blue light. The luminescence 
is a measure for the amount of incorporated BrdU and therefore DNA synthesis.  
VSMC were seeded into black 96 well plates (2 x 104 cells/ well), serum-starved for two 
days (with two PBS-washing steps and change of starvation medium every day), 
pretreated with test compounds or vehicle (DMSO 1%) for 30 min and subsequently 
stimulated with PDGF-BB (20 ng/ml). After 4 h BrdU (10 µM) was added and cells were 
further cultivated for 20 h. Afterwards cells were fixed and stained with an enzyme-
coupled anti-BrdU antibody according to the manufacturer’s instructions. Relative light 
units (RLU) were determined using a 96-well plate reader (TECAN GENios ProTM, 
Mannedorf, Switzerland).  
In vitro kinase assay 
The kinase assays were performed by Friedrich Totzke and Michael Kubbutat (ProQinase 
GmbH, Freiburg, Germany). 
The kinases were expressed as human recombinant GST or His-tagged fusion proteins in 
Sf6 insect cells and purified using GSH-agarose columns (Sigma Aldrich) or NiNTH-
agarose columns (Qiagen AG, Hilden, Germany). In vitro kinase assays were done in 96 
well flash platesTM (Perkin Elmer/NEN, Boston, MA, USA) in 50 µl reaction volumes (60 
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mM HEPES-NaOH pH 7.3, 3 mM MgCl2, 3 mM MnCl2, 3 µM Natriumorthovanadate, 1.2 
mM DTT, 50 µg/ml PEG20000, 1 µM [γ-33P] ATP (~ 6.5 x 105 cpm/well), 10% compound 
solution). LGR1406 dissolved in 10% DMSO was added in serial dilutions from 1 nM to 10 
mM. For substrates and kinases used see Table VI. The plates were incubated at 30°C for 
80 min and the reaction was stopped with 50 µl of 2% (v/v) H3PO4. Plates were aspirated, 
washed two times with 200 µl ddH2O and incorporation of 33Pi was determined with a 
microplate scintillation counter (microbeta, Wallac). Assays were done in duplicates and 
performed with a Beckman Coulter/Segian robotic system. The residual activities for each 
concentration and the IC50 values were calculated using Quattro Workflow V2.0.2.2. 
(Quattro Research GmbH, Munich, Germany).  
 
Table VI. Substrates and kinases used for Prokinase kinase assays 
Migration assays 
 Transwell migration assay 
For this assay cells were seeded into cell culture inserts containing a membrane with 8 
µM pore size (BD Bioscience Pharmingen, San Diego, CA, USA) which were placed into 
medium-filled 24 well plates. We used collagen I coated cell culture inserts to enhance 
and fasten the attachment of cells to the membrane. The pore size of 8 µM prohibits 
dropping of the VSMC (average diameter 13 µM) to the bottom well. Therefore cells have 
to actively migrate from the insert through the membrane to reach the bottom well. Cells 
were stained using the fluorescent dye calcein, also known as fluorescein. In living cells 
the precursor molecule calcein AM (Calbiochem, La Jolla, CA, USA) is converted by an 
intracellular esterase to calcein which displays fluorescent properties with an excitation 
and emission wavelength of 495/ 515nm. The assay was modified from De Gendt et al 176. 
Prior to usage cell culture inserts were coated with 150 µl of a 150 µg/ml rat collagen I 
solution in 0.02 N acetic acid (BD Bioscience Pharmingen, San Diego, CA, USA) 
overnight at 4 °C, thoroughly washed with PBS and dried under sterile conditions. VSMC 
 MATERIALS AND METHODS 
- 67 -  
were seeded into 100 cm2 cell culture flask (4 x 106 cells), serum starved and stained with 
8 µM calcein AM for 20 min at 37 °C and henceforward protected from light. Cells were 
trypsinized, the reaction was stopped with 2% BSA in starvation medium and after 
centrifugation for 4 min at 1400 rpm (373 g) resuspended in starvation medium. Cells 
were counted and seeded into cell culture inserts (2 x 105 cells per insert), pretreated with 
test compounds or vehicle (DMSO 1%) for 30 min and subsequently stimulated with 
PDGF-BB (10 ng/ml) for 5 h. The inserts were then placed into a PBS-containing 24 well 
plate for washing and further on into a 24 well plate with 150 µl of trypsin/ EDTA per well 
for detachment of cells. Aliquots of 50 µl of cell-solutions were pipetted into black 96 well 
plates and fluorescence was measured in a 96 well plate reader (TECAN GENios ProTM, 
Mannedorf, Switzerland) using the following parameters: excitation wavelength: 492 nm; 
emission wavelength: 535 nm; gain: 30.  
 
Fig.11. Calcein AM staining. Serum-starved VSMC were stained for 30 min with 8 µM calcein AM, 
counted and indicated numbers of cells were seeded into 96 well plates. Fluorescence was 
measured after 8 h as described in the methods section. (A) 1000-100,000 cells (B) 80-8000 cells.  
Shown are means ± SD and linear regression lines. 
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To ensure that calcein AM staining is linearly correlated to cell number and was upright 
throughout the assay until the measurement, distinct amount of cells were seeded in 
parallel into a black 96-well plate and a linear calibration curve was determined (Fig.11). 
Calcein AM staining gives a linear correlation with cell numbers from 1000 to 100,000 
cells as well as for smaller cell numbers (Fig.11B). 
 Wound healing assay 
For the wound healing or scratch assay cells were grown to a confluent monolayer, 
scratched and the area of the scratch was determined before and after PDGF-BB-
stimulation. To exclude that proliferation contributes to scratch closure the assay was 
stopped after 20 h because the VSMC used show a generation time of 26-28 h. 
Additionally the known S-phase inhibitor mitomycin C was used as control (Fig.33).  
VSMC were seeded in 6-well plates (0.8 x 106 cells/ well). To ensure that at 0 h and 20 h 
the very same area of each scratch is captured perpendicular lines were drawn at the 
bottom side of the plates. When confluence was reached after 24 h, cells were serum-
starved for 24 h, scratched with a 1000-μl pipette tip and after washing with PBS further 
serum-starved for 24 h. Cells were pretreated with test compounds or vehicle (DMSO 1%) 
for 30 min and subsequently stimulated with PDGF-BB (10 ng/ml) for 20 h. The scratch 
area was captured with a light microscope just before PDGF-treatment and 20 h later. The 
cell re-colonization rate was evaluated by measuring the cell free area of each scratch, 
using Cell Profiler software (www.cellprofiler.org, Broad Institute, Cambridge, MA, USA 94). 
Adhesion assay 
Prior to usage 96 well plates were coated with 150 µl of a 150 µg/ml rat collagen I solution 
in 0.02 N acetic acid (BD Bioscience Pharmingen, San Diego, CA, USA) overnight at 4 °C, 
thoroughly washed with PBS and dried under sterile conditions. VSMC were trypsinized 
and seeded into 96 well plates (5 x 104 cells/ well), pretreated with test compounds or 
vehicle (DMSO 1%) for 30 min and stimulated with PDGF-BB (10 ng/ml). After 3 h cells 
were washed with PBS, immediately fixed and stained with crystal violet staining solution 
(0.5% (m/v) crystal violet in 20% MeOH) for 15 min at room temperature. Plates were 
washed, dried and the dye was re-solubilised in ethanol/sodium citrate solution (50% (v/v) 
sodium citrate in ethanol). Optical density was determined using a 96-well plate reader 
(TECAN SunriseTM, Mannedorf, Switzerland). 
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Phalloidin staining 
Phalloidin belongs to the group of phallotoxins and specifically binds at the interface 
between F-actin subunits. It binds to actin filaments more tightly than to monomers and is 
widely used to stain the actin cytoskeleton of cells. For this assay we used fluorescent-
labled phalloidin to visualise the changes in the actin cytoskeleton of VSMC after PDGF-
treatment. 
 
Coverslips were coated with 350 µg/ml rat collagen I solution in 0.02 N acetic acid (BD 
Bioscience Pharmingen, San Diego, CA, USA) for 2 h at room temperature. Coverslips 
were carefully washed twice with PBS, dried under sterile conditions and stored for up to 3 
days at 4 °C. Cells were seeded at a density of 0.2 x 106 cells/ well on to collagen I coated 
coverslips in 12-well plates for 24 h. Cells were then serum-starved, pretreated with test 
compounds or vehicle (DMSO 1%) for 30 min and subsequently stimulated with PDGF-BB 
(10 ng/ml) for 1-2 h. Samples were briefly rinsed with PBS and extracted with a 
prewarmed solution of 0,25% Triton X-100, 50% glutaraldehyde in CB buffer (pH ~ 6.5-6.8) 
for 1min. Cells were postfixed with 1% glutaraldehyde in CB at room temperature for 15 
min, rinsed and washed with PBS for a few minutes. Coverslips were incubated with 20 µl 
of FITC-labled Phalloidin solution (FITC-Phalloidin 1:150 in PBS) for 30 min in a dark and 
humified chamber at room temperature. Samples were protected from light from this step 
onwards. The coverslips were washed three times with PBS for 5 min and mounted on a 
glass slide using mounting medium (Sigma, MO, USA). After drying overnight in the dark 
the specimens were analysed using a fluorescence microscope (Olympus BX51, Olympus 
Europe GmbH, Hamburg, Germany) and cell imaging software (cell^F software, Europe 
GmbH, Hamburg, Germany). 
Cytoskeleton Buffer (CB): 
150 mM NaCl, 5 mM EGTA, 5 mM MgCl2, 5 mM Glucose, 10 mM MES (2-(N-
Morpholino)-ethansulfonsäure), pH 6.1 with NaOH 
Technical equipment and software 
Cell viability analyser and cell counter Vi-CellTM XR (Beckman Coulter, Fullerton, CA, USA) 
Luminescent image analyser LAS-3000TM (Fujifilm, Tokyo, Japan) 
96-well plate reader TECAN SunriseTM  (TECAN, Mannedorf, Switzerland) 
96-well plate reader TECAN GENios ProTM (TECAN, Mannedorf, Switzerland) 
Fluorescence microscope Olympus BX51 (Olympus Europe GmbH, Hamburg, Germany) 
Analysing software: cell^F software, Europe GmbH, Hamburg, Germany). 
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Light microscope Olympus CKX31 (Olympus Europe GmbH, Hamburg, Germany) 
Camera:  Olympus Live View Digital SLR Camera E-330 (Olympus 
Europe GmbH, Hamburg, Germany) 
Analysing software:  Cellprofiler software (www.cellprofiler.org) 
Flow cytometer FACSCaliburTM (BD Bioscience Pharmingen, San Diego, CA, USA) 
Analysing software:  CellQuest™ Pro software (BD Bioscience Pharmingen, San 
Diego, CA, USA) 
Statistic software program GraphPad PRISMTM, version 4.03 (GraphPad Software Inc, 
San Diego, CA; USA) 
Cell Profiler software (www.cellprofiler.org, Broad Institute, Cambridge, MA, USA) 
 
Statistics 
All statistical analyses were calculated using GraphPad PRISMTM, version 4.03 
(GraphPad Software Inc, San Diego, CA; USA). Data are expressed as means of at least 
three independent experiments ± standard deviation (SD) or standard error (SEM). One-
way or two-way ANOVAs and Student’s t-tests were used for statistical analysis of the 
results, as indicated in the figure legends. A P-value < 0.05 was considered to be 
statistically significant. 
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Isolation and characterisation of Vascular Smooth Muscle 
Cells 
The VSMC used for this study were isolated twice independently from rat thoracic aortas 
of Sprague Dawley rats as described in the materials and methods chapter. To confirm 
the identity of VSMC and to exclude contamination with e.g. fibroblasts, cells were stained 
with a fluorescent labled α-smooth muscle actin antibody (Fig.12), a specific marker for 
smooth muscle cells in general, predominantly found in vascular smooth muscle cells 177. 
Every experiment was performed with both batches of VSMC and we could not detect any 
differences between cells of each batch or different passages used. 
A   B    
 
Fig.12. VSMC of passage 3 stained with FITC-conjugated α-smooth muscle actin antibody. A 
2000x magnification, B 400x magnification 
Roscovitine and Roscovitine-derivatives 
 Screening of Roscovitine-derivatives for anti-proliferative 
activity in VSMC 
The aim of our study was to identify out of a panel of ROSC-derivatives a potent inhibitor 
of VSMC proliferation and to characterise its molecular mechanism of action in 
comparison to ROSC itself. 
 Crystal violet staining 
To identify compounds exerting antiproliferative activity against VSMC we screened a 
panel of ROSC-derivatives using a simple crystal violet staining assay and calf serum (CS) 
as stimulus. Fig.13 shows that LGR1406, LGR1407, LGR1430 and LGR1492 dose-
dependently limited VSMC proliferation. LGR1406 and LGR1492 were giving the best 
results by significantly inhibiting VSMC proliferation already at a concentration of 10 µM. 
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Fig.13. Crystal violet staining after 24 h of serum-stimulation. Serum-starved VSMC were 
pretreated with rising concentrations (3 – 100 µM) of various ROSC-derivatives and subsequently 
stimulated with calf serum (10%). After 24 h cells were stained with crystal violet. The means of 
three independent experiments ± SEM are shown. * P<0.05, *** P<0.001 (one-way ANOVA 
followed by a Bonferroni post-test versus CS-treatment) 
 BrdU incorporation  
We next tested the four most promising substances LGR1406, LGR1407, LGR1430 and 
LGR1492 for their ability to interfere with DNA synthesis. Since CS includes multiple 
growth factors and cytokines, we wanted to use a single stimulus for further experiments. 
PDGF-BB is the most potent proliferative and migratory stimulus for VSMC. PDGF-BB 
stimulated VSMC are therefore often used to investigate the underlying molecular 
mechanisms of hyperproliferation as well as migration of VSMC. Furthermore it is widely 
accepted to use this system to screen for new antiatherogenic compounds. To 
synchronize the cells and to exclude influences of calf serum components that are present 
in the standard cultivation medium we serum-starved the cells prior to all experiments for 
24 h. 
 
As seen in Fig.14, 20 ng/ml of PDGF-BB effectively stimulated DNA synthesis after 24 h. 
All substances inhibited DNA synthesis at concentrations of 3 – 10 µM (Fig.14). As in the 
crystal violet staining assay LGR1406 showed the best result. LGR1430 showed the 
weakest inhibition at 3 µM compared to the other compounds and we therefore excluded 
this compound from further testings. 
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Fig.14. BrdU incorporation after 24 h of PDGF-BB-stimulation. Serum-starved VSMC were 
pretreated with two concentrations (3, 10 µM) of ROSC-derivatives LGR1406, LGR1407, LGR1430 
and LGR1492 and subsequently stimulated with PDGF-BB (20 ng/ml) in the presence of BrdU. 
After 24 h the incorporation of BrdU as a measure of DNA-synthesis was determined using an 
enzyme-coupled anti-BrdU antibody. The means of three independent experiments ± SEM are 
shown. n.s. not significant, ** P<0.01 (one-way ANOVA followed by a Bonferroni post-test versus 
PDGF-treatment) 
 Cell cycle progression 
As we observed a strong inhibition of PDGF-BB-induced DNA synthesis when treating 
VSMC with either LGR1406, LGR1407 or LGR1492, we further investigated whether the 
compounds could interfere with progression through G1 or S-phase of the cell cycle. 
Since VSMC usually show a generation time of about 26 h we treated the cells for 20 h 
with PDGF-BB and stained them with propidium iodide (PI) to measure the DNA content 
of single cells. Subsequent flow cytometric analysis of PDGF-BB-treated control cells 
(black bar) indeed revealed a higher percentage of cells in S- as well as in G2/M-phase 
compared to cells cultured without stimulus (white bar, Fig.15B). Furthermore we found 
that only LGR1406 potently stopped cell cycle progression at both concentrations tested 
(5, 10 µM). Most probably the cells were arrested in G1 phase, however, it should be 
noted that it is difficult to distinguish between a G1 phase arrest and a very early S phase 
arrest, with the method used. Treating VSMC with LGR1406 increased the percentage of 
cells in G1-phase from 68% of PDGF-BB-treated control cells to over 85% and therefore 
even higher as the value of starved control cells without stimulus (81%). 
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Although for the BrdU assay the differences between LGR1406 and LGR1492 were not 
striking (Fig.14) the propidium iodide-based analysis of the cell cycle revealed huge 
differences. LGR1406 potently arrests cells (presumably in G1-phase) already at a 
concentration of 5 µM whereas LGR1492 does not show such an effect even at 10 µM.  
 
LGR1492 did not reduce the number of cells in S-phase but at 10 µM slightly reduced the 
amount of cells in G2/M-phase (from 16% for PDGF-BB treated control cells to 11%). Also 
LGR1407 led to a slight accumulation of cells in G1 phase when used at 20 µM (75% 
compared to 68% for PDGF-BB treated control cells) but this was not significant and the 
level of starved control cells (81%) was never reached (Fig.15). At 20 µM LGR1407 
significantly reduced the number of cells in G2/M-phase (from 16% for PDGF-BB treated 
control cells to 7%), however, the amount of cells in S-phase was not changed (~ 13%). 
As both, LGR1407 and LGR1492 reduced the number of cells in G2/M-phase without 
affecting significantly the percentage of cells in G1- or S-phase they may just slow down 
cell cycle progression without inducing a cell cycle arrest. We therefore concluded that 
neither LGR1407 nor LGR1492 could stop cell cycle progression as potently as LGR1406.  
 
In all experiments addressing VSMC proliferation LGR1406 consistently showed the 
highest antiproliferative potency in a concentration range far below that published for the 
parental compound ROSC (about 15-30 µM, depending on cell type). Therefore we 
decided to continue our investigations using LGR1406, the most promising ROSC-
derivative we tested (for structure see Fig.7).  
  RESULTS 
- 77 -  
 
Fig.15. Cell cycle distribution after 20 h of PDGF-BB-stimulation. Serum-starved VSMC were 
pretreated with different concentrations (5 – 20 µM) of ROSC-derivatives LGR1406, LGR1407 or 
LGR1492 and subsequently stimulated with PDGF-BB (20 ng/ml) for 20 h. After 20 h the 
percentage of cells in each phase of the cell cycle was determined by flow cytometric analysis of 
PI-stained nuclei. (A) Means of three independent experiments. Overview of percentage of cells in 
each cell cycle phase (B) The single cell cycle phases are shown separately. Means ± SEM are 
shown. n.s. not significant, * P<0.05, ** P<0.01 (one-way ANOVA followed by a Dunnet post-test 
versus PDGF-treatment) 
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 Influence of LGR1406 and Roscovitine on VSMC cell cycle 
progression and cytotoxicity 
Using different assays we showed that LGR1406 potently inhibits VSMC proliferation at a 
concentration of 5 µM. In further studies we now wanted to investigate in more detail the 
influence of LGR1406 and ROSC on PDGF-BB-induced cellular responses and signalling 
in VSMC.  
 BrdU incorporation  
We, therefore, compared the influence of both compounds on PDGF-BB (20 ng/ml)-
induced DNA-synthesis using again a BrdU incorporation assay. DNA-synthesis was 
dose-dependently reduced by both compounds with LGR1406 exerting clearly a stronger 
antiproliferative activity on VSMC (IC50: 3 µM) than ROSC (IC50: 17 µM) (Fig.16). The IC50 
for ROSC is fitting well to values found in the literature (about 15-30 µM, depending on 
cell type). 
 
Fig.16. BrdU incorporation after 24 h of PDGF-BB-stimulation. Serum-starved VSMC were 
pretreated with rising concentrations of LGR1406 (0.1–20 µM), ROSC (1–100 µM) and 
subsequently stimulated with PDGF-BB (20 ng/ml) in the presence of BrdU. After 24 h the 
incorporation of BrdU as a measure of DNA synthesis was determined using an enzyme-coupled 
anti-BrdU antibody. IC50 values were calculated by sigmoidal dose-response curve fitting (variable 
slope, GraphPad Prism). The means of three independent experiments ± SEM are shown.   
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 Cytotoxicity  
A reduced BrdU-incorporation does not necessarily mean that cells stop in G1 or early S-
phase but could also indicate enhanced cell death because cells that undergo apoptosis 
or necrosis most likely do not synthesize DNA. To evaluate whether the reduction in BrdU-
incorporation (DNA synthesis) was due to diminished cell proliferation or enhanced cell 
death we next monitored changes in cell morphology over time compared to staurosporine 
as positive control 178. To reflect the situation of the BrdU assay, we serum-starved the 
cells for 24 h, preincubated for 30 min with the compounds or vehicle and stimulated cells 
with PDGF-BB (20 ng/ml). Cells treated with up to 5 µM LGR1406 and 20 µM ROSC, 
respectively, did not show any signs of apoptosis (Fig.17). In contrast, 24 or 48 h 
treatment with staurosporine (25 nM) clearly induced detachment and disintegration of 
cells.  
 
Fig.17. Microscopic pictures of LGR1406 or ROSC-treated VSMC. Serum-starved VSMC were 
pretreated for 30 min with LGR1406 (5 µM), ROSC (20 µM) or vehicle (DMSO 1%) prior to 
stimulation with PDGF-BB (20 ng/ml) for 48 h. After 0 h, 28 h and 48 h photographs were taken 
(magnification 200 x). 
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Consistently in contrast to staurosporine, the cell number of LGR1406-treated (3-10 µM) 
and ROSC-treated (15-25 µM) cells after 48 h did not fall below control as shown by 
crystal violet staining (Fig.18). Additionally trypan-blue staining of LGR1406 (3-10 µM)- 
and ROSC-treated (15-25 µM) cells showed that more than 91% of VSMC were viable 
after up to 48 h of treatment similar to vehicle-treated control cells (viability without PDGF: 
95%, viability with PDGF-BB 20 ng/ml: 91%). In contrast only 63% of the cells treated with 
10 µM of mitomycin C (MitoC) were viable. Like staurosporine, MitoC is a well-described 
agent causing apoptosis in VSMC when used in concentrations from 1-30 µM 179 (Fig.19).  
 
Fig.18. Effect of LGR1406 and ROSC on cell number. Serum-starved VSMC were pretreated for 
30 min with LGR1406 (5 µM), ROSC (20 µM) or vehicle (DMSO 1%) prior to stimulation with 
PDGF-BB (20 ng/ml) for 48 h. After 48 h attached cells were stained with crystal violet. Solubilised 
dye was spectroscopically quantified at OD 595 nm. Bars represent compiled data out of 3 
independent experiments, mean ± SEM. n.s., not significant, * P<0.05 (one way ANOVA followed 
by Dunnett post-test versus t0 control).  
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Fig.19. Trypan blue staining assay. Serum-starved VSMC were pretreated for 30 min with 
LGR1406 (3-10 µM), ROSC (15-25 µM), MitoC (10 µM) or vehicle (DMSO 1%) prior to stimulation 
with PDGF-BB (20 ng/ml) for 48 h. After 48 h cells were trypsinized and viability was determined 
using a cell viability analyser based on trypan blue staining (Vi-CellTM XR, Beckman Coulter, 
Fullerton, CA, USA). Bars represent compiled data out of 3 independent experiments, mean ± SEM. 
n.s., not significant, * P<0.05 (one way ANOVA followed by Dunnett post-test versus t0 control). 
 
Because of these initial experiments we further on used 5 µM of LGR1406 and 20 µM of 
ROSC, a widely used concentration of ROSC also in other cell types 123, 135, 143. 
 Cell cycle progression 
Earlier we showed that LGR1406-treatment clearly led to an arrest of cells (presumably in 
G1-phase) after 20 h of PDGF-BB stimulation (Fig.15). This was in agreement with the 
observation that LGR1406 limits DNA synthesis (Fig.14, Fig.16). ROSC also inhibited 
DNA synthesis, although not as potently as LGR1406 (Fig.16). Therefore we addressed 
the question whether ROSC also leads to a G1-arrest.  
 
When studies on cell cycle progression are to be performed it is better to do timerows in 
order to clearly distinguish between cell cycle arrests and changes in speed of cell cycle 
progression. Only if cells do not progress through the cell cycle for a longer period of time 
it is appropriate to speak of a cell cycle arrest. Therefore we did not analyse a single 
timepoint but performed detailed studies on cell cycle progression using propidium iodide 
staining and subsequent flow cytometric analyses.   
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Fig.20. Influence of LGR1406 and ROSC on PDGF-induced S-phase entry of VSMC. Serum-
starved VSMC were pretreated for 30 min with LGR1406 (5 µM), ROSC (20 µM) or vehicle (DMSO 
1%) and cultured in the presence or absence of PDGF (20 ng /ml). After the indicated periods of 
time the percentage of cells in S-phase was determined by flow cytometric analysis of PI-stained 
nuclei. Columns show the mean of three independent experiments ± SEM. n.s., not significant, 
*P<0.05 (two-way ANOVA followed by a Bonferroni post-test versus PDGF-treatment). 
Representative histograms for depicted timepoints are shown in Fig.21.  
 
Fig.20 and Fig.21 show the time-dependent entry into S-phase of the cell cycle of serum-
starved VSMC upon PDGF-BB stimulation in the absence or presence of LGR1406 and 
ROSC (8-28 h). In unstimulated, vehicle-treated cells no increase of cells in S-phase was 
observed over time (Fig.20, white bars). This can also be seen in the corresponding 
histograms (left column, Fig.21). PDGF-BB-stimulated cells showed a significant increase 
of cells in S-phase as early as 10 h after addition of the stimulus, indicating that the cells 
pass late G1-phase after about 6-8 h and undergo S-phase transition after 8-10 h (Fig.20, 
black bars). The increase of cells in S-phase is also nicely seen in the corresponding 
histograms (second left column, Fig.21). The percentage of cells in S-phase peaked after 
12-15 h (~ 23%) and was thereupon reduced reaching again the basal level after 28 h. 
The increase in cells in S-phase and later on in G2/M-phase was consequently 
accompanied by a decrease of cells in G1-phase (Fig.22 A). Cells reached G2/M phase 
about 18 h after PDGF-BB stimulation. The amount of cells in G2/M phase peaked after 
about 20 h and had not completely reached the basal level after 28 h. In average the 
VSMC used for our experiments underwent G1/ S-phase transition after about 10 h of 
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PDGF-BB-stimulation, finished the S-phase after about 22-24 h and completed the cell 
division after about 28 h (Fig.22 B).  
 
 
 
Fig.21. Corresponding histograms to the data shown in Fig.19 for 15- 20 h of PDGF-BB-treatment. 
The intensity of fluorescence is proportional to the DNA content of single cells. 
 
Treatment with 5 µM LGR1406 completely abrogated the PDGF-BB-induced S-phase 
entry whereas 20 µM ROSC only slightly decreased but delayed cell cycle progression by 
about 8-10 h (Fig.20, grey bars). Consistently, ROSC-treated cells also entered G2/M 
phase approximately 8 h later than control cells (Fig.22). In the corresponding histograms 
  RESULTS 
- 84 -  
already after 15 h the G1-peak is broader for the ROSC-treated cells and after 18 h 
obviously many cells started to synthesize DNA (second right column, Fig.21). 
 
Fig.22. Influence of LGR1406 and ROSC on cell cycle distribution of VSMC upon PDGF-BB 
stimulation. Serum-starved VSMC were pretreated for 30 min with LGR1406 (5 µM), ROSC (20 
µM) or vehicle (DMSO 1%) and cultured in the presence of PDGF (20 ng/ml). After the indicated 
periods of time the percentage of cells in each phase of the cell cycle was determined by flow 
cytometric analysis of PI-stained nuclei. (A) Percentage of cells in G1-phase (B) Percentage of 
cells in G2/M phase. The means of three independent experiments ± SEM are shown. *P<0.05, 
**P<0.01, ***P<0.001 (two way ANOVA followed by Bonferroni post-test versus PDGF-treatment). 
 
To confirm that ROSC does not specifically arrest VSMC in one phase of the cell cycle, 
we performed further experiments using even up to 25 µM ROSC or prolonged treatment 
for up to 48 h. We observed an accumulation of cells in G1-phase after 20 h with the 
highest concentration of 25 µM (82%) but ROSC-treated cells never reached the level of 
starved control cells (87%, see Fig.23 and Table VII). LGR1406 on the other hand 
accumulates cells in G1 phase already at 3 µM more potently than ROSC does at 25 µM.  
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Fig.23. Concentration-dependent alterations in cell cycle distribution of LGR1406 and 
ROSC-treated VSMC. Serum-starved VSMC were pretreated for 30 min with LGR1406 (3-10 µM), 
ROSC (5-25 µM) or vehicle (DMSO 1%) and cultured in the presence of PDGF (20 ng/ml). After 20 
h the percentage of cells in each phase of the cell cycle was determined by flow cytometric 
analysis of PI-stained nuclei. Shown are the means of three independent experiments. The exact 
values and SD are shown in Table VII. 
 
Table VII. Concentration-dependent alterations in cell cycle distribution of LGR1406 
and ROSC-treated VSMC 
ROSC does not lead to an arrest in S- or G2/M-phase either, since we have not observed 
an accumulation of cells in these phases of the cell cycle after 48 h (Fig.24). LGR1406 
obviously stops PDGF-BB-induced cell cycle progression when used in concentrations 
around its IC50 for inhibition of DNA synthesis (3 µM, Fig.14). ROSC, however, when used 
in the corresponding concentration (IC50 ~ 17 µM) seems only to slow down cell cycle 
progression in general rather than to stop it at a distinct point. Maybe concentrations of 
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ROSC higher than 25 µM would lead to a cell cycle arrest, but microscopical observations 
of cells treated with 30 µM indicated that higher concentrations would already lead to 
cytotoxic effects (data not shown). Therefore we conclude that LGR1406 most likely leads 
to a G1-arrest of VSMC whereas ROSC delays cell cycle progression in response to 
PDGF-BB. 
 
 
 
Fig.24. Cell cycle distribution of LGR1406 and ROSC-treated VSMC after 48 h. Serum-starved 
VSMC were pretreated for 30 min with LGR1406 (3-10 µM), ROSC (5-25 µM) or vehicle (DMSO 
1%) and cultured in the presence of PDGF (20 ng/ml). After 48 h the percentage of cells in each 
phase of the cell cycle was determined by flow cytometric analysis of PI-stained nuclei. Shown are 
the means of three independent experiments. The exact values and SD are shown in Table VII. 
 
Table VIII. Concentration-dependent alterations in cell cycle distribution of LGR1406 
and ROSC-treated VSMC 
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 Influence of LGR1406 and Roscovitine PDGF-BB-signalling 
in VSMC 
 Early PDGF-BB-induced signalling events 
As cells treated with LGR1406 seemed to arrest during G1-phase, we subsequently 
investigated whether either of the substances interferes with early signalling events 
downstream of the PDGF receptor. Using western blot analyses we could exclude any 
inhibitory influence of ROSC or LGR1406 on activation of Akt and STAT3 or 
phosphorylation of the mitogen activated kinases (MAPK) p38, ERK and JNK (Fig.25). In 
contrast, treatment with LGR1406 slightly but significantly enhanced activation of the 
MAPK p38 and ERK.  
 
Fig.25. Influence of LGR1406 and ROSC on early signalling events in PDGF-activated VSMC. 
Serum-starved VSMC were pretreated for 30 min with LGR1406 (3-10 µM), ROSC (15-25 µM) or 
vehicle (DMSO 1%) prior to stimulation with PDGF-BB (20 ng/ml) for 10 min. Total cell lysates were 
then subjected to western blot analysis for phosphorylation of p38, ERK, JNK, Akt, STAT3 and total 
α-tubulin. Representative western blots for LGR1406 5 µM and ROSC 20 µM out of at least four 
independent experiments with consistent results are shown. Graphs depict compiled data of the 
densitometrically evaluated phospho-protein/tubulin ratios. Shown are means ± SEM. ** P<0.01 *** 
P<0.001 (one-way ANOVA followed by a Bonferroni post-test versus PDGF-treatment). 
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Since previous reports implicated an interference of ROSC with MAPK activation 127, 144 we 
wanted to additionally confirm these results by using a prolonged time of preincubation 
(15 h) for ROSC as well as higher concentrations of both compounds. With concentrations 
up to 10 µM LGR1406 and 25 µM ROSC, respectively, we could not detect any negative 
impact of either of the substances on the activation of early signalling cascades (Fig.25). 
Also we observed no inhibitory effect of ROSC on the MAPK p38, ERK or JNK when 
preincubating the cells for 15 h (Fig.26).  
 
 
Fig.26. Influence of ROSC on MAPK and Akt activation after 15 h of preincubation. Serum-
starved VSMC were pretreated for 15 h with ROSC (20-25 µM) or vehicle (DMSO 1%) prior to 
stimulation with PDGF-BB (20 ng/ml) for 10 min. Total cell lysates were then subjected to western 
blot analysis for phosphorylation of p38, ERK, JNK, Akt and total α-tubulin. Western blots and 
densitometrically evaluated phospho-protein/tubulin ratios of a single experiment are shown.  
 
In conclusion, the most common immediate early signaling events downstream of the 
PDGFR were not affected by LGR1406 or ROSC.  
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 Cyclins and pocket proteins 
Because we could not detect changes in early signalling events we aimed to study 
proteins directly driving cell cycle progression. We therefore dissected the time-dependent 
changes in expression and activity-linked phosphorylation of key regulators of the cell 
cycle in VSMC upon PDGF-BB stimulation.  
 
 
Fig.27. Impact of LGR1406 and ROSC on expression levels of cyclins. Serum-starved VSMC 
were pretreated for 30 min with LGR1406 (5 µM), ROSC (20 µM) or vehicle (DMSO 1%) prior to 
stimulation with PDGF-BB (20 ng/ml) for the indicated periods of time. Total cell lysates were then 
subjected to western blot analysis for cyclin D1, A, E and α-tubulin. Representative western blots 
out of at least three independent experiments with consistent results are shown for cyclin D1 (a), 
cyclin A (b) and cyclin E (c). Graphs depict compiled data of densitometrically evaluated 
cyclin/tubulin ratios for each timepoint normalised to the respective unstimulated vehicle control. 
Shown are means ± SEM. * P<0.05, ** P<0.01, *** P<0.001 (two-way ANOVA followed by a 
Bonferroni post-test versus PDGF-treatment). 
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First we studied the expression of cyclin D1 responsible for CDK4/ 6 activation and hence 
for progression through G1-phase. In control cells cyclin D1 levels were increased starting 
from 4 h on up to 24 h after PDGF-BB stimulation reaching a peak after 8 h (Fig.27). In 
ROSC- and LGR1406-treated cells cyclin D1 levels stayed elevated until 24 h after PDGF-
BB treatment in contrast to control cells, where cyclin D1-protein levels decreased from 10 
h on. Neither ROSC- nor LGR1406-treatment did reduce but both even markedly 
increased cyclin D1 levels compared to control cells from 12 h on, confirming that there 
was no interference with early signaling events leading to cyclin D1 expression. The 
prolonged expression of the G1-phase cyclin D1 could implicate an interference with 
feedback loops during late G1/ S-phase that normally lead to the downregulation of cyclin 
D1 levels in control cells.  
 
In PDGF-BB-treated control cells the S-phase cyclin A is expressed from 15 h-24 h 
peaking at 20 h. In agreement with the flow cytometric data on S-phase entry LGR1406 
inhibited expression of cyclin A, whereas ROSC only delayed expression of the cyclin 
(Fig.27). This result confirms our assumption that LGR1406 arrests cells in G1-phase 
because we could not detect any expression of the S-phase cyclin A.  
 
Cyclin E is usually expressed during G1 to S-phase transition. However, in our 
experimental setup vehicle treated cells already displayed a high level of cyclin E that was 
only slightly increased after PDGF-BB treatment (Fig.27). Both compounds inhibited this 
slight cyclin E increase to control levels or even below. However, it remains unclear 
whether this effect, given the high basal level, contributes to the impaired cell cycle 
progression. 
 
In summary, LGR1406 and ROSC do not reduce or prevent cyclin D1 expression and 
hence do not interfere with very early events in cell cycle progression. However, both 
compounds reduce cyclin E levels but only LGR1406 prevents cyclin A expression. 
 
Activation of CDK4/6 by binding to cyclin D1 as well as CDK2 by complexing with cyclin A/ 
E leads to the hyper-phosphorylation of the pocket proteins Retinoblastoma protein (Rb) 
and p107. Indeed, both proteins are hyper-phosphorylated from late G1-phase (6-8 h) 
onwards in PDGF-BB-treated control cells (Fig.28) whereas in starved control cells the 
levels of hyper-phosphorylated pocket proteins are almost undetectable. During S-phase 
both proteins are even stronger phosphorylated. The p107 phosphorylation peaks after 15 
h and Rb phosphorylation is further increasing up to 24 h upon PDGF-BB stimulation. 
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LGR1406 treatment completely abolished even early hyper-phosphorylation of both 
proteins again supporting that LGR1406 leads to a G1-phase arrest. ROSC reduced the 
early phosphorylation of p107 and Rb but in summary again only delayed the onset of 
PDGF-BB induced pocket protein hyper-phosphorylation (Fig.28).   
 
Fig.28. Influence of LGR1406 and ROSC on phosphorylation of the pocket proteins 
Retinoblastoma protein and p107. Serum-starved VSMC were pretreated for 30 min with 
LGR1406 (5 µM), ROSC (20 µM) or vehicle (DMSO 1%) prior to stimulation with PDGF-BB (20 
ng/ml) for the indicated periods of time. Total cell lysates were then subjected to western blot 
analysis of retinoblastoma protein phosphorylation (pRbSer807+811), p107/phospho-p107 (p-p107) 
and α-tubulin. (a) Representative western blots out of at least three independent experiments with 
consistent results are shown for pRbSer807+811 and p-p107. (b, c) Graphs depict compiled data of the 
densitometrically evaluated phospho-protein/tubulin ratios for each timepoint normalised to the 
respective unstimulated vehicle control. Shown are means ± SEM. * P<0.05, ** P<0.01, *** 
P<0.001 (two-way ANOVA followed by a Bonferroni post-test versus PDGF-treatment). 
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With this detailed western blot analyses we corroborate our finding that LGR1406 
treatment leads to an arrest of VSMC in late G1-phase as it is affecting pocket protein 
phosphorylation and expression of S-phase cyclin A. ROSC, however, obviously only 
delays cell cycle progression and associated events. 
 In vitro kinase assays for LGR1406 and Roscovitine 
Altogether the studies on early signalling events, cyclin expression and pocket protein 
phosphorylation suggest that ROSC and LGR1406 directly interfere with CDK activity. We 
therefore performed in cooperation with ProQinase GmbH (Freiburg, Germany) in vitro 
kinase assays. Next to LGR1406 we included LGR1407 and LGR1492, two of the other 
ROSC-derivatives that gave promising results in the first screening experiments for 
antiproliferative activity (Fig.14, Fig.15). A panel of kinases was analysed using the 
standardised ProQinase© screening platform, that had already been used for detailed 
profiling of ROSC (Bach et al.)127. Unfortunately only for a few of the kinases that we 
tested with the ProQinase© kinase assay, the corresponding data for ROSC were 
available from Bach et al. who screened mainly different kinases. The kinases that have 
been tested for all derivatives as well as for ROSC with the ProQinase© kinase assay are 
shown in Table IX. In Table X we show the compiled data for all kinases that we tested 
with the new derivatives, including those where no data from Bach et al. were available. 
 
Table IX. In vitro kinase assays comparing ProQinase data for ROSC an derivatives 
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Table X. In vitro kinase assays-complete ProQinase data for ROSC-derivatives  
 
Our screening for antiproliferative activity of the different derivatives revealed that 
LGR1492 was a little more potent than LGR1407 but both were not as potent as LGR1406 
(Fig.13, Fig.14, Fig.15). Comparing the in vitro kinase data it is interesting that although all 
of the derivatives show similar IC50s against CDK1/2/5/6/7/9, LGR1406 and LGR1492 
additionally inhibited CDK4 (Table X). Moreover, LGR1406, the most potent compound 
shows an even lower IC50 against CDK4 than LGR1492 (15 µM for LGR1406 compared to 
22 µM for LGR1492). However, the IC50s were higher than the concentrations used for the 
cell based testings (max. 10 µM). Looking at Table X also reveals that LGR1406 has 
lower IC50s against FAK, PAK4 and RSK3 compared to the other derivatives but those 
kinases are to our knowledge not involved in cell cycle progression. Also it should be 
noted that we tested the derivatives only against a restricted panel of kinases. Since 
LGR1406 in general shows a little lower IC50s against several kinases it is possible that 
this is true for some other kinases as well and that one of those is responsible for the 
better performance of the compound in cell based assays. 
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Comparing ROSC and its most potent derivative LGR1406 it becomes clear that 
LGR1406 had overall lower IC50 values against depicted CDKs than ROSC, especially for 
CDK1 and CDK4.   
 Influence of LGR1406 and Roscovitine on PDGF-BB-
induced migration of VSMC 
As both, proliferation and migration contribute to neointima formation and PDGF-BB is not 
only the most potent proliferative but also the most effective migratory stimulus for VSMC, 
we additionally examined the influence of LGR1406 and ROSC on chemotaxis.  
 
Fig.29. Influence of LGR1406 and ROSC on PDGF-BB-induced migration. Serum-starved, 
scratched VSMC were pretreated for 30 min with LGR1406 (5 µM), ROSC (20 µM) or vehicle 
(DMSO 1%) prior to stimulation with PDGF-BB (10 ng/ml) for 20 h. Scratches were captured at 0 h 
and after 20 h and cell free areas were calculated using Cellprofiler software (www.cellprofiler.org). 
(A) Representative photographs of scratches. (B) Means of five independent experiments ± SEM. 
** P<0.01, *** P<0.001 (one-way ANOVA followed by a Bonferroni post-test versus PDGF-
treatment). 
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In contrast to the antiproliferative effect, ROSC showed a much stronger antimigratory 
potential in a scratch assay (discussed in more detail in chapter 4.3.1) than LGR1406. 
ROSC treatment is reducing the PDGF-BB-stimulated migration by 65% compared to only 
a slight inhibition of 23% observed for LGR1406 (Fig.29). Whether this inhibition is linked 
to CDKs or other side targets of these compounds still needs to be investigated. 
 
In conclusion we show that LGR1406 potently inhibits VSMC proliferation in response to 
PDGF-BB by arresting cells in G1-phase of the cell cycle. Most likely this is due to a direct 
CDK inhibition. ROSC on the other hand does lead to a delay in cell cycle progression 
without leading to a cell cycle arrest. The effect of ROSC on VSMC is most likely also due 
to direct inhibition of CDKs. Additionally ROSC limits VSMC migration in response to 
PDGF-BB much stronger than LGR1406. 
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Indirubine-3’-monoxime 
Since an antiproliferative effect of I3MO has been already shown by Andrea Schwaiberger 
154, we additionally wanted to investigate the potential influence of I3MO on PDGF-BB-
induced migration of VSMC.  
 I3MO inhibits PDGF-BB-induced migration of VSMC 
For VSMC migration assays 10 ng/ml of PDGF-BB was used instead of 20 ng/ml because 
it has been shown, that a lower amount of PDGF elicits rather a migratory response 
whereas higher concentrations cause proliferation 180. This was supported in our lab by 
Andrea Schwaiberger showing that 10 ng/ml of PDGF only slightly enhances cell number 
after 48 h whereas cells treated with 20 ng/ml clearly proliferate 154.  Additionally we 
showed that PDGF-BB from 1 ng/ml on leads to migration of VSMC reaching a significant 
peak at 10 ng/ ml (Fig.30 data partly generated by Mario Kumerz, PhD student).  
 
Fig.30. Concentration-dependent increase in PDGF-BB-induced VSMC migration. Serum-
starved, scratched VSMC were pretreated for 30 min vehicle (DMSO 1%) prior to stimulation with 
PDGF-BB (1-20 ng/ml) for 20 h. Scratches were captured at 0 h and after 20 h and cell free areas 
were calculated using Cellprofiler software (www.cellprofiler.org). Means of 3 independent 
experiments ± SEM. * P<0.05, ** P<0.01 (one-way ANOVA followed by a Bonferroni post-test 
versus PDGF-treatment). Data were in part generated by Mario Kumerz, PhD student. 
 
Therefore 10 ng/ml of PDGF-BB is a reasonable concentration to trigger VSMC migration. 
We used two different models to assess the antimigratory potential of I3MO. First we 
studied a transwell or modified Boyden-chamber model often referred to as model for 
directed migration towards a chemoattractant 176. In this assay the cells have to actively 
migrate through a membrane with a defined pore size along a PDGF-BB gradient. Fig.31 
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shows, that I3MO potently and dose-dependently inhibited PDGF-BB directed migration. 
Interestingly we found that I3MO inhibited migration within the same concentration range 
as it inhibited proliferation shown by Andrea Schwaiberger (around 3 µM).  
 
Fig.31. Influence of I3MO on PDGF-BB directed migration. Serum-starved and calcein AM 
stained VSMC were seeded into transwell cell culture inserts (pore size 8 µM), pretreated for 30 
min with I3MO (1-5 µM) or vehicle (DMSO 1%) and stimulated with PDGF-BB (10 ng/ml) for 5 h. 
Cells were trypsinized and washed of the bottom side of the inserts. Luminescence of migrated 
cells was measured in a 96-well plate reader (TECAN GENios ProTM). The means of 3 independent 
experiments ± SEM are shown. * P<0.05, *** P<0.001 (one-way ANOVA followed by a Bonferroni 
post-test versus PDGF-treatment). 
 
Additionally we employed a simpler scratch or wound healing assay, where a scratched 
cell monolayer is closed by migrating cells in the presence of PDGF-BB. Here no gradient 
of the chemoattractant is present, and therefore the model is used to assess rather 
undirected migration. Also in this assay I3MO potently inhibited migration within the same 
concentration range as in the transwell system (Fig.32).  
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Fig.32. Influence of I3MO on PDGF-BB induced migration in a wound healing assay. Serum-
starved, scratched VSMC were pretreated for 30 min with I3MO (3-5 µM) or vehicle (DMSO 1%) 
prior to stimulation with PDGF-BB (10 ng/ml) for 20 h. Scratches were captured at 0 h and after 20 
h and cell free areas were calculated using Cellprofiler software. (A) Representative photographs 
of scratches. (B) Means of 5 independent experiments ± SEM. *** P<0.001 (one-way ANOVA 
followed by a Bonferroni post-test versus PDGF-treatment). 
 
In contrast to the transwell assay where cells are seeded and immediately allowed to 
migrate, cells have to detach, migrate and reattach to the surface in the scratch assay. 
Therefore the migration is measured after 20 h in contrast to the rather short migration 
time of 5 h in the transwell assay. Although VSMC show a generation time exceeding 20 h 
(26-28 h, see Fig.22), it had to be ruled out that proliferation contributes to the closure of 
the scratch. Therefore we used Mitomycin C (MitoC), a well known antiproliferative agent, 
which is widely used to block cell division in migration assays. It is known to induce a S-
phase arrest in many different cell types by inhibiting DNA-synthesis. MitoC has been 
described to inhibit VSMC proliferation when used in doses from 1-300 nM by an arrest in 
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S-phase 179. Fig.33 shows that 100 nM of MitoC limit cell proliferation but not migration of 
PDGF-BB-stimulated VSMC. Hence our experimental setup indeed allows us to study 
exclusively cell migration not proliferation. 
 
Fig.33. Influence of Mitomycin C on PDGF-BB-induced migration and proliferation. (A) 
Serum-starved, scratched VSMC were pretreated for 30 min with 100 nM Mitomycin C or vehicle 
(DMSO 1%) prior to stimulation with PDGF-BB (10 ng/ml) for 20 h. Scratches were captured at 0 h 
and after 20 h and cell free areas were calculated using Cellprofiler software. Shown are the 
means of three independent experiments ± SEM. *** P<0.001 (one-way ANOVA followed 
Bonferroni post-test versus PDGF-treatment). (B) Serum-starved VSMC were pretreated for 30 min 
with 100 nM Mitomycin C or vehicle (DMSO 1%) and cultured in the presence of PDGF (20 ng/ml). 
After 20 h the percentage of cells in each phase of the cell cycle was determined by flow cytometric 
analysis of PI-stained nuclei. Shown are the means of three independent experiments. 
 
I3MO clearly inhibited PDGF-BB-induced VSMC migration but as impaired migration could 
at least partly be explained by impaired adhesion, we wanted to investigate whether I3MO 
would interfere with cell adhesion. For this purpose serum-starved cells were pretreated 
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with I3MO or vehicle, seeded into collagen I-coated 96-well plates and allowed to attach 
for 3 h. Afterwards the non-adherent cells were washed away and remaining cells were 
stained with crystal violet. Fig.34 shows that I3MO did not interfere with cell adhesion. 
Hence the observed antimigratory effect of I3MO is not due to its antiproliferative activity, 
or an interference with VSMC adhesion. 
 
Fig.34. Influence of I3MO on cell adhesion. Serum-starved VSMC were pretreated for 30 min 
with I3MO (1-5 µM) or vehicle (DMSO 1%), seeded into collagen I-coated 96-well plates and 
stimulated with PDGF-BB (10 ng/ml) for 3 h. Cells were stained with crystal violet and solubilised 
dye was spectroscopically quantified at OD 595 nm.  Shown are the means of 3 independent 
experiments ± SEM. 
 Influence of I3MO on Rac-1 activation  
Key molecules in early migratory signalling are the small G-proteins Rac-1, Rho and 
cdc42 (Fig.6). Rac-1 has additionally been reported to play a critical role in VSMC 
proliferation and neointima formation 181. As I3MO impairs both migration and proliferation, 
we investigated the potential influence of I3MO on Rac-1 activation by GTP pulldown 
assay. Fig.35 shows there was no such inhibition by I3MO upon PDGF-BB stimulation.  
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Fig.35. Influence of I3MO on Rac-1 activation in PDGF-activated VSMC. Serum-starved VSMC 
were pretreated for 30 min with I3MO (3-5 µM) or vehicle (DMSO 1%) prior to stimulation with 
PDGF-BB (20 ng/ml) for 4 min. Total cell lysates were then used for a Rac-1 activity assay where 
active Rac-1 is pulled down and subjected to western blot analysis. A representative western blot 
out of three independent experiments with consistent results is shown. Graph depicts compiled 
data of the densitometric evaluation. Shown are means ± SEM. n.s. not significant, *p<0.05 (paired 
t-test versus PDGF-treatment). 
 
Furthermore we wanted to investigate RhoA and cdc42 as well, but we failed to pull down 
active RhoA and found that PDGF-BB did not change the activity of cdc42 (data not 
shown, experiments done by Mario Kumerz, PhD student). 
 
In summary we found no interference of I3MO with PDGF-BB-induced small GTPase 
signalling. Other immediate early signalling events downstream of the activated PDGFR 
play a role in migration, too (as discussed in section 2.7.2). However, Andrea 
Schwaiberger had already excluded inhibitory effects of I3MO on MAPK and Akt signalling 
but had found an inhibition of STAT phosphorylation. Therefore we next asked the 
question whether the inhibitory effect of I3MO on VSMC migration is linked to STATs. 
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 I3MO inhibits STAT3 phosphorylation without affecting 
other common early signalling pathways  
As mentioned previously it has been shown in our lab that I3MO specifically inhibits 
phosphorylation of STAT1/3/5 without affecting activation of other common early signalling 
pathways downstream of the PDGF-BB receptor (p38, ERK, Akt) 154. Andrea 
Schwaiberger in her thesis stated that the antiproliferative activity of I3MO is most likely 
linked to the inhibition of STAT3. There are indeed some hints from literature suggesting 
that STAT3 also is involved in cell migration (see section 2.7.2.2). 
 
First of all we aimed to repeat the key experiment of Andrea Schwaiberger on STAT3 
phosphorylation using 10 ng/ml of PDGF-BB as used for the migration assays instead of 
20 ng/ml used by Andrea Schwaiberger (data generated by Christa Czaloun, diploma 
student 2009). PDGF-BB in this concentration also led to the activation of ERK and 
STAT3 and I3MO again completely abolished STAT3 phosphorylation even below the 
basal level without affecting ERK (Fig.36). Since STAT3 phosphorylation is enhanced 
even with the lower amount of PDGF-BB it is possible that STAT3 indeed plays a role in 
mediating the antimigratory effect of I3MO. 
 
 
Fig.36. Influence of I3MO on early signalling events in PDGF-activated VSMC. Serum-starved 
VSMC were pretreated for 30 min with I3MO (3-5 µM) or vehicle (DMSO 1%) prior to stimulation 
with PDGF-BB (10 ng/ml) for 10 min. Total cell lysates were then subjected to western blot analysis 
for phosphorylation of ERK, STAT3 and total α-tubulin. Graphs depict compiled data of the 
densitometrically evaluated phospho-protein/tubulin ratios. Shown are means of three independent 
experiments ± SEM. ***p<0.001 (one-way ANOVA followed by a Bonferroni post-test versus 
PDGF-treatment). Data were generated by Christa Czaloun, diploma student. 
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 Comparison of I3MO with chemical inhibitors of common 
signalling pathways 
 Influence on PDGF-BB-induced migration  
Since we hypothesised that STAT3 plays a role in I3MO effects, we next wanted to 
compare the antimigratory potential of I3MO to chemical inhibitors of signalling pathways 
potentially involved in the PDGF-BB-stimulated activation of STAT3.  
 
Basically there are two kinases suspected to be responsible for STAT3 phosphorylation in 
response to PDGF-BB, namely JAK2 and Src (see chapter 2.7.2.2). Therefore we wanted 
to investigate whether inhibitors of these kinases would also affect migration. In Fig.37 it 
can be seen, that the Src inhibitor SU6656 indeed inhibits migration to the same extent as 
I3MO does. For the JAK-2 inhibitor AG490 we also observed an inhibition. However, this 
was only seen using rather high concentrations (25-50 µM). However, AG490 is reported 
in the literature to be used from 10-100 µM 103, 182-184.  
 
As Andrea Schwaiberger showed that STAT3 activation was redox-dependent we 
additionally employed the general flavoprotein inhibitor DPI in the migration assay. This 
compound affects several proteins, amongst others also the Nox-family of proteins which 
is in part responsible for ROS formation in response to PDGF-BB. Again we observed an 
inhibitory effect on VSMC migration when pretreating the cells with 3 µM of DPI.  
 
In conclusion several inhibitors of STAT3 activation, namely a Src, a JAK2 and a Nox 
inhibitor showed a comparable antimigratory effect to I3MO on PDGF-BB induced 
migration of VSMC. 
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Fig.37. Influence of chemical inhibitors on PDGF-BB-induced migration in a wound healing 
assay. Serum-starved, scratched VSMC were pretreated for 30 min with I3MO (3-5 µM), DPI (3 
µM), SU6656 (2 µM), AG490 (10-50 µM) or vehicle (DMSO 1%) prior to stimulation with PDGF-BB 
(10 ng/ml) for 20 h. Scratches were captured at 0 h and after 20 h and cell free areas were 
calculated using Cellprofiler software (www.cellprofiler.org). The means of three independent 
experiments ± SEM are shown. n.s. not significant, ** P<0.01 (one-way ANOVA followed by a 
Dunnett post-test versus PDGF-treatment). 
 
As I3MO is also sold as a GSK3 inhibitor, we investigated the influence of the known 
GSK3 inhibitor LiCl on PDGF-BB induced migration (data generated by Christa Czaloun, 
diploma student) 185. Indeed LiCl at a concentration of 20 mM potently inhibits migration 
(Fig.38). This could not simply be explained by osmotic changes because the same 
concentrations of MgCl or NaCl did not lead to the same results. 
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Fig.38. Influence of LiCl, NaCl and MgCl on PDGF-BB induced migration. Serum-starved, 
scratched VSMC were pretreated for 30 min with 10 mM/ 20 mM of LiCl, NaCl or MgCl or with 
vehicle (DMSO 1%) prior to stimulation with PDGF-BB (10 ng/ml) for 22 h. Scratches were 
captured at 0 h and after 22 h, and cell free areas were calculated using Cellprofiler software 
(www.cellprofiler.org). Means of 5 independent experiments ± SEM. ** P<0.001 (one-way ANOVA 
followed by Dunnett post-test versus PDGF-treatment). Data generated by Christa Czaloun, 
diploma student. 
 
All together the data generated using chemical inhibitors on VSMC migration point in the 
direction of STAT3 inhibition. Several inhibitors of STAT3 signalling showed the same 
effects as I3MO. But an involvement of other I3MO targets as e.g. GSK3 can not be ruled 
out at this point.  
 Influence on PDGF-BB-induced phosphorylation of STAT3  
Consequently we wanted to explore whether next to the ability to inhibit migration the 
chemical inhibitors would indeed also impair STAT3 phosphorylation as I3MO does. 
Andrea Schwaiberger showed that both 2 µM SU6656 and 3 µM DPI inhibited STAT3 
phosphorylation whereas AG490 in a rather low dose (10 µM) had no influence 154.  We 
therefore repeated the experiment only for AG490 in higher concentrations (up to 50 µM). 
In Fig.39 it can be seen, that AG490 even at the highest concentration of 50 µM only 
slightly and not significantly reduces STAT3 phosphorylation (data generated by Christa 
Czaloun). This makes it not very likely that AG490 and I3MO share the very same target, 
namely JAK2. 
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LiCl did not affect STAT3 phosphorylation either (Fig.39) (data generated by Christa 
Czaloun). This was not very surprising because there are only a few articles linking GSK3 
to STAT3 and none of them investigated VSMC or PDGF signalling. Where a link has 
been shown it was attributed to a kind of platform function for GSK3 bringing together 
STAT3 and its upstream kinase 186. This function would not require GSK3 kinase activity 
which is inhibited by LiCl. 
 
Fig.39. Influence of AG490 and LiCl on STAT3 phosphorylation in PDGF-activated VSMC. 
Serum-starved VSMC were pretreated for 30 min with I3MO (5 µM), AG490 (50 µM), LiCl (20 mM) 
or vehicle (DMSO 1%) prior to stimulation with PDGF-BB (10 ng/ml) for 10 min. Total cell lysates 
were then subjected to western blot analysis for phosphorylated STAT3 and total α-tubulin. Graphs 
depict compiled data of the densitometrically evaluated phospho-protein/tubulin ratios of three 
independent experiments. The means ± SEM are shown. n.s. not significant, **p<0.01 (paired t-test 
versus PDGF-treatment). Data were generated by Christa Czaloun 
 Influence of I3MO on STAT3 target genes  
We showed that several chemical inhibitors of STAT3 signalling (DPI, SU6656, AG490) 
inhibited VSMC migration as well as STAT3 phosphorylation comparable to I3MO. As 
STAT3 is a transcription factor we next wanted to investigate the influence of I3MO on 
STAT3 target genes. STAT3 affects amongst others the expression of the cytosolic 
phospholipase A2 (cPLA2) that has been shown to be involved in PDGF-BB migration 103. 
Also it influences the expression of cyclinD1 that is important not only for cell cycle 
progression but has been reported to be involved in migration, too 187, 188.  
 
We therefore tested the ability of I3MO to interfere with cPLA2 and cyclin D1 expression 
under the same conditions used for the transwell migration assay. Consequently we used 
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freshly seeded cells and a stimulation time of 5 h. Fig.40 shows that I3MO indeed 
inhibited the expression of cPLA2 and cyclin D1 upon PDGF-BB stimulation. However, the 
induction of cPLA2 by PDGF-BB was low (about 1.5 fold). Therefore we studied longer 
timeframes (6-20 h) with standard conditions resembling the situation of the scratch assay 
(Christa Czaloun, diploma thesis). Under these conditions the induction of cPLA2 by 
PDGF-BB was a little bit stronger (about 1.7 fold). Again I3MO inhibited the PDGF-BB-
induced expression of this STAT3 target gene (data in Christa Czaloun, 2009, diploma 
thesis).  
 
Fig.40. Influence of I3MO on cPLA2 and cyclin D1 expression in PDGF-activated VSMC. 
Serum-starved VSMC were seeded freshly and subsequently pretreated for 30 min with I3MO (3 
µM) or vehicle (DMSO 1%) prior to stimulation with PDGF-BB (10 ng/ml) for 5 h. Total cell lysates 
were then subjected to western blot analysis for expression of (A) cPLA2,  (B) cyclin D1 and total 
α-tubulin. Representative western blots out of at least three independent experiments with 
consistent results are shown. Graphs depict compiled data of the densitometrically evaluated 
protein/tubulin ratios. Shown are means ± SEM. n.s. not significant, ** p<0.01 (paired t-test versus 
PDGF-treatment). 
 
In summary we showed that I3MO not only inhibits PDGF-BB-induced migration and 
phosphorylation of STAT3 but also expression of STAT3 target genes that are linked to 
migration.  
 Influence of I3MO on reorganisation of the actin 
cytoskeleton  
We showed that I3MO inhibits VSMC migration and that this effect could probably be 
linked to STAT3 or GSK3 but a link between early effects on signalling and migration was 
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still missing. To further limit the possible targets of I3MO, or to identify possible mediators 
of its effects we aimed to investigate its influence on early steps of migration. During the 
first hours of PDGF-BB activation the VSMC start to rearrange the cytoskeleton in order to 
detach from the surface and migrate. This can be visualized using the actin binding fungal 
toxin phalloidin. Already as early as 1 h upon PDGF-BB treatment actin ruffles and stress 
fibres can be observed (Fig.41). But the effects are much better visible after 2 h. I3MO 
blocks the formation of actin ruffles and seems to reduce the number of actin stress fibres 
observed in the PDGF-BB-activated VSMC. This is indicating an interference with early 
steps in cell migration.  
 
Fig.41. Influence of I3MO on rearrangement of actin cytoskeleton in PDGF-activated VSMC. 
Serum-starved VSMC were pretreated for 30 min with I3MO (3-5 µM) or vehicle (DMSO 1%) prior 
to stimulation with PDGF-BB (10 ng/ml) for the indicated periods of time. Cells were fixed and 
stained with fluorescence-labled phalloidin. Membrane ruffles and big actin fibres (stress fibres) are 
marked with arrows.  
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Later on cells also form thin protrusions (filopodia) and broader ones (lamellipodia) (data 
not shown). However, so far we did not analyse the influence of I3MO on these cellular 
rearrangements. The results shown here on cytoskeletal rearrangements are rather 
preliminary and further research with more sophisticated staining methods is needed to 
determine the exact effects of I3MO on VSMC cytoskeleton. 
 
In conclusion we report for the first time that I3MO not only inhibits PDGF-BB-induced 
proliferation but also migration of VSMC. This effect is probably linked to the specific 
inhibition of STAT3 phosphorylation exerted by I3MO. We furthermore showed that I3MO 
also inhibits the expression of STAT3 target genes that are linked to migration.  
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 Influence of LiCl on PDGF-BB induced cell cycle 
progression of VSMC 
The effect of LiCl on migration was impressive and we therefore wanted to examine 
whether the salt can also interfere with PDGF-BB-induced cell cycle progression. Indeed 
LiCl leads to an accumulation of cells in G1-phase of the cell cycle (Fig.42). Whether both 
effects of LiCl (inhibition of migration and proliferation) are due to inhibition of GSK3 or 
another target would be an interesting question to answer in future studies. Also it would 
be worthwhile to investigate whether I3MO and LiCl share the very same target as their 
effects on PDGF-BB-induced proliferation and migration of VSMC seems to be very 
similar. 
 
Fig.42. Influence of LiCl on cell cycle distribution upon PDGF-BB-stimulation. Serum-starved 
VSMC were pretreated for 30 min with 20 mM LiCl or vehicle (DMSO 1%) and cultured in the 
presence of PDGF (20 ng/ml). After 18 h the percentage of cells in each phase of the cell cycle 
was determined by flow cytometric analysis of PI-stained nuclei. The graphs show (A) an overview 
of all cell cycle phases, (B) cells in G1-phase, (C) cells in S-phase and (D) cells in G2/ M phase. 
Shown are the means of three independent experiments ± SEM, *p<0.05 (paired t-test versus 
PDGF-treatment).  
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Roscovitine and Roscovitine derivatives  
Searching for novel antiproliferative compounds acting on VSMC we investigated for the 
first time the antiproliferative effect of ROSC and its derivative LGR1406 on PDGF-BB-
mediated vascular smooth muscle proliferation. We show that both compounds inhibit 
proliferation in VSMC without affecting early signalling pathways downstream of the 
activated PDGFR (Fig.25). LGR1406 is hereby the far more potent antimitotic agent with 
an apparent IC50 of 3.0 µM in the BrdU assay compared with an IC50 of 17 µM of ROSC 
(Fig.16). A detailed molecular analysis showed that both compounds affect entry of cells 
into S-phase of the cell cycle, expression of cyclin A and E as well as phosphorylation of 
pocket proteins presumably by inhibition of CDK activity (Fig.20, Fig.27, Fig.28). But 
whereas ROSC only delayed these events at 20 µM when compared to control cells, 
LGR1406 elicited complete inhibition at 5 µM.  
 
Although ROSC has been studied extensively in different cell types for its antiproliferative 
influence there are only two publications investigating its effect on VSMC 37. Both studies 
do not provide data about ROSC and PDGF signalling, although PDGF-BB is considered 
the major proliferative stimulus for VSMC, also in pathological hyperplasia 144.  
 
However, one study uses the hypertrophic factor Angiotensin II (AngII) and identifies 
ROSC as inhibitor of ERK activity 189. Besides the distinct stimulus our study also differs in 
the treatment protocol from the work of Li et al. Whereas Li et al. pretreated their cells for 
15 h with ROSC prior to AngII stimulation, we only preincubated VSMC with ROSC and 
LGR1406 for 30 min prior to PDGF-stimulation. 15 h of preincubation with ROSC allows 
changes in protein expression pattern between treated and untreated cells that make a 
distinction between direct and indirect effects on AngII-triggered signalling rather difficult. 
Moreover, Li et al. used 30 µM of ROSC which already elicited first signs of toxicity in our 
cells. In order to rule out a common mode of action, namely inhibition of ERK activity, 
underlying our and their observation, we also pretreated our cells for 15 h or with up to 25 
µM of ROSC and 10 µM of LGR1406 and examined PDGF-mediated phosphorylation of 
ERK and other MAPK (Fig.26). Even with these altered settings we did not find a reduced 
phosphorylation of either of the kinases. Furthermore the expression of cyclin D1, a 
known target gene of ERK is not inhibited by ROSC or LGR1406 (Fig.27)145. Therefore we 
conclude that the effects on PDGF-BB-induced cell cycle progression we observed for 
ROSC and LGR1406 were not due to interference with ERK signalling.  Notably cyclin D1 
levels are even enhanced by ROSC and LGR1406 which may be due to a disturbed 
negative feedback loop between cell cycle progression and cyclin D1 expression.  
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The second study investigating ROSC and VSMC used serum as proliferative stimulus  121, 
190, 191. Here the investigators focused on differences in growth of human VSMC from 
healthy vessels and in-stent-restenosis (ISS) lesions. Since ISS-VSMC expressed high 
levels of cyclin E and A, they employed ROSC as known CDK2 inhibitor. Consistent with 
our results, ROSC led to a delayed cell cycle progression and most surprisingly ISS 
VSMC were more susceptible to ROSC treatment than those isolated from healthy 
vessels. These findings additionally highlight ROSC as an interesting lead for an anti-
restenotic therapy. They also showed that higher concentrations of ROSC (30-40 µM) led 
to reduced viability of VSMC which supports the use of lower concentrations as we did in 
our study (15-25 µM). 
 
Comparing ROSC and LGR1406 we clearly demonstrate that ROSC does not completely 
block PDGF-mediated cell cycle progression of VSMC whereas its novel derivative 
LGR1406 does. More precisely, the S-phase transition is blocked by LGR1406 but only 
delayed by ROSC. Given the similar IC50 values in vitro and thus a comparable affinity of 
both compounds for CDK2-the kinase responsible for S-phase entry-the observed distinct 
effects of ROSC and LGR1406 might be either due to differences in their ability to 
permeate cells, their chemical or metabolic stability or due to targets that might be 
affected by LG1406 in addition to CDK2. Since ROSC is currently undergoing phase-II 
clinical trials against breast cancer, there are multiple publications addressing its 
metabolism, pharmacokinetic and stability issues 190. ROSC is stable in human plasma up 
to 48 h at 0, 25 and 37 °C and insensitive to multiple freeze-thawing cycles but easily 
binds to serum albumin 192. Therefore it is likely that chemical stability in cell culture 
medium is not responsible for the weaker activity of ROSC.  
 
Recently a detailed study on ROSC metabolism in vitro and in vivo has been published 193. 
McClue et al. showed that ROSC is rapidly metabolised by rat liver microsomes, leading 
to a 50% reduction of parent compound after 90 min incubation. The major metabolite 
found was a carboxylate (PMF30-128), which has been shown to have exceedingly higher 
IC50 values against CDK1/4 than ROSC itself but only slightly lower activity against CDK2 
194, 195. McClue et al. also identified the responsible P450 proteins, namely CYP3A4 and 
CYP2B6. A panel of different P450 proteins including CYP3A4 has also been found to be 
expressed in VSMC 196. It is therefore conceivable, that in VSMC ROSC is differently or 
faster metabolised than LGR1406 and thus exerts reduced or only transient activity 
towards its CDK targets. In contrast to LGR1406 ROSC is carrying a hydroxyl group which 
is preferentially used for metabolising steps. 
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Another explanation for the different impact of ROSC and LGR1406 on PDGF-BB induced 
growth of VSMC could be the lower IC50 of LGR1406 against CDK4 (15 µM vs. > 75 µM). 
Although the IC50 value (15 µM) is higher than the concentration used for our experiments 
(5 µM) it is possible that LGR1406, at least to some extent inhibits CDK4 activity and 
hereby blocks progression through the cell cycle earlier than ROSC. This notion is 
supported to some extent by the results of kinase assays for another ROSC-derivative 
which was less potent concerning antiproliferative activity than LGR1406 but more potent 
than ROSC, namely LGR1492. LGR1492 showed with 22 µM an intermediate IC50 against 
CDK4 compared to 15 µM for LGR1406 and 75 µM for ROSC (Table II, Table X) reflecting 
the results for antiproliferative activity. Nevertheless this could not account for the fact, 
that ROSC does not completely block cell cycle progression in later CDK4-independent 
stages. 
 
Finally, an alternative reason for the differences between ROSC and LGR1406 could be 
found in the redundancy of CDKs themselves. It has been shown that in CDK2 gene 
targeted mice CDK1 can back-up for CDK2 197. As both ROSC and its major metabolite 
display higher IC50 values against CDK1 than LGR1406 it is plausible that although ROSC 
blocks CDK2, CDK1 compensates to some extent for its activity and drives cell cycle 
progression, whereas in LGR1406-treated cells CDK1 is also inhibited.  
 
It can, however, at this point not be ruled out that LGR1406 has an additional, exclusive 
and so far unknown target. For example LGR1406 strongly affects Aurora A (Aur-A) 
kinase that is not inhibited at all by ROSC. Aur-A, however, is involved only in very late 
stages of cell cycle progression and its activity peaks during the G2/ M transition where it 
is critical for proper formation of the mitotic spindle 198. It should be noted that there is a 
recent publication showing that Aurora B in a complex with survivin and mTOR regulates 
G1 to S-phase transition in T-cells by promoting Rb phosphorylation, cyclin A expression 
as well as Cdk1 and Cdk2 activity. Since Aur-A and Aur-B are structurally very similar 
(they share 71% identity in their C-terminal catalytic domain), it is likely that LGR1406 
inhibits both kinases what would have to be confirmed in future experiments 199. But there 
is no evidence yet that either of them play a role in VSMC G1 to S-phase transition 200. 
There has been another dual inhibitor of CDKs and Aurora kinases described (JNJ-
7706621) and it might be worth investigating whether this compound has similar effects on 
VSMC as LGR1406 201, 202. 
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Taken together, our data on key regulators of the cell cycle and in vitro kinase assays 
support the conclusion that LGR1406 is a more potent CDK inhibitor than ROSC. Possibly 
LGR1406 is more resistant against metabolism and/ or more prone to cross the cell 
membrane. The latter points have to be confirmed in further studies.  
 
An interesting final outcome was the observation that ROSC exerts a stronger 
antimigratory effect than LGR1406 in concentrations that were also used for 
antiproliferative assays. ROSC (20 µM) inhibited PDGF-BB-induced migration by 65% 
compared to only 23% of inhibition by LGR1406 (5µM) (Fig.29). It is not a complete novel 
finding that ROSC is able to inhibit migration because there are some publications 
addressing this issue in cancer cells (e.g.201). However, we are the first to demonstrate 
such an effect in VSMC.  
 
In prostate cancer cells ROSC treatment was shown to result in changes in the 
cytoskeleton and hence loss of cellular polarity and motility 202. Moreover Miyamoto and 
colleagues showed that ROSC impaired the PDGF-dependent migration of primary rat 
oligodendrocyte precursor cells and could mimic this effect using retroviral CDK5 shRNA 
knockdown 203. The authors of these and other studies therefore linked the antimigratory 
effect of ROSC to inhibition of CDK5. In keratinocytes ROSC inhibited adhesion of cells to 
fibronectin and hence migration, associated with reduced active beta1 integrin 127. Also 
here the authors state that the effects observed were due to CDK5 inhibition. As shown in 
Table II and Table X, ROSC and LGR1406 inhibit CDK5 with comparable IC50 values of 
0.16 µM and 0.4 µM, respectively. Therefore we would expect to see similar effects of 
both substances on VSMC migration if they were CDK5 mediated. Moreover we were not 
able to detect CDK5 protein in western blot analysis in VSMC (data not shown), and there 
are no data available from literature showing CDK5 protein levels in VSMC. However, 
there were two publications in the early nineties showing mRNA levels for CDK5 in VSMC. 
Hence it can not be ruled out that ROSC indeed impairs VSMC migration via the inhibition 
of CDK5. If this is the case it would be interesting to investigate why LGR1406 does not 
exert the very same effect. It is also still possible that ROSC inhibits another kinase that is 
not affected by LGR1406. Among the published 150 kinases tested for inhibition by ROSC 
in enzyme-based assays there is none that seems really promising concerning migration 
117. But as there are much more protein kinases known in mammals (> 850 present in 
human genome 34) this possibility can not be excluded at this point. Alternatively LGR1406 
may additionally inhibit an antimigratory kinase that counteracts its action on CDK5, but 
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this is highly speculative. Therefore more research concerning open questions related to 
ROSC and LGR1406 and migration is needed.   
 
The ideal stent-coating agent is still to be found and most probably is not a single 
compound but rather a mixture of anti-proliferative/ anti-migratory compounds on the one 
hand and endothelium-protective factors on the other hand in order to achieve re- 
endothelialisation without neointima formation 154. However, with this study we provide first 
evidence that optimised ROSC-derivatives such as LGR1406 could serve as anti-
proliferative agents against VSMC in drug eluting stents.   
Indirubine-3’-monoxime 
In her PhD Thesis Andrea Schwaiberger showed that I3MO attenuated PDGF-BB-induced 
proliferation of VSMC and neointimal hyperplasia in an experimental animal model 180. We 
demonstrated in the present study that I3MO not only acts as antiproliferative compound 
but also strongly inhibits PDGF-BB-induced VSMC migration (Fig.31, Fig.32). This was 
shown using two different approaches, namely the scratch and transwell assay, and 
interestingly I3MO exerts both the antimigratory and antiproliferative effect within the 
same concentration range (3-5 µM), possibly suggesting a common target for both. We 
could exclude any inhibitory activity on cell adhesion (Fig.34). As discussed in section 
4.3.1, we used 10 ng/ml of PDGF-BB for migration assays instead of 20 ng/ml that was 
used for the studies on proliferation because we achieved maximal migratory response 
with this concentration (Fig.30). Also it has been shown, that a lower amount of PDGF 
elicits rather a migratory response whereas higher concentrations rather cause 
proliferation 204-206. We repeated some crucial experiments with this lower amount of 
PDGF-BB and confirmed that I3MO completely abolishes STAT3 phosphorylation without 
affecting ERK phosphorylation (Fig.36).   
 
Although indirubin is intensively investigated there is very poor knowledge about its 
antimigratory potential. In fact only three publications addressed this question up to now 
205. Just recently it has been reported that I3MO is able to block microglial migration in a 
scratch assay using a mouse cell line 64, 166. This finding could be easily explained since 
I3MO is known to inhibit amongst others CDK5 which in turn has been reported to be 
essential for neuronal migration 204. However, Yuskaitis and colleagues claim that their 
observation is solely due to inhibition of GSK3 and do not mention CDK5 or other possible 
targets at all.  
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There is also one article describing the influence of I3MO on migration in the context of 
the cardiovascular system 206. Tran et al. reported that I3MO did not significantly affect 
human endothelial cell migration in a transwell assay but inhibited angiogenesis in an in 
vitro angiogenesis assay for tube formation. 
It has also been published that I3MO can even augment migration in response to several 
interleukins in a transwell assay but this was only reported for human leukaemia cancer 
cells 207. The authors of this study showed that I3MO had differentiation-promoting activity 
and promoted expression of typical neutrophil receptors via CDK inhibition. They 
concluded that the suppressive effect against leukaemia of I3MO is mediated through its 
differentiation-promoting activity. 
 
Taken together I3MO elicits antimigratory or promigratory responses or does not affect 
migration at all depending either on cell type, organism or stimulus used. Also the authors 
of the different studies do not agree on the underlying mechanism of action of I3MO and 
either suggest CDK or GSK3 inhibition to be responsible. Obviously much more research 
is needed to understand the mechanistic and influence of I3MO on cell migration.   
 
Therefore our study adds on important information showing for the first time an 
antimigratory potential of I3MO in VSMC. 
 
Key regulators of VSMC migration are the small GTPases of the Rho protein family (Rac-
1, cdc42, RhoA) 208, 209. They all play crucial roles in cytoskeletal rearrangements upon 
stimulation with chemotactic agents such as PDGF-BB. We found that I3MO inhibits such 
rearrangements as e.g. membrane ruffling or stress fibre formation (Fig.41). Therefore we 
addressed the question whether I3MO influences small GTPases. We could exclude any 
inhibitory activity on the activation of Rac-1 (Fig.35). Cdc42 has been reported to be 
constitutively activated in VSMC and it has been shown that PDGF-BB does not enhance 
the levels of activated (GTP-bound) Cdc42 208, 210. Also in our lab we found that cdc42 was 
constitutively activated and failed to induce an increase in active cdc42 with PDGF-BB 
(data not shown). Therefore it is unlikely that I3MO suppresses VSMC migration via the 
inhibition of cdc42. Unfortunately we failed to detect active RhoA (personal 
communication Mario Kumerz, PhD student, data not shown). However, RhoA activity in 
response to PDGF-BB has been reported for VSMC, and future investigations are 
warranted 154. 
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In her thesis Andrea Schwaiberger demonstrated that I3MO impaired the activation of 
STAT1/3/5/6 without affecting other common early signalling pathways (p38, ERK, Akt) 
and suggested that the effect on STAT3 may be at least partially responsible for the 
antiproliferative activity of I3MO 211. Substantial evidence is found in the literature 
supporting that STAT3 is involved in cell migration, motility, and invasiveness under 
normal and pathological situations 212, 213. Especially for cancer cells where it is often 
overexpressed or constitutively active, STAT3 has been shown to mediate not only cell 
proliferation but also migration and to be involved in neoangiogenesis 103, 112, 214, 215. 
Studies in other cell types including keratinocytes, fibroblasts, epithelial cells and VSMC 
have been shown that STAT3 is essential for migration there, too 216. Its role in migration 
has been attributed mostly to its function as transcription factor that is dependent on its 
tyrosine phosphorylation. Among the STAT3 target genes are indeed several that are 
implicated in cell migration and cell adhesion such as e.g. metalloproteinases, platelet-
endothelial cell adhesion molecule (PECAM-1), vav-2 (another member of the Rho 
GTPase family) and others 102, 103. Moreover, Rao and colleagues reported that STAT3 is 
indispensable for VSMC migration in response to thrombin and PDGF-BB because it is 
responsible for the transcription of the cytosolic phospholipase A2 (cPLA2) that in turn 
cleaves membrane lipids and leads to the accumulation of arachidonic acid and its 
metabolites 103. These metabolites have been implicated in VSMC migration. Neeli et al. 
showed that expression of a dominant negative STAT3 abolished PDGF-BB-induced 
migration of VSMC and that this effect could be rescued by adding arachidonic acid 211. 
The relevance of other STAT3 target genes and direct evidences for their role in migration 
has, however, not been established so far 217. Additionally, it should be noted that there 
are also publications showing that STAT3 exerts effects on cell migration that are 
independent of tyrosine-phosphorylation and transcription. Ng et al. demonstrated that 
non–tyrosine-phosphorylated STAT3 can stabilize the polymerization of microtubules 
through a direct interaction with the tubulin-binding protein stathmin 154. However, for our 
setting the latter aspect does not seem to be important because we only observed an 
impaired STAT3 phosphorylation with I3MO but no changes in overall STAT3 levels 39. 
 
We further supported the role of STAT3 for PDGF-BB induced migration using the JAK2 
inhibitor AG490 as well as the Src inhibitor SU6656 that both impaired VSMC migration 
(Fig.37). JAK2 and Src have also been implicated in PDGF-BB induced phosphorylation 
of STAT3 154. We confirmed this in our group by showing that both compounds indeed 
impair STAT3 phosphorylation (see Fig.39 for AG490 and Andrea Schwaiberger, 2008 for 
SU6656 188). As the Src inhibitor completely abrogated STAT3 phosphorylation but the 
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JAK2 inhibitor only reduced it by about 70% we conclude that in our settings the Src 
kinase takes over the major part in the phosphorylation of STAT3 but that both kinases 
contribute to STAT3 activation as well as to VSMC migration.  
 
Since we found several hints suggesting that STAT3 is important for VSMC migration, we 
further focused on the transcription of STAT3 target genes that might be involved. We 
found that I3MO reduced the PDGF-BB induced expression of cPLA2 as well as cyclin D1 
(Fig.40). The role of cPLA2 in migration has already been pointed out. Cyclin D1 has been 
shown to play a role in migration next to its proliferative function in embryonic fibroblasts 
but data on VSMC migration are missing 205, 218. However, it is not clear whether the 
reduced levels of cPLA2 and cyclinD1 could mediate the antimigratory effect of I3MO we 
observed. First, the basal levels of cPLA2 are already rather high and PDGF-BB only 
elicits a small enhancement, and therefore it is questionable whether this reduction of 
cPLA2 levels could lead to the complete abolishment of migration seen in our experiments. 
Second, we monitored differences in cytoskeletal rearrangements of I3MO treated cells as 
early as 1-2 h upon PDGF-BB stimulation. This timeframe is clearly too short to include 
protein expression in the considerations (Fig.41). Nevertheless, it seems plausible that 
I3MO exerts its antimigratory effect through multiple ways and that one of those is 
mediated via the downregulation of cPLA2 and/ or cyclin D1 or other so far unknown 
STAT3 target genes. 
 
Whether there is a causal link between inhibition of STAT3 phosphorylation and inhibited 
migration still needs to be shown. For this purpose we want to study the impact of a 
constitutively active mutant of STAT3 on PDGF-BB-induced VSMC migration. Additionally 
we will use gene silencing strategies for STAT3 and study the influence on VSMC 
migration. It is also possible that STAT3 does not play a role at all in mediating I3MO 
effects. It should be noted that STAT5 shares many properties with STAT3, for example it 
also influences cyclin D1 expression and is phosphorylated by Src. Moreover suppression 
of STAT5b has been shown to reduce neointima formation as well as VSMC migration 219, 
220. 
 
As I3MO is marketed as GSK3 inhibitor and a few publications suggest a role for this 
kinase in migration, we addressed the question whether other GSK3 inhibitors could 
mimic the antimigratory effect of I3MO 221-223. LiCl, a known GSK3 inhibitor strongly 
impairs PDGF-BB induced migration of VSMC (Fig.38). Other salts did not lead to such an 
effect ruling out osmotic changes as reason for the inhibition seen with LiCl. However, LiCl 
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did not mimic the effect of I3MO on STAT3 phosphorylation (Fig.39). Therefore we 
exclude STAT3 as common antimigratory target of LiCl and I3MO. However, it can not be 
ruled out at this stage that the inhibition of migration by I3MO is independent of inhibition 
of STAT3 phosphorylation and that I3MO indeed inhibits migration just as LiCl most likely 
does via GSK3 inhibition.   
 
The strong effect of LiCl on VSMC migration is completely novel, and we furthermore 
were interested whether LiCl would also influence VSMC proliferation. Indeed LiCl 
treatment led to an accumulation of cells in G1 phase (Fig.42). Further investigations 
should address whether GSK3 inhibition is really the underlying mechanism for our 
observations by using other GSK3 inhibitors, siRNA approaches or expression of a 
constitutively active GSK3. 
 
Another interesting finding of Andrea Schwaiberger was the antioxidative effect of I3MO in 
activated VSMC, especially because the generation of ROS has been shown to be very 
important for VSMC migration 223. Weber et al. showed that PDGF-induced VSMC 
migration is ROS dependent and identified a Src-dependent signalling pathway as an 
important ROS-sensitive mediator of VSMC migration 154. Although in this article STAT3 is 
not mentioned it could be involved because we found that Src inhibition leads to STAT3 
inhibition and that STAT3 activation is ROS sensitive (Andrea Schwaiberger, 2008 224). 
ROS are generated through multiple pathways and enzymes in a cell. In VSMC the 
NAD(P)H oxidases (Noxes), xanthine oxidase,  lipoxygenases, the mitochondrial 
respiratory chain and nitric oxide synthases have been identified so far as sources of ROS 
225. Particularly the Nox protein family which belongs to the flavoproteins plays a pivotal 
role in the controlled production of ROS in response to the activation of numerous 
receptors 206. We therefore used the rather unspecific flavoprotein inhibitor DPI to block 
ROS generation (data on DPI and ROS production in Schwaiberger, PhD Thesis, 2008) 
and could again mimic the effect of I3MO on PDGF-BB-induced migration. An 
antioxidative effect of I3MO could definitely play a role in its antimigratory activity. This 
should be followed in future experiments using other antioxidants or siRNA approaches 
targeting ROS-producing proteins. Additionally it should be investigated whether STAT3, 
as its activation is redox-sensitive, is involved in connecting the antioxidative and 
antimigratory effects or not.  
 
Next to STAT3, GSK3 inhibition and the antioxidative effect of I3MO, there is at least one 
other possible alternative explanation for its antimigratory effect. As already mentioned it 
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has been suggested that I3MO exerts its antimigratory activity in cancer cells through 
inhibition of CDK5 51. In our studies we found that two different CDK5 inhibitors, I3MO and 
ROSC inhibit VSMC migration. But LGR1406 did not exert a potent antimigratory effect, 
although it is able to inhibit CDK5 as well. Moreover as discussed in section 5.1 we were 
neither able to detect CDK5 in western blot analysis in VSMC (data not shown) nor did we 
find data published showing CDK5 protein levels in VSMC. However, it can at this point 
not completely be ruled out that I3MO impairs VSMC migration at least partly via the 
inhibition of CDK5.  
 
Taken together, we clearly demonstrated that I3MO inhibits PDGF-BB-induced migration 
of VSMC, and our data suggests that this effect is probably mediated via the reduction of 
ROS production in the cell and consequent inhibition of Src and subsequent STAT3 
phosphorylation. We already had shown in previous studies, that I3MO inhibits VSMC 
proliferation and neointima formation in vivo. Also I3MO has been shown to exert 
antiinflammatory activities, which would also be beneficial for the treatment of restenosis. 
The present study shows that I3MO additionally has antimigratory activity against VSMC 
and hereby further substantiates that I3MO is a promising compound for e.g. stent coating. 
However, there are still some open questions regarding its direct molecular targets. 
Especially the role of STAT3 or other STATs in I3MO effects seen in in vitro and in vivo 
experiments needs to be clarified. 
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Abnormal vascular smooth muscle cell (VSMC) proliferation and migration contribute to 
vascular narrowing during the pathogenesis of atherosclerosis. There are various 
treatment modalities either preventing the progression of atherosclerosis or re-widening 
diseased arteries. However, even if an artery has been re-widened its lumen is often 
reduced again, a process called restenosis. The latter is also characterized by the 
proliferation and migration of VSMC and the subsequent formation of a new inner layer of 
the vessel wall (neointima). To maintain the vessel lumen often mesh-like structures, so 
called stents are implanted. Eventually these stents are coated with antiatherogenic drugs. 
An ideal compound for treating atherosclerosis and restenosis should impair both 
proliferation and migration of VSMC. Therefore, finding drugs that specifically inhibit these 
processes is an important subject of research. 
 
A major proliferative stimulus and the strongest chemoattractant for VSMC is the Platelet 
Derived Growth Factor-BB (PDGF-BB). PDGF-BB-stimulation leads to the activation of 
several signalling cascades and ultimately to cell migration as well as to cell cycle 
progression. The latter requires the activation of cyclin-dependent kinases (CDKs) through 
their association with regulatory subunits called cyclins. During each phase of the cell 
cycle different CDK/cyclin holoenzymes are specifically activated and in turn 
hyperphosphorylate pocket proteins. Reinduction of positive cell-cycle control genes in 
VSMC, like CDK2 and cyclin A and E is a hallmark of atherosclerosis and restenosis and 
therefore CDKs are expedient drug targets to combat vascular proliferative diseases. 
 
Roscovitine (ROSC) is a derivative of the plant hormone Isopentylalanin that is able to 
unspecifically inhibit kinases. However ROSC itself shows a high specificity for CDKs and 
has been cocrystalized with CDK2. Research has been primarily focused on ROSC 
(Seliciclib) as an anti cancer drug and is currently in clinical trials phase II against breast 
cancer. ROSC is well known to act as a CDK inhibitor but most of the publications only 
show in vitro data and other potential targets have been published as well. There are only 
two publications mentioning effects on VSMC and none of them solved its mechanism of 
action satisfyingly. We therefore wanted to investigate the mode of action of ROSC and 
promising derivatives in PDGF-BB stimulated VSMC and define the changes in cell 
signaling. During screening a panel of synthetic ROSC-derivatives for a general 
antiproliferative activity in VSMC we identified several derivatives with significant higher 
potencies than ROSC itself. The most potent of which was LGR1406. We, therefore, 
compared the influence of ROSC and its most promising derivative LGR1406 on PDGF-
BB induced proliferation and migration of VSMC. We showed that LGR1406 and ROSC 
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both inhibit proliferation of VSMC without affecting early signalling pathways downstream 
the activated PDGF receptor. LGR1406 is hereby the far more potent compound with an 
apparent IC50 of 3.0 µM in the BrdU assay compared with an IC50 of 17 µM of ROSC. A 
detailed molecular analysis using western blot analysis as well as in vitro kinase assays 
showed that both compounds affect entry of cells in to S-phase of the cell cycle, 
expression of cyclin A and E as well as phosphorylation of pocket proteins presumably by 
inhibition of CDK activity. However, ROSC only delayed these events whereas LGR1406 
permanently blocked cell cycle progression in G1-phase of the cell cycle. We conclude 
that LGR1406 could be used for further development as e.g. stent coating agent but in 
vivo studies as well as further investigations on its molecular mechanism are needed. 
With this study we provide first evidence that optimised ROSC-derivatives such as 
LGR1406 could serve as anti-proliferative agents against VSMC growth in drug eluting 
stents.  
 
Indirubin-3'-monoxime (I3MO) is a derivative of indirubin which is an active component 
from a recipe of traditional chinese medicine exerting anti-cancer function as well as 
inhibiting inflammatory reactions. All together there have been a number of biological 
activities contributed to I3MO many of which seem to be cell type specific. However, 
studies on VSMC were missing until Andrea Schwaiberger in our group addressed this 
issue (PhD thesis, Vienna, 2008). She found that I3MO used at 3-5 µM potently blocks 
VSMC cell cycle progression in response to PDGF-BB. In cooperation with Prof. Binder 
from the Medical University of Vienna she furthermore showed that I3MO inhibits 
neointima formation in a mouse model. However, the molecular mechanism of action of 
I3MO is not completely understood so far. In vitro kinase assays showed that indirubin 
can target different kinases and therefore may affect several targets in a cell. Furthermore 
Andrea Schwaiberger showed that is suppresses the activation of members of the STAT 
protein family in response to PDGF-BB without interfering with other common early 
signalling events. The work was further focused on STAT3 and it was suggested that the 
inhibitory effect on STAT3 may be at least partially responsible for the antiproliferative 
activity of I3MO. As both proliferation and migration contribute to neointima-formation we 
therefore not only wanted to further investigate the underlying molecular mechanism of 
I3MO-effects on proliferation but also its potential influence on migration of VSMC. In this 
study we now showed that I3MO dose-dependently inhibits PDGF-BB-induced migration 
of VSMC in the same concentration range as it limits PDGF-BB-induced proliferation. Also 
we found that I3MO interferes with early cytoskeletal rearrangements involved in cell 
migration upon PDGF-BB-stimulation. I3MO did not affect the activation of the small 
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GTPase Rac-1 that is crucial for VSMC migration. We also found that I3MO reduces the 
expression of STAT3 target genes involved in migration. Additionally we were comparing 
the effects exerted by I3MO with chemical inhibitors of common PDGF-BB-induced 
signalling pathways involved in migration. We found that I3MO exerts similar effects as a 
Src kinase inhibitor and a flavoprotein inhibitor which reduces the levels of reactive 
oxygen species (ROS) in a cell. We clearly demonstrated that I3MO inhibits PDGF-BB-
induced migration of VSMC and our data suggests that this effect is probably mediated via 
the reduction of ROS production in the cell and consequent inhibition of STAT3 
phosphorylation. Our studies further substantiate that I3MO is a promising compound for 
e.g. stent coating but still there are some open questions regarding its molecular targets. 
Especially the role of STAT3 or other STATs in conducting the effects of I3MO seen in in 
vitro and in vivo experiments needs to be clarified. 
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Abbreviations 
  Abbreviations 
  
4EBP1 eIF4E binding protein 1 
  
A  
  
ABP Actin-binding proteins 
ACE Angiotensin-converting enzyme 
AhR Co-transcriptional factor aryl hydrocarbon receptor  
Akt AKT8 virus oncogene cellular homolog 
ALK Anaplastic lymphoma kinase 
AMPK AMP-activated protein kinase 
Ang II Angiotensin II 
ANOVA  Analysis of variance between groups 
APS  Ammonium persulphate 
Arp2/ 3  Actin-related protein 2/3 
ATP  Adenosine triphosphate 
Aur-A Aurora A 
Aur-B Aurora B 
  
B  
  
bFGF basic fibroblast growth factor 
BrdU  BrdU Bromodeoxyuridine 
BRK Breast tumor kinase 
BSA  Bovine serum albumin 
  
C  
  
cdc42 A small GTPase of Rho family 
CDK  Cyclin dependent kinase 
CAK CDK activating kinase 
CKI CDK inhibitor proteins  
c-myc Similar to myelocytomatosis viral oncogene 
COX Cyclooxygenase 
CRM Chromosome region maintenance 1 
CRP C-reacitve protein  
CS Calf serum 
cyc Cyclin 
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  Abbreviations 
  
D  
  
ddH2O  Double distilled water 
DNA Desoxyribonucleic acid 
DES Drug-eluting stent 
DMSO Dimethylsulphoxide 
DPI  Diphenylen iodonium 
DTT Dithiothreitol 
  
E  
  
EC Endothelial cells 
ECL Enhanced chemiluminescence 
ECM Extracellular matrix 
EDTA  Ethylenediamintetraacetic acid 
EGF Epidermal growth factor 
EGFR Epidermal growth factor receptor 
EGTA  Ethylene glycol-bis(2-aminoethylether)-tetraacetic acid 
ERK Extracellular signal-regulated kinase 
  
F  
  
FACS  Fluorescence-activated cell sorter 
FAK Focal adhesion kinase 
FGF Fibroblast growth factor 
FGFR Fibroblast growth factor receptor 
FITC Fluorescein isothiocyanate 
FSC Forward scatter 
Fyn A src family tyrosine-protein kinase 
  
G  
  
GAP  GTPase activating protein 
GATA-6  Gastric transcription factor-6 
GAX  Growth Arrest Homeobox 
GFP Green fluorescent protein  
Grb2 Growth factor receptor-bound protein 3 
GSK-3 Glycogen synthase kinase-3 
GST Glutathion-S-Transferasen 
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  Abbreviations 
  
H  
  
HBSS Hanks` balanced salt solution 
HEPES N-(2-hydroxyethyl)piperazine-'L-(2-ethanesulphonic acid) 
HFS Hypotonic fluorochrome solution 
HRP Horse radish peroxidase  
  
I  
  
I3MO Indirubine-3'-monoxime 
IFN Interferon 
IFN-γ  Interferon  γ  
IGF Insulin like growth factor 
IL Interleukin 1 
INK4 Inhibitor of CDK4 
IRSE IFN-stimulated response element 
  
J  
  
JNK c-jun N-terminal kinase 
  
K  
  
kDa Kilo Dalton 
KIP Kinase Inhibitor Protein  
  
L  
  
LCK  Lymphocyte-specific protein tyrosine kinase 
LDL Low density lipoprotein 
Lyn A src family tyrosine-protein kinase 
  
M  
  
MAP Microtubule-associated protein 
MAPK MAPK Mitogen activated protein kinase 
MCP-1 Monocyte chemoattractant protein 1  
M-CSF Monocyte-colony stimulating factor  
mDia1/ 2 Mammalian Diaphanous-related formins 1/2 
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  Abbreviations 
  
M  
  
MEK MAPK/ERK kinase 
MMP Metalloproteinase 
MTOC Microtubule-organisation centres 
mTOR Mammalian target of rapamycin 
  
N  
  
NCK Nck adaptor protein 
NFAT Nuclear factor of activated T cell  
NF-κB Nuclear factor-κB 
NLK Nemo-like kinase 
NO Nitric oxide  
Nox  NAD(P)H-oxidase 
  
P  
  
PAA  Polyacrylamide 
PAK p21-activated protein kinase  
PBD p21-binding domain  
PBS Phosphate buffered saline 
PCI Percutaneous coronary intervention  
PCNA Proliferating cell nuclear antigen 
PDGF Platelet derived growth factor 
PDXK Pyridoxalkinase 
PI Propidium iodide 
PI3K Phosphoinositol 3 kinase 
PIP3 Phosphatidylinositol-3-phosphat  
PLC Phospholipase C 
PMSF Phenylmethylsulphonylfluoride 
PTA  Percutaneous transluminal angioplasty 
p-TEFb Positive transcription elongation factor b  
PTEN Phosphatase and tensin homologue deleted on chromosome ten 
PTP Protein tyrosine phosphatase 
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  Abbreviations 
  
R  
  
Rac A small GTPase of Rho family 
Raf Ras-activated factor 
Ras Rat sarcoma GTP protein 
RAS  Renin-angiotensin system 
Rb  Retinoblastoma protein 
RhoA  A small GTPase of Rho family 
RLU Relative light units  
ROCK Rho-associated, coiled-coil-containing protein kinase 
ROS Reactive oxygen species 
ROSC Roscovitine 
RSK3 Ribosome S6 Kinase 3 
RTK  Receptor tyrosine kinase domain 
  
S  
  
S6K1  p70 ribosomal protein S6 kinase 1 
SDS  Sodium dodecyl sulphate 
SDS-PAGE  Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
SEM  Standard error of the mean 
Ser Serine 
SGK  Serum/glucocorticoid-regulated kinase 
SH2 Domain Src-homology 2 domain 
SHP SH2-containing protein-tyrosine phosphatase 
α-SMA Smooth muscle alpha actin (α-SMA) 
SMPC Smooth muscle progenitor cells 
Sos Son of sevenless guanine nucleotide exchange factor 
Src Rous sarcoma oncogene cellular homolog 
SSC Side scatter 
STAT Signal transducer and activator of transcription 
  
T  
  
TBS-T Tris-buffered saline containing Tween 20 
TEMED N,N,N’,N’-tetramethylethylene diamine 
TGF Transforming growth factor 
TGFα /β Ttransforming growth factor α and β 
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  Abbreviations 
  
T  
  
TIMP Tissue inhibitors of metalloproteinase 
TNF Tumor necrosis factor 
TNF-α Tumour necrosis factor-α 
Tyr Tyrosine 
  
V  
  
VASP Vasodilator-stimulated phosphoprotein 
VCAM Vascular cell adhesion molecule 
VEGFR Vascular endothelial growth factor receptor 
VSMC  Vascular smooth muscle cells 
  
W  
  
WASP Wiskott-Aldrich syndrome protein 
WAVE Verprolin-homologous protein 
  
Y  
  
Yes  A src family tyrosine-protein kinase 
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BD Bioscience Pharmingen (San Diego, CA, USA) 
Beckman Coulter (Fullerton, CA, USA) 
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Calbiochem (La Jolla, CA, USA)  
Carl Roth (Karlsruhe, Germany) 
Cell Biolabs (San Diego, CA, USA) 
Fluka (Buchs, Switzerland) 
Fujifilm (Tokyo, Japan) 
GraphPad Software Inc (San Diego, CA, USA) 
Invitrogen (Carlsbad, CA, USA)  
Lonza Group Ltd. (Basel, Switzerland)  
New England Biolabs (Beverly, MA, USA) 
Olympus Europa GmbH (Hamburg, Germany) 
Promega (Mannheim, Germany) 
ProQinase GmbH (Freiburg, Germany) 
Qiagen AG (Hilden, Germany) 
Quattro Research GmbH (Munich, Germany) 
Raytest GmbH (Straubenhardt, Germany) 
Roche Diagnostics (Basel, Switzerland)  
Santa Cruz (Santa Cruz, CA, USA) 
Sigma Aldrich (MO, USA) 
TECAN (Mannedorf, Switzerland) 
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Whatman plc (Kent, UK) 
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